<SEC-DOCUMENT>0001178913-24-002418.txt : 20240806
<SEC-HEADER>0001178913-24-002418.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806070042
ACCESSION NUMBER:		0001178913-24-002418
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		241177020

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431742.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cgen="http://cgen.com/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2024</title></head><body><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20240630" id="FFact_306">0001119774</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20240101to20240630" id="FFact_307">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20240630" id="FFact_309">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20240101to20240630" id="Fdei_DocumentFiscalPeriodFocus20220803133013452">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="C_20240101to20240630" id="Fdei_DocumentPeriodEndDate20220803135349061">2024-06-30</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20240630.xsd"/>
        </ix:references></ix:header></div><div>
  <div>
    <div>
      <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
          <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
        </div>
      </div>
      <div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:18pt;margin-bottom:0pt;text-align:center"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>UNITED STATES</span></span></span></strong></div>
      <div>
        <div>
          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:14pt"><span>SECURITIES AND EXCHANGE COMMISSION</span></span></span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span>Washington, D.C. 20549</span></span><br/>&#160;</span></span></div>
          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Form <ix:nonNumeric id="Fxbrl_20220803132217335" name="dei:DocumentType" contextRef="C_20240101to20240630">6-K</ix:nonNumeric></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</span></span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For the month of August <ix:nonNumeric id="Fxbrl_20220803135229207" name="dei:DocumentFiscalYearFocus" contextRef="C_20240101to20240630">2024</ix:nonNumeric></span></span></span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Commission File Number <ix:nonNumeric id="Fxbrl_20220803132624667" name="dei:EntityFileNumber" contextRef="C_20240101to20240630">000-30902</ix:nonNumeric></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16pt"><span><ix:nonNumeric id="Fxbrl_20220803132653437" name="dei:EntityRegistrantName" contextRef="C_20240101to20240630">COMPUGEN LTD.</ix:nonNumeric></span></span></span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Translation of registrant&#8217;s name into English)</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20220803132710165" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20240630">26 Harokmim Street</ix:nonNumeric></span></span></span></div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20220803132729395" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20240630">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20220803132743972" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20240630">5885849</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20220803132757086" name="dei:EntityAddressCountry" contextRef="C_20240101to20240630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Address of Principal Executive Offices)</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Form 20-F &#9746;&#8195;&#8195;Form 40-F &#9744;</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Compugen Ltd.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25">
            <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On August 6, 2024, Compugen Ltd. (the &#8220;<span style="font-weight:bold">Company</span>&#8221;) issued a press release reporting the Company&#8217;s 2024 second quarter results (the &#8220;<span style="font-weight:bold">Press Release</span>&#8221;), a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K. With the exception of the 2<sup style="vertical-align:text-top;line-height:1;font-size:smaller">nd</sup>, 3<sup style="vertical-align:text-top;line-height:1;font-size:smaller">rd</sup> and 4<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup> paragraphs of the Press Release, the information contained in the Press Release is hereby incorporated by reference herein.</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Second Quarter 2024 Financial Results</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The unaudited interim consolidated financial statements of the Company and its subsidiary as of June 30, 2024 and December 31, 2023 and for the six months ended June 30, 2024 and 2023 are furnished as Exhibit 99.2 to this Report on Form 6-K and incorporated by reference herein. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2024 are furnished as Exhibit 99.3 to this Report on Form 6-K and incorporated by reference herein.</span></span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3, File No. 333-270985.</span></span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
          </div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Exhibits</span></span></span></div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Exhibit</span></span></span></div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:72pt;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold;text-decoration:underline">Number</span></span></span></span></div>
                </td>
                <td style="width:auto;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold;text-decoration:underline">Description of Exhibit</span></span></span></span></td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:72pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-1.htm">99.1</a></span></span></span></td>
                <td style="width:auto;vertical-align:top">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-1.htm">Press Release dated August 6, 2024.</a></span></span></span></div>
                </td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:72pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-2.htm">99.2</a></span></span></span></td>
                <td style="width:auto;vertical-align:top">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-2.htm">Unaudited interim consolidated financial statements as of June 30, 2024 and December 31, 2023 and for the six months ended June 30, 2024 and 2023.</a></span></span></span></div>
                </td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:72pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-3.htm">99.3</a></span></span></span></td>
                <td style="width:auto;vertical-align:top">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-3.htm">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2024.</a></span></span></span></div>
                </td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:72pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>101</span></span></span></td>
                <td style="width:auto;vertical-align:top">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following financial information from Compugen Ltd.&#8217;s Report on Form 6-K, formatted in Inline XBRL (ieXtensible Business Reporting Language): (i) interim consolidated balance sheets as of June 30, 2024 and December 31, 2023; (ii) interim consolidated statements of comprehensive loss for the six months ended June 30, 2024 and 2023; (iii) interim consolidated statements of changes in shareholders&#8217; equity for the six months ended June 30, 2024 and 2023; (iv) interim consolidated statements of cash flows for the six months ended June 30, 2024 and 2023; and (v) notes to interim consolidated financial statements.</span></span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Signatures</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:50%;vertical-align:bottom">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td colspan="3" style="vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>COMPUGEN LTD.</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="4" style="vertical-align:middle">
                  <div style="line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Date: August 6, 2024</span></span></span></div>
                </td>
                <td style="width:3%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>By: </span></span></span></div>
                </td>
                <td style="width:35%;vertical-align:bottom;border-bottom:2px solid black">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>/s/ Eran Ben Dor </span></span></span></div>
                </td>
                <td style="width:12%;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width:50%;vertical-align:bottom">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:3%;vertical-align:bottom">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td style="width:35%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Eran Ben Dor</span></span></span></div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>General Counsel</span></span></span></div>
                </td>
                <td style="width:12%;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
        </div>
      </div>
    </div>
  </div>
  <div>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;page-break-after:always;text-align:center"/>
  </div>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><font style="font-weight: bold;"><u>Exhibit 99.1</u></font><br>
    </div>
    <br>
    <div style="line-height: 1.25;"><img width="123" height="35" src="image0.jpg"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE&#160;&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Reports Second Quarter 2024 Results</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc674c8c58efa4b169ffdd01433554deb">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zead61b4c0ba943eab89e7a75c66f0aa2">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7b7339d89d58403c9d16d461260098ba">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and
              mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f33b5595fc8439d928e95ff8220d434">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Solid balance sheet with cash runway expected to fund operations into 2027</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">HOLON, ISRAEL,&#160;August 6, 2024&#160;- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today&#160;announced financial results for the second
      quarter ended June 30, 2024, and provided a corporate update.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">&#8220;Continuing our track record in delivering on our plans, we have executed well in the second quarter of 2024,&#8221; said Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen. &#8220;We achieved FDA IND
      clearance for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics, triggering a right to receive a $30 million milestone payment from our partner Gilead. We are on track to initiate a Phase 1 clinical trial
      for COM503, as monotherapy and in combination with the anti-PD1 zimberelimab in advanced solid tumors, in the fourth quarter of 2024.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Dr. Cohen-Dayag continued, &#8220;We are also on track to present data from our COM701 + COM902 + pembrolizumab study in platinum resistant ovarian cancer in the fourth quarter of 2024. There is a significant unmet medical
      need for women with ovarian cancer who could benefit from potentially safe, efficacious and durable alternative treatment options.&#160;We previously demonstrated encouraging data in this patient population, including monotherapy activity, overall
      response rate of 20% and durable responses with some patients benefiting from treatment for over 16 months comparing favorably to standard of care. We believe showing data consistent with what we have previously reported in this indication, will once
      again confirm that COM701 combinations are active. We plan to share next steps for COM701 combinations at the time of data presentation in the fourth quarter of 2024."</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Dr. Cohen-Dayag added, &#8220;Our partner, AstraZeneca, is advancing development of rilvegostomig, their PD-1/TIGIT bispecific, and provided a non-risk-adjusted peak year revenue target of more than $5 billion for this asset,
      reflecting the potential of rilvegostomig.&#160;Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Upcoming Expected Milestones</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">COM701 +COM902 + pembrolizumab proof-of-concept study</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa049492fb474293834b52fbc7ee2b46">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Platinum resistant ovarian cancer - data presentation in the fourth quarter of 2024</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">COM503 (licensed to Gilead; Compugen leads through Phase 1 development)</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1325ae04b8f84e398e746717e19cca6c">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Initiation of COM503 Phase 1 trial in the fourth quarter of 2024</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Rilvegostomig (AstraZeneca&#8217;s PD-1/TIGIT bispecific, TIGIT component derived from COM902)</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z672ca2f736904171a4052d065b760bce">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>AstraZeneca anticipates data from Phase 1/2 ARTEMIDE-01 trial in the second half of 2024; poster presentation from Phase 2 GEMINI-Gastric trial accepted at ESMO 2024</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Second Quarter 2024 Financial Highlights</div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Cash:</font> As of June 30, 2024, Compugen had approximately $92.3 million cash, cash equivalents, short-term bank deposits, restricted cash and short-term bank deposit, and cash
      investments, compared with approximately $51.1 million as of December 31, 2023. Compugen expects that its cash and cash-related balances together with the additional expected $30 million milestone payment on COM503 IND clearance achieved in July,
      which is subject to a 15% withholding tax, will be sufficient to fund its operating plans into 2027. The Company has no debt.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Revenues:</font> Compugen reported approximately $6.7 million in revenues for the second quarter ended June 30, 2024, compared to no revenues for the comparable period in 2023. The
      revenues reported reflect recognition of a portion of the upfront payment from the license agreement with Gilead and the clinical milestone from the license agreement with AstraZeneca in the amount of $5 million.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">R&amp;D expenses</font> for the second quarter of 2024 were approximately $6.2 million compared with approximately $7.8 million for the comparable period in 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">G&amp;A expenses</font> for the second quarter of 2024 were approximately $2.2 million, compared with approximately $2.4 million for the comparable period in 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Net loss</font> for the second quarter of 2024 was approximately $2.1 million, or $0.02 per basic and diluted share, compared with a net loss of approximately $9.3 million, or $0.11 per
      basic and diluted share, in the second quarter of 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Full financial tables are included below.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Conference Call and Webcast Information</div>
    <div style="line-height: 1.25;">Compugen will hold a conference call today, August 6, 2024, at 8:30 AM ET to review its second quarter 2024 results. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or
      +972-3-918-0644 internationally. The call will be available via live webcast through Compugen&#8217;s website, located at the following <u>lin</u><u>k</u>. Following the live webcast, a replay will be available on Compugen&#8217;s website.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About&#160;Compugen</div>
    <div style="line-height: 1.25;">Compugen&#160;is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for
      developing cancer immunotherapies.&#160;Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,&#160;a potential best-in-class antibody targeting TIGIT for the treatment of
      solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen&#8217;s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of
      bispecific and multispecific antibodies.&#160;In addition, the Company&#8217;s therapeutic pipeline of early-stage&#160;immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program,
      COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen&#160;is headquartered in Israel, with offices in San Francisco, CA. Compugen&#8217;s shares
      are listed on Nasdaq and the Tel Aviv&#160;Stock Exchange under the ticker symbol CGEN.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities
      Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain
      these identifying words. Forward-looking statements include, but are not limited to, statements relating to our expectation to present data from our ongoing trials and the relevant timing thereof; statements relating to potential of rilvegostomig and
      potential long-term revenue source for Compugen thereof; statements relating to our expectation that our cash is expected to fund operations into 2027; statements relating to receipt of a milestone payment from Gilead; statements regarding our
      expectation to initiate a Phase 1 study for COM503, as monotherapy and in combination with the anti-PD1 zimberelimab in advanced solid tumors, in fourth quarter of 2024; statements regarding our belief that showing data in platinum resistant ovarian
      cancer consistent with what we have previously reported in this indication, will once again confirm that COM701 combinations are active; and statements regarding our plans to share next steps for COM701 and timing thereof; and statements relating to
      data presentations from different rilvegostomig clinical trials. These and other forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially
      different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen&#8217;s business model is substantially dependent on entering into collaboration agreements with third
      parties, and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen&#8217;s approach to the discovery of therapeutic products is based on its proprietary computational target discovery
      infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; the general market, political and economic conditions in the
      countries in which Compugen operates, including Israel; and the effect of the evolving nature of the recent war in Israel, and the related evolving regional conflicts. These and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of
      Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. While we believe that we have a
      reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot
      be certain. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to
      update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
    <div style="line-height: 1.25;">Yvonne Naughton, Ph.D.</div>
    <div style="line-height: 1.25;">VP, Head of Investor Relations and Corporate Communications</div>
    <div style="line-height: 1.25;">Email:&#160;ir@cgen.com</div>
    <div style="line-height: 1.25;">Tel: +1&#160;(628)&#160;241-0071&#160;&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z76e9450d35db4dc19975e80d38d4701c">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except for share and per share amounts)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" class="cfttable" id="zb3862de0399042a5aee10ad5f920f52c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Three Months Ended</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Six Months Ended,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">2023</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">2023</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Revenues</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">6,702</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">9,261</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Cost of revenues</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">1,552</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">3,654</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Gross profit</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">5,150</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">5,607</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Operating expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="line-height: 1.25;">Research and development expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">6,183</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">7,761</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">12,593</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">15,206</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Marketing and business development expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">157</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">49</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">248</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">165</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">General and administrative expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">2,222</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">2,404</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">4,670</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">4,977</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Total operating expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">8,562</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">10,214</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">17,511</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">20,348</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Operating loss</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(3,412</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(10,214</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(11,904</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(20,348</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Financial and other income, net</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">1,300</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">889</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">2,528</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">1,697</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Loss before taxes on income</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(2,112</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(9,325</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(9,376</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(18,651</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Tax benefit (expense)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">(11</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">49</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">(14</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">36</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Net loss</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(2,123</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(9,276</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(9,390</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">(18,615</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Basic and diluted net loss per ordinary share</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">(0.02</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">(0.11</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">(0.10</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">(0.21</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; width: 52%;">
            <div style="line-height: 1.25;">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">89,531,937</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">87,182,839</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">89,518,778</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">86,903,741</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z57c769af84f149dcbafe44cbf6f9cae8">

        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED BALANCE SHEETS DATA</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars, in thousands)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" class="cfttable" id="ze1faa746e49c4951a588c055220d8f0a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">2023</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">ASSETS</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Current assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Cash and cash equivalents</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">11,877</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">13,890</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Restricted cash</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">365</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Short-term bank deposits</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">47,439</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">25,053</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Restricted short-term bank deposit</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">333</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Investment in marketable securities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">32,688</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">11,742</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Trade receivables</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">5,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">61,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Other accounts receivable and prepaid expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">4,796</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">2,529</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Total current assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">102,133</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">114,579</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Non-current assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Long-term prepaid expenses</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">922</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">1,233</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Severance pay fund</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">3,023</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">2,977</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Operating lease right to use asset</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">3,061</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">1,329</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Property and equipment, net</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,028</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,216</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">Total non-current assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">8,034</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">6,755</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
            <div style="line-height: 1.25; font-weight: bold;">Total assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">110,167</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">121,334</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25; font-weight: bold;">LIABILITIES AND SHAREHOLDERS EQUITY</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25; font-weight: bold;">Current liabilities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Other accounts payable, accrued expenses and trade payables</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">13,068</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">14,485</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Short-term deferred revenues</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">11,252</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">11,149</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Current maturity of operating lease liability</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">449</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">632</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">Total current liabilities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">24,769</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">26,266</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25; font-weight: bold;">Non-current liabilities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Long-term deferred revenues</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">21,028</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">25,392</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Long-term operating lease liability</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">2,580</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">719</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Accrued severance pay</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">3,450</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">3,398</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">Total non-current liabilities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">27,058</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">29,509</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">Total shareholders' equity</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">58,340</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">65,559</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
            <div style="line-height: 1.25; font-weight: bold;">Total liabilities and shareholders' equity</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">110,167</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">121,334</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cgen="http://cgen.com/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2024</title></head><body><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20230101to20230630" id="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72" unitRef="usd" xsi:nil="true"/><ix:footnote id="FN20230728141130882" xml:lang="en-US">Represents an amount lower than $ 1.</ix:footnote>
<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220727223630806" unitRef="usd" xsi:nil="true"/><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" id="Fxbrl_20240730203500532" unitRef="usd" xsi:nil="true"/><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521" unitRef="usd" xsi:nil="true"/><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" id="Fxbrl_20240730211801692_xbrl_20230728101905592" unitRef="usd" xsi:nil="true"/><ix:nonFraction name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" contextRef="C_20231231" id="Fxbrl_20240730224938615_xbrl_20240730224858104" unitRef="usd" xsi:nil="true"/><ix:footnote id="FN20230728102035190" xml:lang="en-US">Represents an amount lower than $1</ix:footnote>
<ix:footnote id="FN20240730225406527" xml:lang="en-US">Represents an amount lower than $1.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20240630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211110"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180301to20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240731_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:Plan2010Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240731_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:EmployeeSharePurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cgen:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtStatementGeographicalAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtStatementGeographicalAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-14</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="NIS_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20220727223630806" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20240730203500532" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20240730211801692_xbrl_20230728101905592" toRefs="FN20230728102035190"/><ix:relationship fromRefs="Fxbrl_20240730224938615_xbrl_20240730224858104" toRefs="FN20240730225406527"/><ix:relationship fromRefs="FFact_298" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_299" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_300" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_301" toRefs="FN20220720121444312"/></ix:resources></ix:header></div><div><div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:right"><hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline;font-weight:bold">Exhibit 99.2</span></span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF JUNE 30, 2024</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. DOLLARS IN THOUSANDS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><div style="line-height:1.25"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS_integixAnchor">Interim Consolidated Balance Sheets</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2 - F-3</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#COMPREHENSIVELOSS_integixAnchor">Interim Consolidated Statements of Comprehensive Loss</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-4</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SHAREHOLDERSEQUITY_integixAnchor">Interim Consolidated Statements of Changes in Shareholders' Equity</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS_integixAnchor">Interim Consolidated Statements of Cash Flows</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-6</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALSTATEMENTS_integixAnchor">Notes to Interim Consolidated Financial Statements</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-7 - F-18</span></span></div></td></tr></table><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">- - - - - - - - - - - - -</span></span></div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div></div>
  <div>
    <div>
      <div style="font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED BALANCE SHEETS<span id="BALANCESHEETS_integixAnchor"></span></span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASSETS</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT ASSETS:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,877</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,890</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_4" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_5" name="us-gaap:OtherShortTermInvestments" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,439</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_6" name="us-gaap:OtherShortTermInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,053</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted short-term bank deposit</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191448508_Fact_5" name="us-gaap:RestrictedInvestmentsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">333</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191448508_Fact_6" name="us-gaap:RestrictedInvestmentsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728025352671_Fact_5" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,688</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728025352671_Fact_6" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730181947327_xbrl_20230728025352671_Fact_5" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730181947327_xbrl_20230728025352671_Fact_6" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts receivable and prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,796</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_10" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> current assets</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_11" name="us-gaap:AssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,133</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_12" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,579</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT ASSETS:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_13" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_14" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance pay fund</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_15" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_16" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,977</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right to use asset</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_17" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,061</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_18" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,329</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_19" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_20" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> non-current assets</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_21" name="us-gaap:AssetsNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,034</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_22" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,755</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> assets</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_23" name="us-gaap:Assets" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,167</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_24" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the interim consolidated financial statements.</span></span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 2</span></span></span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED BALANCE SHEETS</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LIABILITIES AND SHAREHOLDERS' EQUITY</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20220719213713620_0" name="us-gaap:AccountsPayableCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,378</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20220719213713621_1" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,502</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term deferred revenues</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713621_2" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,252</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_3" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,149</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturity of operating lease liability</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_4" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">449</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_5" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191521156_20220719213713622_4" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191521156_20220719213713622_5" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts payable and accrued expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_6" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,472</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_7" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> current liabilities</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_8" name="us-gaap:LiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,769</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_9" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,266</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON- CURRENT LIABILITIES:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term deferred revenues</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191548740_20220719213713624_12" name="cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,028</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730191548740_20220719213713625_13" name="cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,392</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long term operating lease liability</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713624_12" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_13" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued severance pay</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_14" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,450</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_15" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,398</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> non-current liabilities</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713627_16" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,058</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713627_17" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,509</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <p style="margin-left:2.85pt;line-height:1.25">COMMITMENTS AND CONTINGENT&#160;LIABILITIES (NOTE 6)</p>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><strong><ix:nonFraction id="Fxbrl_20240731133215233" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20240630" unitRef="usd" xsi:nil="true"/></strong></td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><strong><ix:nonFraction id="Fxbrl_20240731133231257" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"/></strong></td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS' EQUITY:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share capital:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160;Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20220719214834949" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_18" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_20220719214917721" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_20" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized on June 30, 2024, and December 31, 2023; <ix:nonFraction id="Fxbrl_20220719215055193" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_22" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,531,937</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20220719215111705" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_24" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></ix:nonFraction> shares issued and outstanding on June 30, 2024, and December 31, 2023, respectively</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_26" name="us-gaap:CommonStockValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_27" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_28" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">542,032</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713631_29" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive income (loss)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730190751125_20220719213713630_28" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730190751125_20220719213713631_29" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20220719213713631_30" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">483,917</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20220719213713632_31" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> shareholders' equity</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713632_32" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,340</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713632_33" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> liabilities and shareholders' equity</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713633_34" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,167</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713633_35" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the interim consolidated financial statements.</span></span></div>
    </div>
  </div>
  <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
    <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 3</span></span></span></span></span></span></span></div>
  </div>
  <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
    </div>
  </div>

  <div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS<span id="COMPREHENSIVELOSS_integixAnchor"></span></span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730192631151_Fact_61" name="us-gaap:Revenues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730192631151_Fact_62" name="us-gaap:Revenues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730192632885_Fact_61" name="us-gaap:CostOfRevenue" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,654</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730192632885_Fact_62" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross profit</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730192634852_Fact_61" name="us-gaap:GrossProfit" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,607</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730192634852_Fact_62" name="us-gaap:GrossProfit" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_61" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,593</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_62" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,206</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_63" name="us-gaap:BusinessDevelopment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_64" name="us-gaap:BusinessDevelopment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_65" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_66" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,977</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_67" name="us-gaap:OperatingExpenses" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,511</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_68" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,348</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730192637254_Fact_61" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,904</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730192637254_Fact_62" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,348</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial income, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_69" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,528</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_70" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730192002297" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,376</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_72" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,651</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefit (expense)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719215810562_Fact_71" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719215810562_Fact_72" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_75" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_76" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive loss:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;Change in unrealized gains (losses) on marketable securities:</span></span></div>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; &#160;Unrealized gains (losses) arising during the period, net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230728034213148" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="-sec-ix-hidden:Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72">*</span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total comprehensive loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728030537018_Fact_75" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,415</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728030537018_Fact_76" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20220719220126329" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_77" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20220719220147427" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_78" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012025614" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_81" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,518,778</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012118943" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_82" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,903,741</ix:nonFraction></ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>* Represents an amount lower than $1.</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the interim consolidated financial statements.</span></span></div>
    </div>
  </div>
  <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
    <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 4</span></span></span></span></span></div>
  </div>
  <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span>
            <p style="margin:0pt">&#160;</p>
          </div>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY<span id="SHAREHOLDERSEQUITY_integixAnchor"></span></span></span>
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-family:'Times New Roman',serif;font-size:11pt;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Ordinary</span><span>&#160;<span style="font-weight:bold">shares</span></span></span></span></div>
              </td>
              <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;text-align:center">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">other</span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">comprehensive</span></span></div>
              </td>
              <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217;</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">income</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                <div style="line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">equity</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203355538" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727223132738_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_96" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,609,123</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223710614" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_98" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,150</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_99" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_xbrl_20220720105058426" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_Fact_126" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_xbrl_20220720105006668" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_Fact_127" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive income (loss) from marketable securities, net</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521">*</span></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;padding-bottom:2px;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105044504" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105025339" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730204146662" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_128" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_129" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;padding-bottom:4px;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of June 30, 2023 (unaudited)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_130" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">88,233,766</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_131" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_132" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">536,145</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730203500532">*</span></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823781_Fact_133" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,388</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_134" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,001</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2024</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203526337" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_114" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,744</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220727223630806">*</span></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_116" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203617529" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_xbrl_20220720104943489" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_117" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_96" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">292,728</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223710614" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_98" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203638338" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_99" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:28%;vertical-align:bottom;height:0px">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_126" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203654521" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_127" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive loss from marketable securities, net</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730203841073_xbrl_20240730203654521" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;padding-bottom:2px;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105044504" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105025339" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730203708038" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_128" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_129" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:28%;padding-bottom:4px;vertical-align:bottom">
                <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of June 30, 2024 (unaudited)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_130" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,531,937</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_131" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_132" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">542,032</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730204035595" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_133" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">483,917</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_134" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,340</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>* Represents an amount lower than $1.</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the interim consolidated financial statements.</span></span></div>
      </div>
    </div>
    <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 5</span></span></span></span></span></div>
    </div>
  </div>
  <div>
    <div>
      <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          <div style="text-align:right;line-height:1.25;font-weight:bold">&#160;</div>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="CASHFLOWS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM&#160;</span></span><span style="font-size:10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span>
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728044607285" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728044615653" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_137" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_138" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_139" name="us-gaap:Depreciation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">238</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_140" name="us-gaap:Depreciation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728052415879_Fact_139" name="cgen:AmortizationOfDiscountOnMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728052415879_Fact_140" name="cgen:AmortizationOfDiscountOnMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Realized gain on sale of marketable securities, net</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728052418474_Fact_139" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728052418474_Fact_140" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in severance pay, net</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111210380" name="cgen:SeverancePayNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111218731" name="cgen:SeverancePayNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences loss (gain) on cash balances</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010405127_xbrl_20240301111210380" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010405127_xbrl_20240301111218731" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">44</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease right of use asset</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_145" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">332</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_146" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">290</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in interest receivables and exchange differences on short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010448920_xbrl_20230214015508662" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">299</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010448920_Fact_0000000000236" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in trade receivables</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010456201_Fact_0000000000238" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">56,000</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010456201_Fact_0000000000239" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in other accounts receivable and prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010511242_Fact_0000000000241" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,267</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010511242_Fact_0000000000242" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in long-term prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728053037345" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">311</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_154" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719232044563" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,137</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728053025234" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">85</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in other accounts payable and accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010554260_xbrl_20230214015610319" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">293</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010554260_Fact_0000000000251" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">894</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease liability</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_159" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">386</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_160" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">394</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in deferred revenues</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010540990_xbrl_20240228013913681_xbrl_20230214015610319" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,261</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731010540990_xbrl_20240228013913681_Fact_0000000000251" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in deferred participation in R&amp;D expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_161" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_162" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) operating activities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_163" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,703</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_164" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,573</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_165" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,011</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_166" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,350</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_167" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,086</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_168" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,220</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of marketable securities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728052423298_Fact_139" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,825</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728052423298_Fact_140" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728052426602_Fact_139" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,000</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728052426602_Fact_140" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,536</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_169" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_170" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_173" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">42,287</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_174" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,531</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of ordinary shares, net</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_175" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_176" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of options</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_180" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_181" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">563</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_182" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effect of exchange rate changes on cash</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010623321_xbrl_20240301111408147" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240731010623321_xbrl_20240301111411299" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">44</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in cash, cash equivalents and restricted cash</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719232250681" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,033</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728053102843" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,265</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the beginning of the period</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_185" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,910</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_186" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the end of the period</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_187" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,877</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,686</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230728044639062" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230728044646863" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset obtained in exchange for operating lease liability</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230728052431875_Fact_139" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,064</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230728052431875_Fact_140" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230728052434971_Fact_139" name="cgen:IssuanceExpenses" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230728052434971_Fact_140" name="cgen:IssuanceExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the interim consolidated financial statements.</span></span></div>
          </div>
        </div>
        <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
          <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 6</span></span></span></span></span></div>
        </div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div>
          <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS<span id="FINANCIALSTATEMENTS_integixAnchor"></span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20240730183507230" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
        <div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL<br/>&#160;</span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. <span style="color:rgb(0, 0, 0)">The Company</span>&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from the Company&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trials. The Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced <span style="color:rgb(0, 0, 0)">early-stage </span>program, COM503, was licensed to Gilead Sciences, Inc. (&#8220;Gilead&#8221;) in December 2023, see also Note 12. COM503 is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#8217;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
              </tr>
              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $<ix:nonFraction id="Fxbrl_20230802202124242" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction> during the six months ended June 30, 2024, has an accumulated deficit of $<ix:nonFraction id="Fxbrl_20230802202128417" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">483,917</ix:nonFraction> as of June 30, 2024, and has an accumulated negative cash flow from operating activities in the amount of $<ix:nonFraction id="Fxbrl_20230802202134755" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,703</ix:nonFraction> for the six months ended June 30, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
                </tr>

            </table>
          </div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 7</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
              <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 1:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                      <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">GENERAL (Cont.)</span></span></span></div>
                      <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:exclude></div>
          <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $<ix:nonFraction id="FFact_193" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and additional aggregate milestone payments of approximately $<ix:nonFraction id="Fxbrl_20230728104443796" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,000</ix:nonFraction>. </span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902. Rilvegostomig entered the clinic in September 2021, initiated a Phase 3 with first patient dosing in the first indication Phase 3 study in December 2023, and first patient dosing in the second indication Phase 3 study in May 2024. Compugen received a $<ix:nonFraction id="Fxbrl_20230802201751108" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment and received or accrued $<ix:nonFraction id="Fxbrl_20230802201758034" name="cgen:AccruedMilestonePayment" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,500</ix:nonFraction> milestone payments out of up to $<ix:nonFraction id="Fxbrl_20230802201804474" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb Company (&#8220;Bristol Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></span></span></div>
                  <div>&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.<br/>&#160;<br/>In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="FFact_199" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20181010" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 7a.</span></span></span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220728112859416" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211110" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 7a.<br/>&#160;<br/>On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 8</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </div>
            </div>
            <div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
              <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 1:-</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">GENERAL (Cont.)</span></span></span></div>
                      </td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </div>
            </div>
          </ix:exclude></div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On December 18, 2023, the Company entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate (&#8220;COM503 License&#8221;), and additional products that may be so developed by Gilead (together with COM503, the &#8220;Licensed Products&#8221;).<br/>&#160;<br/>Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $<ix:nonFraction id="Fxbrl_20240730185336641" name="cgen:NonRefundableUpfrontPayment" contextRef="C_20240101to20240131" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">60</ix:nonFraction> million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company is eligible to receive from Gilead $<ix:nonFraction id="Fxbrl_20240730185916012" name="cgen:MilestonePaymentReceivable" contextRef="C_20240101to20240131" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">30</ix:nonFraction> million in the form of a milestone payment upon clearance of the IND for COM503, see also Note 12. The Company is also eligible to receive up to approximately $<ix:nonFraction id="Fxbrl_20240730190011813" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" contextRef="C_20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">758</ix:nonFraction> million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti- PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.<br/>&#160;<br/>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.<br/>&#160;<br/>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gilead withheld at source <ix:nonFraction id="Fxbrl_20240730190156394" name="cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid" contextRef="C_20240101to20240131" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin:0pt">&#160;</p>
        </div>
      </ix:nonNumeric>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 9</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </div>
  </div>

  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20240730190419712" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">
            <div style="line-height:1.25">
              <div style="text-align:justify;line-height:1.25">&#160;</div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="font-family:Times New Roman, Times, serif;width:16pt">&#160;</td>
                  <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:40pt">&#160;</td>
                  <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                    <div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, are applied consistently in these interim consolidated financial statements.</span></span></div>
                      <div style="line-height:1.25">&#160;</div>
                      <ix:nonNumeric id="Fxbrl_20240730190507632" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">
                        <div>
                          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently Accounting Pronouncements</span></span></div>
                          <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></div>
                          <div style="line-height:1.25">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></div>
                        </div>
                      </ix:nonNumeric>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
    </div>
  </div>
  <p style="margin:0pt">&#160;</p>

  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20240730190633689" name="cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock" contextRef="C_20240101to20240630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating results for the six-month period ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ended December 31, 2024.</span></span></div>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 10</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240730225731047" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">MARKETABLE SECURITIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following is a summary of available-for-sale marketable securities as of June 30, 2024 and December 31, 2023</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240730225623383" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_20240101to20240630" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amortized cost</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized gains</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized losses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728101843888" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,711</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728101901825" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728101905592" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728101909777" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,688</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_xbrl_20230728101843888" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,740</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_xbrl_20230728101901825" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_xbrl_20230728101905592">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730211801692_xbrl_20230728101909777" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2024 and </span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">December 31, </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023, and the length of time that those investments have been in a continuous loss position:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240730225639031" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" contextRef="C_20240101to20240630" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less than 12 months</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12 months or greater</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized loss</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Gross</span></span></strong></span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>unrealized loss</span></span></strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224851563" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,688</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224858104" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224900895" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224903439" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_xbrl_20240730224851563" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">992</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_xbrl_20240730224858104">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_xbrl_20240730224900895" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730224938615_xbrl_20240730224903439" name="cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company had no significant unrealized losses related to marketable securities (which were accumulated in a period of less than 12 months) and determined the unrealized losses are not due to credit related losses, therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, all of the Company&#8217;s available-for-sale marketable securities were due within one year.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no sales of marketable securities during the six-month periods ended June 30, 2024 and 2023, and accordingly no realized gains or losses were recorded.</span></span></div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 11</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240731003515663" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FAIR VALUE MEASUREMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <ix:nonNumeric id="Fxbrl_20240731003432350" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_20240101to20240630" escape="true">
          <div>
            <div>
              <div style="margin-left:63pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="3" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;text-indent:2pt">&#160;</div>
                      </td>
                      <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Short-term investments:</span></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. government bonds</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731003317319" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,688</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731003321695" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_20230630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
              <div>&#160;</div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
    </ix:nonNumeric>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240731004811654" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></span></span></div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $<ix:nonFraction id="Fxbrl_20230802221055283" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction> in favor of its offices and car leases in Israel.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="Fxbrl_20220720062450451" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="Fxbrl_20220720062556413" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of <ix:nonFraction id="Fxbrl_20220720062648820" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the six-month periods ended June 30, 2024 and 2023, the Company recorded royalties to the IIA as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ <ix:nonFraction id="Fxbrl_20240731004745902" name="us-gaap:PaymentsForRoyalties" contextRef="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction> and $ <ix:nonFraction id="Fxbrl_20240731004750701" name="us-gaap:PaymentsForRoyalties" contextRef="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $<ix:nonFraction id="Fxbrl_20220720062746091" name="cgen:RoyaltyContingentObligations" contextRef="C_20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,870</ix:nonFraction>.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2024 and 2023, the Company did not incur Contingent Fees.</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 12</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;width:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="vertical-align:top;text-align:justify;width:auto">
                  <div style="font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES </span><span>(Cont.)</span></span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On <ix:nonNumeric id="Fxbrl_20230802220955963" name="cgen:AgreementStartDate" contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to <ix:nonFraction id="Fxbrl_20240731004146118" name="cgen:ParticipationRights" contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions.<ix:nonNumeric id="Fxbrl_20240731004001019" name="cgen:AgreementTerminationDescription" contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</ix:nonNumeric></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the six months ended June 30, 2024 and 2023, the Company has not paid nor accrued any expenses related to the May 2012 Agreement.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div>Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="Fxbrl_20240805154741994" name="cgen:PercentageOfRoyaltiesOnNetSales" contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2024 and 2023, the Company did not incur milestone payments. We also entered into a CLA in February 2024 with the European cell line development company for COM503. Under the agreement the Company is required to pay an annual maintenance fee and certain amounts upon the occurrence of specified milestones events.</div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2024 and 2023 the Company did not incur milestone payments.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="FFact_289" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 7:-</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS' EQUITY</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>a.</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Issuance of Shares:</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of <ix:nonFraction id="FFact_223" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,316,457</ix:nonFraction> Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $<ix:nonFraction id="FFact_224" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.95</ix:nonFraction> per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction id="FFact_225" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">4,253,165</ix:nonFraction> additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants were exercisable at a price of $<ix:nonFraction id="FFact_226" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.74</ix:nonFraction> per Ordinary Share and had a term of <ix:nonNumeric id="FFact_227" name="cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $<ix:nonFraction id="FFact_228" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,767</ix:nonFraction> (net of $<ix:nonFraction id="FFact_229" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction> issuance expenses).</span></span></span></span></span></span></span></span></div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 13</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                </div>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 7:-</span></span></span></span></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></span></span></span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            </ix:exclude></div>
          </div>
        </div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20230728024501070" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,955,696</ix:nonFraction> Ordinary Shares were exercised with proceeds of approximately $<ix:nonFraction id="Fxbrl_20230728024514846" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,750</ix:nonFraction>, and the remaining warrants to purchase up to <ix:nonFraction id="Fxbrl_20230728024526061" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">297,469</ix:nonFraction> Ordinary Shares expired in June 2023.<br/>&#160;</span></span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="FFact_235" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased <ix:nonFraction id="FFact_236" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="FFact_237" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_238" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of the Company&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $<ix:nonFraction id="FFact_239" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $<ix:nonFraction id="FFact_240" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $<ix:nonFraction id="FFact_241" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220720034631668" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="Fxbrl_20220720034743180" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="Fxbrl_20220720034904580" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" scale="0" decimals="5" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fxbrl_20220720034949299" name="cgen:PercentageOfClosingPrice" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $<ix:nonFraction id="Fxbrl_20220720035100582" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $<ix:nonFraction id="Fxbrl_20220720035407188" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20220720035509163" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of <ix:nonFraction id="FFact_242" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,333,334</ix:nonFraction> of the Company&#8217;s ordinary shares at a price to the public of $<ix:nonFraction id="FFact_243" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">9.00</ix:nonFraction> per share (and a price of $<ix:nonFraction id="FFact_244" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction> per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional <ix:nonFraction id="FFact_245" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">483,005</ix:nonFraction> ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of <ix:nonFraction id="FFact_246" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,816,339</ix:nonFraction> ordinary shares in the offering with proceeds of $<ix:nonFraction id="FFact_247" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction> (net of $<ix:nonFraction id="FFact_248" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction> issuance expenses).</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 14</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                </div>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>NOTE 7:-</span></span></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            </ix:exclude></div>
          </div>
        </div>
      </div>
    </div>
    <div>
      <div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $<ix:nonFraction id="Fxbrl_20230728031246595" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of its ordinary shares. As of June 30, 2024, <ix:nonFraction id="Fxbrl_20230728031257218" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,905,550</ix:nonFraction> shares were issued and sold through the ATM, with proceeds of approximately $<ix:nonFraction id="Fxbrl_20230728031311578" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,643</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20230728031320267" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">530</ix:nonFraction> issuance expenses).</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share option plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions related to the grant of options to employees, directors and non-employees under the Company&#8217;s 2010 Share Option Plan, as amended, during the six-month period ended June 30, 2024, were as follows:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240730214959874" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20240101to20240630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate intrinsic</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214617051" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,373,745</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440322_Fact_0000000000541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.65</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240731023155518" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.61</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240731020116330" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440323_Fact_0000000000545" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">40,500</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440323_Fact_0000000000546" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">2.08</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000549" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,744</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">0.84</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">282,455</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.55</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">140,000</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000552" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">8.08</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000553" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,990,046</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.58</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240730214440324_Fact_0000000000555" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.19</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440324_Fact_0000000000556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,205</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440325_Fact_0000000000557" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,245,345</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440325_Fact_0000000000558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.68</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240730214440325_Fact_0000000000559" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">4.99</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214440325_Fact_0000000000560" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month period ended June 30, 2024, the Company&#8217;s Board of Directors granted <ix:nonFraction id="Fxbrl_20220720040533152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">40,500</ix:nonFraction> options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $<ix:nonFraction id="Fxbrl_20220720040558485" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.80</ix:nonFraction> to $<ix:nonFraction id="FFact_251" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">2.09</ix:nonFraction> per share, with vesting to occur in up to <ix:nonNumeric id="FFact_252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20240101to20240630" format="ixt-sec:durwordsen">four years</ix:nonNumeric>.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240730213706599" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20240101to20240630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222002683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">92.7</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222015231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">95.9</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222026940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">75.9</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222103489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.4</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222244528" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727233307366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727233317706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.3</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727235651276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727235701651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20240630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727235716123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220727235725275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240630" format="ixt-sec:duryear">4.02</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230728030223347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.0</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230728030231097" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">5.1</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 15</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">Weighted average fair value of options granted during the six-month periods ended June 30, 2024 and 2023 were $</span><span><ix:nonFraction id="FFact_267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.41</ix:nonFraction><span style="color:rgb(0, 0, 0)"> and $<ix:nonFraction id="FFact_268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20230630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">0.53</ix:nonFraction>, respectively.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2024 and 2023, the Company recorded share based compensation related to stock options in a total amount of $</span><span><ix:nonFraction id="FFact_269" name="us-gaap:StockOptionPlanExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction><span style="color:rgb(0, 0, 0)"> and $<ix:nonFraction id="FFact_270" name="us-gaap:StockOptionPlanExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction>, respectively.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">As of June 30, 2024, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $</span><span><ix:nonFraction id="FFact_271" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,405</ix:nonFraction><span style="color:rgb(0, 0, 0)"> which is expected to be recognized over a weighted average period of approximately</span><span style="font-weight:bold;color:rgb(0, 0, 0)">&#160;</span><ix:nonNumeric id="FFact_272" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20240101to20240630" format="ixt-sec:duryear">1.85</ix:nonNumeric><span style="color:rgb(0, 0, 0)"> years.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2024 and 2023, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="Fxbrl_20220720041818515" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,002,799</ix:nonFraction><span style="color:rgb(0, 0, 0)">&#160;</span>and <ix:nonFraction id="FFact_274" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,460,568</ix:nonFraction>, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240730215035617" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20240101to20240630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730214455558_Fact_0000000000578" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">805</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730214455558_Fact_0000000000579" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214455562_Fact_0000000000581" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240730214455562_Fact_0000000000582" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214455565_Fact_0000000000584" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">785</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730214455565_Fact_0000000000585" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">821</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730214502424_Fact_0000000000587" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240730214502424_Fact_0000000000588" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20240730195846781" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">FINANCIAL INCOME, NET</span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
          </div>
          <ix:nonNumeric id="Fxbrl_20220727231515518" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20240101to20240630" escape="true">
            <div>
              <div style="margin-left:90pt">
                <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                    <tr>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td rowspan="1" style="vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
                      </td>
                      <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_290" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,770</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_291" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,671</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730200046696_Fact_290" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730200046696_Fact_291" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220720002002984" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">38</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_293" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_294" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,528</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_295" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
    </div>
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 16</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20240731004145161" name="cgen:RevenueDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 9:-</span></span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">REVENUES</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
        </div>
      </div>
      <div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following represents the total revenue for the six-month periods ended June 30, 2024 and 2023 by region based on the invoicing address of customers<span style="font-weight:bold">:</span></span></span></span></div>&#160;<div style="margin-left:63pt">
        <ix:nonNumeric id="Fxbrl_20240731004159739" name="cgen:ScheduleOfRevenueTableTextBlock" contextRef="C_20240101to20240630" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2024</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unaudited</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue from sales to customers:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>United States</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240731004232764" name="us-gaap:Revenues" contextRef="C_20240101to20240630_srtStatementGeographicalAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,261</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240731004238489" name="us-gaap:Revenues" contextRef="C_20230101to20230630_srtStatementGeographicalAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Europe</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240731004255449_xbrl_20240731004232764" name="us-gaap:Revenues" contextRef="C_20240101to20240630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20240731004255449_xbrl_20240731004238489" name="us-gaap:Revenues" contextRef="C_20230101to20230630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Total revenues</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240731004257177_xbrl_20240731004232764" name="us-gaap:Revenues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240731004257177_xbrl_20240731004238489" name="us-gaap:Revenues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      <div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Contract Balances</span></span></span></div>
      <div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Of the $ <ix:nonFraction id="Fxbrl_20240731005201296" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,541</ix:nonFraction> of deferred revenue recorded as of December 31, 2023, the Company recognized $ <ix:nonFraction id="Fxbrl_20240731005208072" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,261</ix:nonFraction> as revenue during the six months ended June 30, 2024. The Company had no deferred revenues as of December 31, 2022.</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Remaining Performance Obligation</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#8217;s remaining performance obligations are comprised of revenue not yet delivered. As of June 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $<ix:nonFraction id="Fxbrl_20240731005233655" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,280</ix:nonFraction>, that the Company expects to recognize as revenue. As of June 30, 2024, the Company expects to recognize <ix:nonFraction id="Fxbrl_20240731005354782" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="C_20240630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">35</ix:nonFraction>% of its remaining performance obligations as revenue over the next 12 months.</span></span></span></div>
    </div>
  </ix:nonNumeric>
  <div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

      <div>
        <div>
          <ix:nonNumeric id="Fxbrl_20220727224715083" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
            <div>
              <div>
                <div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">
                        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                            <tr>
                              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></span></span></div>
                              </td>
                            </tr>

                        </table>
                        <div style="line-height:1.25">&#160;</div>
                      </div>
                    </div>
                  </div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balances with related parties:</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="margin-left:63pt">
                    <ix:nonNumeric id="Fxbrl_20240730193838627" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20240101to20240630" continuedAt="F20240730193845773" escape="true">
                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade and other payables (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_298" name="cgen:TradeAndOtherPayablesRelatedParties" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_299" name="cgen:TradeAndOtherPayablesRelatedParties" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </ix:nonNumeric>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <div><ix:exclude>
                    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 17</span></span></p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INTERIM</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                      </div>
                    </div>
                    <div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                                <tr style="margin-top:0pt;margin-bottom:0pt">
                                  <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 10:-</span></span></td>
                                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">
                                      <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">RELATED PARTY BALANCES AND TRANSACTIONS (Cont.)</span></span></div>
                                    </div>
                                  </td>
                                </tr>

                            </table>
                            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
                          </div>
                        </div>
                      </div>
                    </div>
                  </ix:exclude></div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related parties' expenses:</span></span></div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="margin-left:63pt">
                    <ix:continuation id="F20240730193845773">
                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_300" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_301" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    </ix:continuation>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:56.75pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                        <td style="width:28.3pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></td>
                        <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:footnote id="FN20220720121444312" xml:lang="en-US">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</ix:footnote></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>

  <ix:nonNumeric id="Fxbrl_20240730195318260" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="line-height:1.25">
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25">
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 11:-</span></span></td>
                          <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                            <div style="font-weight:bold">
                              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">LOSSES PER SHARE</span></span></span></div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share for the six-month periods ended June 30, 2024 and 2023:</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="margin-left:63pt">
            <ix:nonNumeric id="Fxbrl_20240730195348408" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20240630" escape="true">
              <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20240730141359513_1" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,390</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20240730141359513_2" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730195604484" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20240730141359513_3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,518,778</ix:nonFraction></ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240730195622412" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20240730141359513_4" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,903,741</ix:nonFraction></ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="F20240730141359514_12" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20240730141359514_7" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="F20240730141359514_13" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20240730141359514_8" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>

  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
    <ix:nonNumeric id="Fxbrl_20220728193545297" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div>
          <div>
            <div>
              <div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25">
                            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                                <tr>
                                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 12:-</span></span></span></td>
                                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                                    <div style="font-weight:bold">
                                      <div style="font-weight:bold">
                                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>SUBSEQUENT EVENTS</span></span></span></div>
                                      </div>
                                    </div>
                                  </td>
                                </tr>

                            </table>
                            <div style="line-height:1.25">&#160;</div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
                <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On July 29, 2024, the Company announced that the U.S. Food and Drug Administration has cleared the IND application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead. The IND clearance triggered a $<ix:nonFraction id="Fxbrl_20240731022746637" name="cgen:ClearanceTriggeredMilestonePayment" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,000</ix:nonFraction> milestone payment from Gilead which is expected in the third quarter of 2024.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On July 31, 2024, following recommendation of the compensation committee, the Company&#8217;s board of directors increased the total number of shares reserved for issuance under the Company&#8217;s 2010 Plan by <ix:nonFraction id="Fxbrl_20230728015337735" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_20240731_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">300,000</ix:nonFraction> and reduced the total number of shares reserved for issuance under the ESPP by <ix:nonFraction id="Fxbrl_20230728015343566" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_20240731_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">114,146</ix:nonFraction> to zero.</span></span></span></span></span></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <div style="text-align:justify;margin-left:56.9pt;line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:center;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F - 18</span></span></span></span></span></span>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;width:100%;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
  </div>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>exhibit_99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.3</font></u><br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FINANCIAL CONDITION</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RESULTS OF OPERATIONS</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Six months ended June 30, 2024 and 2023</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Revenues</font>. Revenues for the first six months of 2024 were approximately $9.3 million, compared with no revenues in the comparable
        period of 2023. The revenues for 2024 include the portion of the upfront payment from the license agreement with Gilead Sciences, Inc. (&#8220;Gilead&#8221;) allocated to the IND research and development activities and the clinical milestone from the license
        agreement with AstraZeneca in the amount of $5 million. </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Cost of Revenues</font>. Cost of revenues for the first six months of 2024 were approximately $3.7 million, compared with no cost of
        revenues in the comparable period of 2023.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Cost of revenues for the first six months of 2024 represents royalty payments in connection with our revenues and costs of the IND research and development activities.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Research and Development Expenses</font>. Research and development, or R&amp;D expenses decreased by approximately 17% to approximately
        $12.6 million for the first six months of 2024 from approximately $15.2 million for the comparable period of 2023. The decrease is mainly due to the classification of the IND research and development activities to cost of revenues and the
        classification of the set-up activities related to the COM503 Phase 1 clinical trial to prepaid expenses, offset by an increase in clinical trial expenses in the first six months of 2024. R&amp;D expenses, as a percentage of total operating
        expenses, decreased to 72% for the first six months of 2024 from 75% for the comparable period of 2023.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Marketing and Business Development Expenses</font>. Marketing and business development expenses amounted to approximately $0.2 million for
        the first six months of 2024 and 2023. Marketing and business development expenses, as a percentage of total operating expenses, were 1% for the first six months of 2024 and 2023.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">General and Administrative Expenses</font>. General and administrative expenses decreased by approximately 6% to approximately $4.7 million
        for the first six months of 2024 from approximately $5.0 million for the comparable period of 2023. The decrease is mainly due to a reduction in the cost of our D&amp;O insurance premium. General and administrative expenses, as a percentage of
        total operating expenses, increased to 27% for the first six months of 2024 from 24% for the comparable period of 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Financial and other Income, Net</font>. Financial and other income, net, were approximately $2.5 million for the first six months of 2024
        compared with approximately $1.7 million for the comparable period of 2023. The increase is mainly due to increased interest income due to a higher level of cash, deposit balances and marketable securities.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">LIQUIDITY AND CAPITAL RESOURCES</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Provided By (Used in) Operating Activities. </font>Net cash provided by operating activities was approximately $39.7 million in
        the first six months of 2024 compared with net cash used in operating activities of approximately $18.6 million in the comparable period of 2023. The higher net cash provided by operating activities during the first six months of 2024 is mainly due
        to the collection of the $61 million trade receivables during the first six months of 2024 from the upfront payment of Gilead pursuant to the license agreement therewith and milestone payment from AstraZeneca pursuant to the license agreement
        therewith.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Provided by (Used in) Investing Activities. </font>Net cash used in investing activities during the first six months of 2024 was
        approximately $42.3 million compared with net cash provided by investing activities of approximately $23.5 million in the comparable period of 2023. Changes in net cash provided by investing activities is mainly due to changes in the level of cash
        deposited or withdrawn from bank deposits and due to net investments in marketable securities. Net cash provided by (used in) investing activities is dependent on capital raising, cash needs to fund our operating activities and changes in the level
        of the Company&#8217;s cash and cash equivalents.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Provided by Financing Activities. </font>Net cash provided by financing activities was $0.6 million in the first six months of
        2024 compared with $1.4 million in the comparable period of 2023. The lower net cash provided in the first six months of 2024 is due to lower net proceeds received from sales of ordinary shares in the first six months of 2024 under the Company&#8217;s
        existing at the market offering facility pursuant to a sales agreement with Leerink Partners.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Liquidity. </font>Liquidity refers to liquid financial assets available to fund the Company&#8217;s business operations and pay for near-term
        obligations. These liquid financial assets mostly consist of cash and cash equivalents, as well as short-term bank deposits and investment in marketable securities. As of June 30, 2024, the Company had total cash, cash equivalents, restricted
        hort-term bank deposit, short-term bank deposits and investment in marketable securities of approximately $92.3 million.</div>
    </div>
    <div> <br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cgen-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20240630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" targetNamespace="http://cgen.com/20240630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap-ebp/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbs" id="cgen-cbs">
        <link:definition>0002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-socise1" id="cgen-socise1">
        <link:definition>0005 - Statement - INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap1" id="cgen-sap1">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements" id="UnauditedInterimConsolidatedFinancialStatements">
        <link:definition>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIES" id="MARKETABLESECURITIES">
        <link:definition>0010 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTS" id="FAIRVALUEMEASUREMENTS">
        <link:definition>0011 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac" id="cgen-cac">
        <link:definition>0012 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se1" id="cgen-se1">
        <link:definition>0013 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fin" id="cgen-fin">
        <link:definition>0014 - Disclosure - FINANCIAL INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Revenue" id="Revenue">
        <link:definition>0015 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0016 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lps" id="cgen-lps">
        <link:definition>0017 - Disclosure - LOSSES PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESTables" id="MARKETABLESECURITIESTables">
        <link:definition>0020 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables" id="FAIRVALUEMEASUREMENTSTables">
        <link:definition>0021 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set" id="cgen-set">
        <link:definition>0022 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fint" id="cgen-fint">
        <link:definition>0023 - Disclosure - FINANCIAL INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RevenueTables" id="RevenueTables">
        <link:definition>0024 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lpst" id="cgen-lpst">
        <link:definition>0026 - Disclosure - LOSSES PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd1" id="cgen-gd1">
        <link:definition>0027 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails" id="MARKETABLESECURITIESDetails">
        <link:definition>0028 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails" id="MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails">
        <link:definition>0029 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails" id="FAIRVALUEMEASUREMENTSDetails">
        <link:definition>0030 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails" id="ShareholdersEquityIssuanceOfSharesDetails">
        <link:definition>0032 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" id="ShareholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>0033 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails" id="ShareholdersEquityScheduleOfStock-basedCompensationDetails">
        <link:definition>0034 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesosced" id="cgen-sesosced">
        <link:definition>0035 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-find" id="cgen-find">
        <link:definition>0036 - Disclosure - FINANCIAL INCOME, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RevenueNarrativeDetails" id="RevenueNarrativeDetails">
        <link:definition>0037 - Disclosure - REVENUES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RevenueDetails" id="RevenueDetails">
        <link:definition>0038 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbatd" id="cgen-rpbatd">
        <link:definition>0039 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" id="LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
        <link:definition>0040 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails" id="SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>0041 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" id="cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AgreementMember" id="cgen_AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" id="cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" id="cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmortizationOfDiscountOnMarketableSecurities" id="cgen_AmortizationOfDiscountOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmountIncurredMilestonePayments" id="cgen_AmountIncurredMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtMarketOfferingProgramMember" id="cgen_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" id="cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClearanceTriggeredMilestonePayment" id="cgen_ClearanceTriggeredMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CollaborationAgreementWithUSAntibodyCompanyMember" id="cgen_CollaborationAgreementWithUSAntibodyCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialLicenseAgreementMember" id="cgen_CommercialLicenseAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBmsInRdExpenses" id="cgen_DeferredParticipationOfBmsInRdExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DevelopmentRegulatoryAndCommercialMilestonesCompensation" id="cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DocumentAndEntityInformationAbstract" id="cgen_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesDirectorsAndNonEmployeesMember" id="cgen_EmployeesDirectorsAndNonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeSharePurchasePlanMember" id="cgen_EmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GileadSciencesIncMember" id="cgen_GileadSciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsLineItems" id="cgen_GovernmentAndOtherGrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsMember" id="cgen_GovernmentAndOtherGrantsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsTable" id="cgen_GovernmentAndOtherGrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredRevenues" id="cgen_IncreaseDecreaseInDeferredRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceExpenses" id="cgen_IssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LongTermDeferredParticipationinResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentReceivable" id="cgen_MilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" id="cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonRefundableUpfrontPayment" id="cgen_NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfExpectedFromUpfrontPaymentAmountPaid" id="cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSales" id="cgen_PercentageOfRoyaltiesOnNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Plan2010Member" id="cgen_Plan2010Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseOfPropertyAndEquipmentAsNonCashTransaction" id="cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyBalancesAndTransactionsAbstract" id="cgen_RelatedPartyBalancesAndTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelativeFairValueOfDeferredParticipation" id="cgen_RelativeFairValueOfDeferredParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RevenueAbstract" id="cgen_RevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RevenueDisclosureTextBlock" id="cgen_RevenueDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RevenueLineItems" id="cgen_RevenueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RevenueTable" id="cgen_RevenueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAgreementWithLeerinkPartnerLlcMember" id="cgen_SalesAgreementWithLeerinkPartnerLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRevenueTableTextBlock" id="cgen_ScheduleOfRevenueTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNonCurrent" id="cgen_SeverancePayFundNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingLeaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TradeAndOtherPayablesRelatedParties" id="cgen_TradeAndOtherPayablesRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsAbstract" id="cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsTextBlock" id="cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cgen-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_9" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_9" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_9" xlink:to="loc_cgen_SeverancePayFundNonCurrent_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_18" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_21" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_StockholdersEquity_25" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_CommonStockValue_25" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_GrossProfit_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_2" xlink:to="loc_us-gaap_Revenues_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_2" xlink:to="loc_us-gaap_CostOfRevenue_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_OperatingExpenses_5" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_BusinessDevelopment_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_10" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11" order="100" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_15" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16" order="150" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_17" order="160" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_18" order="170" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_19" order="180" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_25" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_29" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3" order="20" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cgen-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#FAIRVALUEMEASUREMENTSDetails" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#RevenueDetails" roleURI="http://cgen.com/role/RevenueDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_May2012AgreementMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_CommercialLicenseAgreementMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_23" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_PaymentsForRoyalties_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ContingentFees_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ParticipationRights_34" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RetainerFee_35" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_36" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_37" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_38" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AmountIncurredMilestonePayments_39" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_52"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_cgen_RegisteredDirectOfferingMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_cgen_UnderwritersMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_WarrantMember_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" xlink:to="loc_us-gaap_EmployeeStockMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_39" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_41" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_42" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockOptionPlanExpense_45" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_46" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_49" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_51" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_52" order="310" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GileadSciencesIncMember" xlink:label="loc_cgen_GileadSciencesIncMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClearanceTriggeredMilestonePayment" xlink:label="loc_cgen_ClearanceTriggeredMilestonePayment_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_cgen_Plan2010Member_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_cgen_EmployeeSharePurchasePlanMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_10" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_10" xlink:to="loc_cgen_GileadSciencesIncMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_10" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cgen_ClearanceTriggeredMilestonePayment_16" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" xlink:to="loc_us-gaap_EmployeeStockMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_10" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_10" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/RevenueDetails">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueLineItems" xlink:label="loc_cgen_RevenueLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueTable" xlink:label="loc_cgen_RevenueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cgen_RevenueLineItems_0" xlink:to="loc_cgen_RevenueTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_RevenueTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_US_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_us-gaap_EuropeanUnionMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_RevenueLineItems_0" xlink:to="loc_us-gaap_Revenues_7" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cgen-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClearanceTriggeredMilestonePayment" xlink:label="loc_cgen_ClearanceTriggeredMilestonePayment_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClearanceTriggeredMilestonePayment" xlink:label="loc_cgen_ClearanceTriggeredMilestonePayment_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClearanceTriggeredMilestonePayment" xlink:label="loc_cgen_ClearanceTriggeredMilestonePayment_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GileadSciencesIncMember" xlink:label="loc_cgen_GileadSciencesIncMember_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GileadSciencesIncMember" xlink:label="loc_cgen_GileadSciencesIncMember_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_140"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_141"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_142"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_143"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_144"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_145"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_146"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_147"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_148"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_149"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_150"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_151"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_152"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_153"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_154"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_155"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_156"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_157"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_158"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_159"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_160"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_161"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_162"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_163"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueAbstract" xlink:label="loc_cgen_RevenueAbstract_164"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueDisclosureTextBlock" xlink:label="loc_cgen_RevenueDisclosureTextBlock_165"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueDisclosureTextBlock" xlink:label="loc_cgen_RevenueDisclosureTextBlock_166"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueDisclosureTextBlock" xlink:label="loc_cgen_RevenueDisclosureTextBlock_167"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueLineItems" xlink:label="loc_cgen_RevenueLineItems_168"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueLineItems" xlink:label="loc_cgen_RevenueLineItems_169"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueTable" xlink:label="loc_cgen_RevenueTable_170"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_171"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_172"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_173"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_174"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_175"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_176"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_177"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_178"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_179"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ScheduleOfRevenueTableTextBlock" xlink:label="loc_cgen_ScheduleOfRevenueTableTextBlock_180"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ScheduleOfRevenueTableTextBlock" xlink:label="loc_cgen_ScheduleOfRevenueTableTextBlock_181"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ScheduleOfRevenueTableTextBlock" xlink:label="loc_cgen_ScheduleOfRevenueTableTextBlock_182"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_183"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_184"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_185"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_186"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_187"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_188"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_189"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_190"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_191"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_192"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_193"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_194"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_195"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_196"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_197"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_198"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_199"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_200"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_201"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_202"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_203"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_204"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_205"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_206"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_207"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_208"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_209"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_210"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_211"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_212"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_213"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_214"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_215"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_667"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">Represents the amount of accrued milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AccruedMilestonePayment_2" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0" xml:lang="en-US">Adjustment For Exchange Rate Differences Loss Gain On Cash Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementMember_0" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementMember_1" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Start date of the agreement, in CCYY-MM-DD format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Agreement termination description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1" xml:lang="en-US">Increase in interest receivables and exchange differences on short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2" xml:lang="en-US">Increase in interest receivables and exchange differences on short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0" xml:lang="en-US">Amortization Of Discount And Accrued Interest On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1" xml:lang="en-US">Represent the amount of Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2" xml:lang="en-US">Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_0" xml:lang="en-US">Represent the amount of amortization of discount on marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_1" xml:lang="en-US">Amortization of discount on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_2" xml:lang="en-US">Amortization Of Discount On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmountIncurredMilestonePayments_0" xml:lang="en-US">Amount incurred milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmountIncurredMilestonePayments_1" xml:lang="en-US">Amount incurred milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AtMarketOfferingProgramMember_0" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AtMarketOfferingProgramMember_1" xml:lang="en-US">At Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AtMarketOfferingProgramMember_2" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_1" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_2" xml:lang="en-US">Available-for-Sale Securities, fair value, greater than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_1" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_2" xml:lang="en-US">Available-for-Sale Securities, gross unrealized losses, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_2" xml:lang="en-US">Available-for-Sale Securities, fair value, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_0" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_1" xml:lang="en-US">Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2" xml:lang="en-US">Available-for-Sale Securities, gross unrealized losses, less than 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClearanceTriggeredMilestonePayment_0" xml:lang="en-US">Clearance Triggered Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClearanceTriggeredMilestonePayment_1" xml:lang="en-US">Represents the amount of clearance triggered milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ClearanceTriggeredMilestonePayment_2" xml:lang="en-US">Clearance triggered mlestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CommercialLicenseAgreementMember_0" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CommercialLicenseAgreementMember_1" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0" xml:lang="en-US">Deferred participation of BMS in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1" xml:lang="en-US">Deferred Participation Of Bms In Rd Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0" xml:lang="en-US">Development, regulatory and commercial milestones compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1" xml:lang="en-US">Development, regulatory and commercial milestones compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0" xml:lang="en-US">Employees Directors And Non Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1" xml:lang="en-US">Information about the employees, directors and non-employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeeSharePurchasePlanMember_0" xml:lang="en-US">Information about the Employee Share Purchase Plan member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeeSharePurchasePlanMember_1" xml:lang="en-US">Employee Share Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">The aggregate of financial and other income net of expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_4" xml:lang="en-US">Financial income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GileadSciencesIncMember_0" xml:lang="en-US">Gilead Sciences, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GileadSciencesIncMember_1" xml:lang="en-US">This member is stand for Gilead Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsDomain_0" xml:lang="en-US">Government And Other Grants [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_0" xml:lang="en-US">Government And Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_1" xml:lang="en-US">Government and Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_0" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_1" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_0" xml:lang="en-US">Government And Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_1" xml:lang="en-US">Government and Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Decrease in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_0" xml:lang="en-US">Increase Decrease In Deferred Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_1" xml:lang="en-US">Represent the amount of deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_2" xml:lang="en-US">Decrease in deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Decrease in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceExpenses_0" xml:lang="en-US">Represent the amount of Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceExpenses_1" xml:lang="en-US">Issuance Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_IssuanceExpenses_2" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participationin Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum authorized proceeds from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">Information pertaining to the May 2012 Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MilestonePaymentReceivable_0" xml:lang="en-US">Milestone Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MilestonePaymentReceivable_1" xml:lang="en-US">Amount of milestone payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MilestonePaymentReceivable_2" xml:lang="en-US">Milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xml:lang="en-US">Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NonRefundableUpfrontPayment_0" xml:lang="en-US">Non Refundable Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NonRefundableUpfrontPayment_1" xml:lang="en-US">Amount of non-refundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NonRefundableUpfrontPayment_2" xml:lang="en-US">Non-refundable upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_0" xml:lang="en-US">Percentage Of Expected From Upfront Payment Amount Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_1" xml:lang="en-US">Percentage of expected from upfront payment amount paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_2" xml:lang="en-US">Percentage of expected from upfront payment amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_0" xml:lang="en-US">Percentage of royalties on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_1" xml:lang="en-US">Percentage of royalties on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_Plan2010Member_0" xml:lang="en-US">Information about the plan 2010 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_Plan2010Member_1" xml:lang="en-US">Plan 2010 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0" xml:lang="en-US">The amount of purchase property and equipment as non cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2" xml:lang="en-US">Purchase Of Property And Equipment As Non Cash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables On Account Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_2" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xml:lang="en-US">Related Party Balances And Transactions Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_0" xml:lang="en-US">Relative fair value of deferred participation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_1" xml:lang="en-US">Relative Fair Value Of Deferred Participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_2" xml:lang="en-US">Relative fair value of deferred participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0" xml:lang="en-US">Addition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Additional Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Represents Research and development grant one member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RevenueAbstract_0" xml:lang="en-US">Revenue [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RevenueDisclosureTextBlock_0" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RevenueDisclosureTextBlock_1" xml:lang="en-US">The entire disclosure for revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RevenueDisclosureTextBlock_2" xml:lang="en-US">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RevenueLineItems_0" xml:lang="en-US">Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RevenueLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RevenueTable_0" xml:lang="en-US">Revenue [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_0" xml:lang="en-US">Information about the Sales Agreement with Leerink Partner LLC member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_1" xml:lang="en-US">Sales Agreement With Leerink Partner Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_2" xml:lang="en-US">Sales Agreement With Leerink Partner LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfRevenueTableTextBlock_0" xml:lang="en-US">Schedule Of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfRevenueTableTextBlock_1" xml:lang="en-US">Tabular disclosure of  revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ScheduleOfRevenueTableTextBlock_2" xml:lang="en-US">Schedule of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNonCurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNonCurrent_1" xml:lang="en-US">Severance Pay Fund Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayFundNonCurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Increase in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0" xml:lang="en-US">Weighted average remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees And Directors Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0" xml:lang="en-US">Represent the Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1" xml:lang="en-US">Supplemental Right Of Use Asset And Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_0" xml:lang="en-US">Trade and other payables related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_1" xml:lang="en-US">Trade And Other Payables Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_2" xml:lang="en-US">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0" xml:lang="en-US">The entire disclosure of unaudited interim consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2" xml:lang="en-US">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_US_1" xml:lang="en-US">United States</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain_0" xml:lang="en-US">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_StatementGeographicalAxis_1" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated other comprehensive income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_0" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1" xml:lang="en-US">Assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1" xml:lang="en-US">Gross unrealized gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1" xml:lang="en-US">Gross unrealized losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1" xml:lang="en-US">Amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_1" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Ordinary shares, par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2024, and December 31, 2023; 89,531,937 and 89,237,465 shares issued and outstanding on June 30, 2024, and December 31, 2023, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_1" xml:lang="en-US">Governmental bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_2" xml:lang="en-US">U.S. government bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue_1" xml:lang="en-US">Cost of revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Related parties' expenses amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" xml:lang="en-US">Schedule of available-for-sale marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">LOSSES PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Period over which compensation expense will be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Unrecognized estimated compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0" xml:lang="en-US">Share based compensation ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EuropeanUnionMember_0" xml:lang="en-US">European Union [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EuropeanUnionMember_1" xml:lang="en-US">Europe</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" xml:lang="en-US">Schedule of fair value measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_0" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0" xml:lang="en-US">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_0" xml:lang="en-US">Gain Contingencies, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis_0" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_1" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">TAXES ON INCOME [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Tax benefit (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Tax benefit (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase in other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Decrease in other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Increase in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1" xml:lang="en-US">Decrease in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Increase in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0" xml:lang="en-US">Increase in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0" xml:lang="en-US">Schedule of Financial And Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0" xml:lang="en-US">Investment Income, Amortization of Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1" xml:lang="en-US">Amortization of discount on marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_1" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_2" xml:lang="en-US">Interest Income, Deposits with Financial Institutions, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_0" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" xml:lang="en-US">MARKETABLE SECURITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_0" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1" xml:lang="en-US">Investments in marketable securities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_0" xml:lang="en-US">Realized gain on sale of marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_5" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_6" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right to use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">GENERAL [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xml:lang="en-US">Other comprehensive loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_1" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2" xml:lang="en-US">FINANCIAL INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1" xml:lang="en-US">Exchange rate differences and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRoyalties_0" xml:lang="en-US">Payments for Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRoyalties_1" xml:lang="en-US">Royalties paid to the IIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from Maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" xml:lang="en-US">Proceeds from Maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1" xml:lang="en-US">Proceeds from equity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyLeaseGuaranteeMember_0" xml:lang="en-US">Office leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_0" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_1" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent_0" xml:lang="en-US">Restricted Investments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent_1" xml:lang="en-US">Restricted short-term bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0" xml:lang="en-US">Percentage of workforce reduction from restructuring activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_1" xml:lang="en-US">Remaining performance obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_1" xml:lang="en-US">Remaining performance obligations percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenue from sales to customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues_2" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of computation of basic and diluted losses per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Schedule Of Option Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_1" xml:lang="en-US">Schedule of gross unrealized losses and fair values on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2" xml:lang="en-US">Schedule of unrealized loss on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_0" xml:lang="en-US">Marketing and business development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_0" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Expected risk free interest rates range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Expected risk free interest rate range, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Expected risk free interest rates range, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance | shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of options granted during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1" xml:lang="en-US">Number of shares purchased for ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_0" xml:lang="en-US">Short-Term Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_1" xml:lang="en-US">Short-term investments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1" xml:lang="en-US">Issuance of ESPP shares, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of shares, net, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Ordinary shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1" xml:lang="en-US">Issuance of ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Value of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense_0" xml:lang="en-US">Share based compensation stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplyCommitmentAxis_0" xml:lang="en-US">Supply Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_1" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_2" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_3" xlink:to="lab_cgen_AccruedMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_6" xlink:to="lab_cgen_AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_7" xlink:to="lab_cgen_AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_8" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_9" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_10" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_11" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_12" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_13" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_14" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_15" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_16" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_17" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_18" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_19" xlink:to="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_20" xlink:to="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_21" xlink:to="lab_cgen_AmortizationOfDiscountOnMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_22" xlink:to="lab_cgen_AmountIncurredMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_23" xlink:to="lab_cgen_AmountIncurredMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_24" xlink:to="lab_cgen_AtMarketOfferingProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_25" xlink:to="lab_cgen_AtMarketOfferingProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_26" xlink:to="lab_cgen_AtMarketOfferingProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_27" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_28" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_29" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_30" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_31" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_32" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_33" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_34" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_35" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_36" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_37" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_38" xlink:to="lab_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_39" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_40" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_41" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClearanceTriggeredMilestonePayment_42" xlink:to="lab_cgen_ClearanceTriggeredMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClearanceTriggeredMilestonePayment_43" xlink:to="lab_cgen_ClearanceTriggeredMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClearanceTriggeredMilestonePayment_44" xlink:to="lab_cgen_ClearanceTriggeredMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_45" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_46" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_47" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_48" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_49" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_50" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_51" xlink:to="lab_cgen_CommercialLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_52" xlink:to="lab_cgen_CommercialLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_53" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_54" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_55" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_56" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_57" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_58" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_59" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_60" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_61" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_62" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_63" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_64" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeSharePurchasePlanMember_65" xlink:to="lab_cgen_EmployeeSharePurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeSharePurchasePlanMember_66" xlink:to="lab_cgen_EmployeeSharePurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_67" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_68" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_69" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_70" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_71" xlink:to="lab_cgen_FinancialIncomeExpenseNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GileadSciencesIncMember_72" xlink:to="lab_cgen_GileadSciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GileadSciencesIncMember_73" xlink:to="lab_cgen_GileadSciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_74" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_75" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_76" xlink:to="lab_cgen_GovernmentAndOtherGrantsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_77" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_78" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_79" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_80" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_81" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_82" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_83" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_84" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_85" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_86" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_87" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_88" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_89" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_90" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_91" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_92" xlink:to="lab_cgen_IssuanceExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_93" xlink:to="lab_cgen_IssuanceExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_94" xlink:to="lab_cgen_IssuanceExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_95" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_96" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_97" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_98" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_99" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_100" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_101" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_102" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_103" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_104" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_105" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_106" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_107" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_108" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_109" xlink:to="lab_cgen_MilestonePaymentReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_110" xlink:to="lab_cgen_MilestonePaymentReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_111" xlink:to="lab_cgen_MilestonePaymentReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_112" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_113" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_114" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_115" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_116" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_117" xlink:to="lab_cgen_NonRefundableUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_118" xlink:to="lab_cgen_NonRefundableUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_119" xlink:to="lab_cgen_NonRefundableUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_120" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_121" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_122" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_123" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_124" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_125" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_126" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_127" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_128" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_129" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_130" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_131" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_Plan2010Member_132" xlink:to="lab_cgen_Plan2010Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_Plan2010Member_133" xlink:to="lab_cgen_Plan2010Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_134" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_135" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_136" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_137" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_138" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_139" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_140" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_141" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_142" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_143" xlink:to="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_144" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_145" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_146" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_147" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_148" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_149" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_150" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_151" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_152" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_153" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_154" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_155" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_156" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_157" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_158" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_159" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_160" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_161" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_162" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_163" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueAbstract_164" xlink:to="lab_cgen_RevenueAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueDisclosureTextBlock_165" xlink:to="lab_cgen_RevenueDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueDisclosureTextBlock_166" xlink:to="lab_cgen_RevenueDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueDisclosureTextBlock_167" xlink:to="lab_cgen_RevenueDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueLineItems_168" xlink:to="lab_cgen_RevenueLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueLineItems_169" xlink:to="lab_cgen_RevenueLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RevenueTable_170" xlink:to="lab_cgen_RevenueTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_171" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_172" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_173" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_174" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_175" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_176" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_177" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_178" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_179" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfRevenueTableTextBlock_180" xlink:to="lab_cgen_ScheduleOfRevenueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfRevenueTableTextBlock_181" xlink:to="lab_cgen_ScheduleOfRevenueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfRevenueTableTextBlock_182" xlink:to="lab_cgen_ScheduleOfRevenueTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_183" xlink:to="lab_cgen_SeverancePayFundNonCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_184" xlink:to="lab_cgen_SeverancePayFundNonCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_185" xlink:to="lab_cgen_SeverancePayFundNonCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_186" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_187" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_188" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_189" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_190" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_191" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_192" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_193" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_194" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_195" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_196" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_197" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_198" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_199" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_200" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_201" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_202" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_203" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_204" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_205" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_206" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_207" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_208" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_209" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_210" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_211" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_212" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_213" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_214" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_215" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_216" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_217" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_218" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_219" xlink:to="lab_country_US_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_220" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_221" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_222" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_223" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_224" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_225" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_226" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_227" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_228" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_229" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_230" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_231" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_232" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_233" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_234" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_235" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_236" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_237" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_238" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_239" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_240" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_241" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_242" xlink:to="lab_srt_SegmentGeographicalDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_243" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_244" xlink:to="lab_srt_StatementGeographicalAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_245" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_246" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_247" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_248" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_249" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_250" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_251" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_252" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_253" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_254" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_255" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_256" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_257" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_258" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_259" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_260" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_261" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_262" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_263" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_264" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_265" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_266" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_267" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_268" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_269" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_270" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_271" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_272" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_273" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_274" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_275" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_276" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_277" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_278" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_279" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_280" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_281" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_282" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_283" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_284" xlink:to="lab_us-gaap_BusinessDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_285" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_286" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_287" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_288" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_289" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_290" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_291" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_292" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_293" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_294" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_295" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_296" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_297" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_298" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_299" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_300" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_301" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_302" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_303" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_304" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_305" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_306" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_307" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_308" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_309" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_310" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_311" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_312" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_313" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_314" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_315" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_316" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_317" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_318" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_319" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_320" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_321" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_322" xlink:to="lab_us-gaap_CostOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_323" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_324" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_325" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_326" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_327" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_328" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_329" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_330" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_331" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_332" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_333" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_334" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_335" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_336" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_337" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_338" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_339" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_340" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_341" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_342" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_343" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_344" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_345" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_346" xlink:to="lab_us-gaap_EuropeanUnionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_347" xlink:to="lab_us-gaap_EuropeanUnionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_348" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_349" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_350" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_351" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_352" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_353" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_354" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_355" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_356" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_357" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_358" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_359" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_360" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_361" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_362" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_363" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_364" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_365" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_366" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_367" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_368" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_369" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_370" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_371" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_372" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_373" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_374" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_375" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_376" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_377" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_378" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_379" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_380" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_381" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_382" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_383" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_384" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_385" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_386" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_387" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_388" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_389" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_390" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_391" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_392" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_393" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_394" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_395" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_396" xlink:to="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_397" xlink:to="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_398" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_399" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_400" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_401" xlink:to="lab_us-gaap_InvestmentIncomeInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_402" xlink:to="lab_us-gaap_InvestmentIncomeInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_403" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_404" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_405" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_406" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_407" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_408" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_409" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_410" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_412" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_413" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_414" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_415" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_416" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_417" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_418" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_419" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_420" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_421" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_422" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_423" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_424" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_425" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_426" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_427" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_428" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_429" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_430" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_431" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_433" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_434" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_435" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_436" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_437" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_438" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_439" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_440" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_441" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_442" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_443" xlink:to="lab_us-gaap_NetIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_444" xlink:to="lab_us-gaap_NetIncomeLoss_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_445" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_446" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_447" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_448" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_449" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_450" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_451" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_452" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_453" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_454" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_455" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_456" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_457" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_458" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_459" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_460" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_461" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_462" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_463" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_464" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_465" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_466" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_467" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_468" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_469" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_470" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_471" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_472" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_473" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_474" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_475" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_476" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_477" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties_478" xlink:to="lab_us-gaap_PaymentsForRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties_479" xlink:to="lab_us-gaap_PaymentsForRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_480" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_481" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_482" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_483" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_484" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_485" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_486" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_487" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_488" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_489" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_490" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_491" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_492" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_493" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_494" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_495" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_496" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_497" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_498" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_499" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_500" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_501" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_502" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_503" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_504" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_505" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_506" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_507" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_508" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_509" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_510" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_511" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_512" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_513" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_514" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyLeaseGuaranteeMember_515" xlink:to="lab_us-gaap_PropertyLeaseGuaranteeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_516" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_517" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_518" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_519" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_520" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_521" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_522" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_523" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_524" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_525" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_526" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_527" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_529" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsCurrent_530" xlink:to="lab_us-gaap_RestrictedInvestmentsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsCurrent_531" xlink:to="lab_us-gaap_RestrictedInvestmentsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_532" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_533" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_534" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_535" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_536" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_537" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_538" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_539" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_540" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_541" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_542" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_543" xlink:to="lab_us-gaap_Revenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_544" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_546" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_547" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_548" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_549" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_550" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_551" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_552" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_553" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_554" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_555" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_556" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_557" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_558" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_559" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_560" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_561" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_562" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_563" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_564" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_565" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_566" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_567" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_568" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_569" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_570" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_574" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_577" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_578" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_579" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_580" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_581" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_584" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_585" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_586" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_587" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_588" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_589" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_590" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_593" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_594" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_596" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_597" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_598" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_599" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_600" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_601" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_602" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_603" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_604" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_605" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_607" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_609" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_610" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_611" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_612" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_613" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_614" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_615" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_616" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_617" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_618" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_619" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_620" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_621" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_622" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_623" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_624" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_625" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_626" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_627" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_628" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_629" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_630" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_631" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_632" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_633" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_634" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_636" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_637" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_639" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_640" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_641" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_642" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_643" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_644" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_645" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_646" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_647" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_648" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_649" xlink:to="lab_us-gaap_StockOptionPlanExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_650" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_651" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_652" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_653" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_654" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_655" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_656" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_657" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_658" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis_659" xlink:to="lab_us-gaap_SupplyCommitmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_660" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_661" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_662" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_664" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_665" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_666" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_667" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cgen-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-sap1" roleURI="http://cgen.com/role/cgen-sap1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#UnauditedInterimConsolidatedFinancialStatements" roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-cac" roleURI="http://cgen.com/role/cgen-cac"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-se1" roleURI="http://cgen.com/role/cgen-se1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-fin" roleURI="http://cgen.com/role/cgen-fin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-fint" roleURI="http://cgen.com/role/cgen-fint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-gd1" roleURI="http://cgen.com/role/cgen-gd1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-rpbatd" roleURI="http://cgen.com/role/cgen-rpbatd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#MARKETABLESECURITIES" roleURI="http://cgen.com/role/MARKETABLESECURITIES"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#MARKETABLESECURITIESTables" roleURI="http://cgen.com/role/MARKETABLESECURITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-lps" roleURI="http://cgen.com/role/cgen-lps"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-lpst" roleURI="http://cgen.com/role/cgen-lpst"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#Revenue" roleURI="http://cgen.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#RevenueTables" roleURI="http://cgen.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#RevenueNarrativeDetails" roleURI="http://cgen.com/role/RevenueNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#FAIRVALUEMEASUREMENTSDetails" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#FAIRVALUEMEASUREMENTSTables" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#FAIRVALUEMEASUREMENTS" roleURI="http://cgen.com/role/FAIRVALUEMEASUREMENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20240630.xsd#RevenueDetails" roleURI="http://cgen.com/role/RevenueDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine3_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_16" order="150" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_10" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_10" xlink:to="loc_cgen_SeverancePayFundNonCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_10" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_10" xlink:to="loc_us-gaap_AssetsNoncurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableCurrent_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_20" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_22" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrent_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_25" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_31" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_CommonStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_14" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_20" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_NumberOfWarrantsExercised_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfDiscountOnMarketableSecurities_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_17" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_18" order="160" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_19" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_31" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_32" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" xlink:to="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" xlink:to="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" xlink:to="loc_cgen_IssuanceExpenses_41" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xlink:to="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_AccruedMilestonePayment_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_NonRefundableUpfrontPayment_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_MilestonePaymentReceivable_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_13" order="120" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_14" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_14" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_May2012AgreementMember_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_CommercialLicenseAgreementMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_18" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_18" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_18" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsLineItems_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_PaymentsForRoyalties_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyContingentObligations_25" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ContingentFees_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ParticipationRights_27" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RetainerFee_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementStartDate_29" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementTerminationDescription_30" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_31" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AmountIncurredMilestonePayments_32" order="110" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_us-gaap_EmployeeStockMember_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_18" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_22" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_28" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_PercentageOfClosingPrice_29" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockOptionPlanExpense_41" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_42" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_44" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_45" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_46" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_47" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_EmployeeStockMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbatd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cgen_TradeAndOtherPayablesRelatedParties_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_GileadSciencesIncMember" xlink:label="loc_cgen_GileadSciencesIncMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ClearanceTriggeredMilestonePayment" xlink:label="loc_cgen_ClearanceTriggeredMilestonePayment_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4" xlink:to="loc_us-gaap_PlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_cgen_Plan2010Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_cgen_EmployeeSharePurchasePlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_8" xlink:to="loc_cgen_GileadSciencesIncMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11" xlink:to="loc_cgen_ClearanceTriggeredMilestonePayment_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lps">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lpst">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareBasic_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Revenue">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueAbstract" xlink:label="loc_cgen_RevenueAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueDisclosureTextBlock" xlink:label="loc_cgen_RevenueDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_cgen_RevenueDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RevenueTables">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueAbstract" xlink:label="loc_cgen_RevenueAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_ScheduleOfRevenueTableTextBlock" xlink:label="loc_cgen_ScheduleOfRevenueTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_cgen_ScheduleOfRevenueTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RevenueNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueAbstract" xlink:label="loc_cgen_RevenueAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses" xlink:label="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_7" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTSTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FAIRVALUEMEASUREMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RevenueDetails">
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueAbstract" xlink:label="loc_cgen_RevenueAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueTable" xlink:label="loc_cgen_RevenueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20240630.xsd#cgen_RevenueLineItems" xlink:label="loc_cgen_RevenueLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueAbstract_0" xlink:to="loc_cgen_RevenueTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_US_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_us-gaap_EuropeanUnionMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueTable_1" xlink:to="loc_cgen_RevenueLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RevenueLineItems_5" xlink:to="loc_us-gaap_Revenues_5" order="0" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0T!WX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(;<0YSA?NW'^L/\ #_K.OMU]A0__  7E^,0V[8<Y&/NW/W_[O^L_,=?84_\
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M9:R@HK7"@J1F0=%''8?C7]YDG_!&;X1/,\P6)=[EMH\G&#_#C9P/IQ[4T?\
M!&7X2J6QY8W-D_ZCIUQ_JQ]*_=,9XR9-6H>RIPES2A"#E[-+E44KV_Q/5^G1
MW9^&T/!?/H59U)NFE*6D54Z)+E^?1[VUNWNOX+&\">(-S@6<N/LQ<?NVYE_N
MCCK_ +-5_P#A"M<_Y]).+?GY'_UW]SIU]J_O7_X<R?"-2,^4?GW=(>@[<(?S
MJF?^"+/PAR2?+^:Y\[K">>P_U?2L5XSY;R4H>RD_9QC#F]GK)1Y$K^=E_GJC
MRGX!YU*527UGEO/FM[31*3;MNMM.FSL?P;CP;K>PQFT?'D;Q\C_Z_P#N=/T_
M6GQ>#=:&U#:N (O,^X^?/Z;.GK_#WZ5_>(?^"+'PA'4I_P ?/G]8>OI_J^GM
M0?\ @BQ\(1U*?\?!GZP_B/\ 5_=]JT7C5ER4%[*5E=?!NVDE]U_^&MH?\0#S
MM._UK;EC_$^S=.V[^_\ '<_@Y_X1#69Y(HFM9 5(8?NV^^. N.#^'IWI!X+U
M@SF$V\F?-W\(W^LZ;.N?PZ_2O[PQ_P $5/A"MP)\IGS1)U@/X8\OIZ?RS2G_
M ((J_"$7/V@E,^=Y@_U'Y8V?C_3-4O&K+5R)4YV4)6]Q:S;6CTOI?^M#V8^"
MV<**3J0NFIOW_2\'>^C=[?\  /X.QX+U@SF$V\F?-W\(W^LZ;.N?PZ_2E7P7
MK'VCRC;29$WF8\LG]X#]SD_IR?I7]X9_X(J_"$7/V@E,^=Y@_P!1^6-GX_TS
M0?\ @BK\(1<_:"4SYWF#_4?EC9^/],TEXU9;:*=.37LY)W@O>G))6=ETOT_R
M*7@QG"=U4@FIJHGS[;>YMIY7_0_A,T_POK5_O2XLF5M%U ZE%\C#+6^-JDGG
M&>W&?6H9?"6N6NJW6O1V\SC687LR"&*K-.=P10.AQC ]LU_=VG_!%GX1QW%U
M("@%S$ZMCR/XSD\!,?7/7Z\5')_P18^$)L;:UW1_Z-?K?*?W.<H,!<^6..X%
M1AO&;+L/-2A2;2L^50T[Z^N[\S/$^#6<5XZU%'E;4O?LW"UY6757_'3R7\)R
M^#=7Q)"UO+^[MVE^Z3^]'\/U!SQ^M(GA'5Y(6@:&3Y8/M .#GS<?=]/3C/!_
M&O[M!_P17^$<C22;T'F.6(S">N,C[G SVIO_  Y1^$6=WF)G/_3'&WTQL_R*
M]"I](/EY84J;Y$XJ47?X8J*5N[C9Z?=J<%/Z/$ZD*,ZE52:7,]5JV[QO?^5-
M]-S^$RU\&ZP6&;>7:80X^5C^^[)P <^PJ=/ ^L3$P2P2A6)=_E88<<[>1V/\
MZ_NPC_X(L_"*,(-R92X\T',(Z<8SY0XJ9O\ @B]\(R)6#1@NY?/[GC)_ZYDC
M/3MGOTYYX>.&!]O[25*;YW&4ERO1IIQ=M=F_PWTT[L!X&8RC1Q&'G5A&+3]E
M44DY7@[PNO-/7R/X0_\ A!/$<,;3"SF,=X=TF8V(4VW,?YD#ZYQSV_3_ /X(
MK^$_$U__ ,%(/@SXHU*PDCM;(ZZDSM%(JH/[+>)#DC'S<=N?3K7]0;_\$<OA
M*8H[4B/8,AF_<_AU0X'X?A7OG[./_!-OX;_L\^/],^(>A+#]NTTR^4ZB'(,L
M?EDAE4$9![=,5XO&OB[@LXRK$8.@FE6P\Z<JLTXV52"A.[>FBU6WPKU->!?!
MO,,LXACC\7.*I0K0;C&2<DJ=2$XRBK:WNH2]+'ZAH,(H'0 ?RIU1Q'*#V 'X
M=C^525_-\)JI"-2-^6<5)7WLU?7S[^9_5-N7W?Y=%Z+1!1115 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4A. 2>@&?RI:1ONMGI@Y_*@"D+BVVQN#_K'V ^I
MST)Z'GM5EPHQDX^;(_SQ_7Z&J<$-O-#'L *QR%EP>C ]?\C\>M6VYDP>@&['
MX?Y_SC"A3@FFHI6[;Z*RMW>RUW(JR?+;?FE&-I;:M;Z[*U_5(FHIH<$9]\=O
MS^E*3C&>YJK/L_N*4DU=--=_781E#8SV.:4C=CV/^12T47?W.X<J=]-[7\[;
M?<-90V,]CFAE#8SV.:=11=_<[@XIWNOBM?SMM]PA&['L?\B@C=CV/^12T47?
MW.X<J=]-[7\[;"$;L>Q_R*"-V/8_Y%+11=_<[ARIWTWM?SML>&_'+]H3X=?L
M^:#I_B'XB:A+8Z?JFI1Z5:M (7=KJ92R*5EFB&-H/()/&,5\P7'_  4R_9?M
M=K2^(KX(0%&(K(\Y]#?#M7XO?\'&?QEUCP[:?#KX?Z5>202?VGI?B$QQRF-M
MN)(BQ (XR._'UYQ_*C)\8/'>JW_V<:C>&%$V?\?#_P"M!ZGYNW^>M?N' _AC
ME_$>78;&8O&5J,\1'VCA3DE:+?NV33U:3\N_E^ <;>*6:9#FV,P.$PN&J0PE
M?V2E4C*4FDXW3M)+UZ^1_HE0_P#!3[]EAOE3Q'J!);&/)LQS_P"!W\O7I3W_
M ."H'[+*-L;Q%J&=VWB&S//_ (&U_G8'XH^-[=R%U"[W)+Y9/VB3[X_X%^5)
M+\4O&\H,G]H7FYI/+4>?(?WA[G#<?YXSU^K_ .((Y2Z[A]>Q3C=6]^+E)-[J
MRM;EW[/R/DGX\9S2I*<\!@XKDW]G-1Y[WY5[W5;7ZVMH?Z* _P""G'[+;G(\
M1:@?F_YXV7!Z?\_WX9Z?C35_X*=_LM,KX\1W^%;:?W-F>1D<8ON?\]:_SN/^
M%L>.(59CJ%X56/RSBY?'G#/^V?\ ]7:HXOBMXUVB0:A>&-@3)_I#C]X?^!GO
MW_E6;\%<K4DOK^(M*24/?BK)-/WKQT;T^=^ECU*?C7BI4/:.A@E4E!-1:E;G
ME%-Q>M[VLO7TN?Z(TW_!3/\ 9<2.YG;Q%?B*+9YC"*RS\W3'^FC/OSQ_+T?X
M5?MO_ ;XU^)M)\"^"=;O+O6-7\YK2.6.U57^SIYK@F.ZD/ !/"\=_4_YO47Q
M8\;OI]Y!/J%Z"-OG_P"D29P3^[Z,.1P,C\>*_5#_ ((J?%C7[W]OWX)>&M4O
MKB2*Z_X2(21O,[@A--D9<JS=.A&>_OQ7A<6>%6497D^+Q%#%XBO.E@ZE9TYS
MBXU+1CRK1)ZJ[T=[6=DSVN$_%2OFN:4J,Z6&I^VQ-*$:M)-.%.K6A?=VLG=M
M_):61_H"18VC'T_+_/\ GO)4%NZR1*Z_=))'^>:GK\#C35)*FE91TUWT[^;/
MWRG/VE.%2ZESPC*ZV?,D[KR[!1113+"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_'EK_K\8].N/_P!5'_#F3XS>7Y7]AS[/)WX\M?\ 7XQZ=<?_ *J_O(^Q6?\
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MW<?\?:?E]/UH_P"%E^"?^AGT?[N/^/M/R^GZT_JF(_Y]3_\  9?Y"_M/!_\
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M9_&OQV4HQ=I22:W7W_Y/[F?N*UV_+^NZ%HHHJ@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4$X!/I110"\]C&GU.*$VYQN:XF$.,#(R<9(_/G\^O/ >/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5726+>Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"O$YF$H(QMD9!U[8Y'H/3TI)9##Y2
M@%MSJI/U/4^OO2S%H_+\L?>E4/@?PGJ?P_*I67)4XS@@=,_C43E)15M;3CS:
M=-.:WRL:<L%-57'22<4K]K+6^EKZW_$?133C)SUV_IZT8'O]W'X>OUIMSO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY_X]4Z>O_P!;I[4O_"$>$?\ H7M*Y_Z=4_S^5<S\9,[FW&-.*<9)MJ;ZV?\
M6^MM2JG@ED%7E]I7G+EC*$;QV4E9V5_3H?YR!_X)J_M QVU[<KX,U8RQ20&,
M?8+H[@[C?P%)^4?YS6_J?_!.K]H&&"Y$/@K5&\];7=C3[@_=V[N=G4'/^-?Z
M(:^#?"QFN8SX;TORU*;?]%3#>O48X-6'\%>%"3GP[I9X''V:/^OIUQ^%<E7Q
M5X@KN,N=Q<4TGSO^9/\ 6*7DC7#>#G#F YN3F=]_W?\ ,[K7;3EM9;::7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT<G_ ."PO[4[7ET_]O78@-R[P#S(O]2<E<>OMWSV[42_\%?OVJ870OKMWMD
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MFWL?LN@ 4 ?6G5'%()$#KR#D#\#BI*_E&]]>^I_8UG'W;6Y=+6M:VFP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%,O@&YA"ZU9GS?,Q^^(_U?7O50?&347%YG92O&W/\=HR=K=;17W>@O8<#_\
M/O*>VU/NE^;5O0YZX_X)C?L_B\M@=$M/]&W^7^Y;'S@9[?T^GI7W3\'?A3X;
M^#G@O3O WA:!+?2=,$OD11KM5?/<R/@$=V)^G'T'R7H7_!0/X)>+M8TW2]+U
M:UEO-0G$$")*Q8N75,8)Y/(].U??UG*EQ:PSQG/GPPS*?5945U]".&]NW>O-
MS?'9O6I4Z>95L5-QC_"KMMWBXIM)]VEY:'1D67970Q>(GE]#"QA[9U(5:,4K
M*HI/E375._HN[19B18T"KT&<?B34E(!@8%+7@1ORQOO97MWMJ?7MMMMZM[L*
M***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *L\_E)+(>1$"Q&/[HS]:IK+/)
M#%*K@>9,'P>#Y1Z#'7/O^GI)%;OYTWFG=&X88)XYX_PZ=Z_*+]L+_@IO\._V
M4?BK:_#[7V268^'8]6(4Q,%'FM&4^=U(;@Y !^O2M,HRO'YCB9PHQG5?LY2]
MDKN5^?2WJO3\3SL\SG Y%AHU<56A"%6<(*<FDD[)REZ06LK='\S]:RZ]#_=S
MU_3_ .O41>-06(Z#UY_Q_"OYZ(_^"[GP@FW.(@%*%AD0=.N/]9U/;_.&C_@N
MM\(9-P$6=B^8V!".!U4Y<\^O?D5]9_J#G]6*J3RNM**<?>E'X6[-)/OK_D?'
MU/$3(X1<H8RDTT^67,K2]Z,4_37\=3^AQ)59<C@;<]?TZ<4_>/TS_P#6Z?KT
MK^>5/^"[?P? 5?) )P_*P?=/;_6?_6J5_P#@N]\'BRJL*Y W'Y8!QG&/]9_]
M;M7+/A+.X2</[/KJW2VR5O)_UVV.V'&^2NGS2QU'FO"-KK64K7MZ7UZ>9_0K
MO'Z9_P#K=/UZ4;Q^F?\ ZW3]>E?SU/\ \%WO@\655A7(&X_+ .,XQ_K/_K=J
M27_@N_\ !W( A7Y1N/RP#@=O]9_]:I_U4SO3_8*^JOMZ>7F6^-<C7._K]'W9
M**U6K=F[?X;O3RW/Z%#*!CW&>_\ A2F4#'O]?RZ5_//_ ,/W?@Z>L(X_>CY8
M#\G8?ZSK^E'_  _=^#O>)>GFCY8#\OI_K.OZ5K_J?GVG_"=7\_=?6WIJNRL9
M?Z\9)K_M]#I;5>5_EOY_@?T,&4#'O]?RZ4&0#'O_ #_*OYY_^'[OP=[Q+T\T
M?+ ?E]/]9U_2C_A^[\'>\2]/-^[!]WT_UG!_2C_4_/M/^$ZOY^Z^O^796#_7
MC)-?]OH=+:KRO\M_,_H.FN%0.P'**9&YSQ_0_P"-?&W[;GQ\LO@-^SUXY\;W
M;H"FC:A;0JTOE$->:?=1QX.#G#$8'?MR0:_*V\_X+P_!R"YAMFMP?M\2JA"P
M$?O3P/\ 68S@>@_2ORU_X*>?\%/?#_[3_P *-3^$7@F62WO-6CMWPA"C9"")
M!^[<GD-R-O3CZ^YPUP3F.,S"A3JX*=.C":K592@W%QIVE*+5NKTUW7EM\3QA
MXBX/!X"M4P>84_;U:%2%&,7K%\UE/M;V>J\]4C\([CXY_%;4KW5[ZWUKRX=4
MUS6+JT5C<DQ12:C<2X8BY&<HX QC Y]*B3XO_%KS9R=<PIV>7S=';QAO^7DY
MSSVX%><&":(?9H6"@[1#@_<9?]<>G!9@<GZYYJ:<7!:55;:;CRS'S]SRL;_I
MNP?K7]9\/Y#0PV"HJ6&U2A-J<?>?*Z<7R]E9I^35UW/XZSCC+-L9B?W6+K1B
MXSDGS:N'NJ4DTMU%<KZMH]'_ .%Q_%N-T=->12@8+DW)^_PW'VGG/Z'--3XQ
M_%N)E==?3<F['S71^_UX^T^_%>8/)<W%RJ1N5$BG R>#&,'CGK[<^M0Q-=S.
MD8<@OO\ XCQY?X>G^<5Z<L%E<.>,\L4I0@G)\J]]Z)K7T3UTU1R+,>(9KF>:
MUX.48R<?:27+%J#2VV5TOO[:>L)\8/B>L%PLFN S.,QL&N0!W?\ Y><'()QT
MQWJII_Q<^)+V;2G6?G1F^S_//\N2?,W?Z1W[>G'7I7FJ6M[="(+*0TQ<#)/&
MS(.1[\C\><U9%M-:QBS\U0\^3'@_=V?,_'4=^0>??N>RRF"YHY6O=Y91C&"Y
M9.+=.ZLK:QAKW3>KZYRQ_$,?BS2NXRE#DE[66J;@II[? ]7?I97V/TG_ .":
M5_\ %3XO_MI_"/P4=69]'U._O;B8 7$GE_885N6W[KG;\^PXRO\ +-?Z+^D6
M[6NGV,#'<;>RM+=CC&6A@CC8X[9*FOXE/^#=[X+W7BKX_P#BGXK7,):V^'1M
M!:3.F0IU2VEMY/+.. S=<'ZU_;Q;JR1*K=>3^9S7\7^(-6$^(L?&FE"E&O45
M.DE94TYN\%V248R2VM*ZW/[X\-+SX<RVI4E*I5J8:G5K3;>E2-.G'7NY2E5;
M?6W5(FHHHKX0_2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[OW#Q[>O8"E_X<8_$7&,IT\OK)_J?3[G3';KG\Z/^(E\(_R4._PKX^_P_#Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M32[25['ZO_\ "9^%/^@_IG7;_P ?*=?3K1_PF/A;_H8-,ZY_X^8^GIU_6O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0Y.,>H)
M^E+1122LV]=;7^7;L 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF8;?NS\N.G^?_U?
MC3Z/^ )-N^C5FUZ^?S"BBB@84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/M7;'P0KN*E_:5KQ7V%I4M=QW_$\:?C_ (6$I)Y9I&+E?VGHULG?3S[]=O\
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M+EBT]7>Z[6>GWH6BBBF2%%%% !1110 4444FTMVEZL HHHI@%%%% !1111<
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G )/04 +12 Y (Z&EH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A8 @'J>E "T444
M%%%(3@$TF[)MZ)*[?DMP%HI <@&EH33M9WNKKS7< HHI"P&,]SBF M%,884_
M[V?SXQ5=9#]H$.#C8)-W.,^GUQ_^NN>5>49J#IN[M;WD]9.R5[%*+:;72[MY
M*UW^.Q;HHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH CE7<O7&*_G?_ ."Q'[17Q8M- NO@O\/=#U-Y=<M'1=7L5ES"
M;A'M^/+C/W?O</7]#LN)(6P>,'GK[>N/UKS77/A+X \77*7OB+P_8ZM=QXVS
MW$4<CKM.0,LC'@^_],=6"QOU/$0JRI<ZA.'LWNN:]VGTU5UWZ['%C\!#&X:K
M3]I[.52/(^MXV5I+LXOL?YINH?LA_&G[8FLZOX<U?4;^5Q?W=Q-;SL\TI)9R
MQ*,26;GDYJ.;]D#XP:Q?1W0\*:M$BH+A5^S3X !X3[@P,?C^-?Z4,O[/_P )
MI@ _@_2V P,&W@^[Z?ZKI[4+^S_\)8A\G@[2QA=N!;0=/^_7'X5^N95XMXK+
M:2I1P;GJDGSI66B4=NEORZ'X]F?@_ALRG4G/&J#<;*7)=]V_6_7<_P VB3]C
MWXOQ223'PKJK;(S*<6\_*@YVG$??I[<4D?['WQ>,BW"^$]54/'YS#[-/RI/W
M>8^GZFO])G_A0/PF=>?!^E\C!_T>'I_WZZ?_ *Z4? #X2@ #P?I> ,8^SP]/
M3_5=/;I7TW_$>Z]K?V2F[6;]HK-:=.^FY\D_H[825Y+-VG*^U)Z1EK;?O]W2
MQ_FR2_L=_%[+3CPKJG&9 HM9NG8?ZO\ 3''//2H#^Q]\7\G/A35?N?:?^/:;
M!_V?]7W_ #K_ $HO^% _";&/^$/TO&,8^SP$8^ABQ3?^&?\ X2_]"=I?W=O_
M ![0=/\ OU7'/QSQ<[.66KF4E)24U]E))-6_7\V=5+Z/V$IPY/[5D]$OAEVB
MGN^MG]Y_FT1?L@?%^,^=_P (IJK'R1/C[-/]T'[G^J/&>]2C]D3XOB07 \)Z
MJ"(OM  MI\A<_=_U7X=?QK_24_X4!\)<8_X0[2\;=O\ Q[0=/3_54G_"@/A+
MC'_"':7C;M_X]H.GI_JJX7XT8Z3<G@]7H[35K/?IOV_0[/\ B N6_P#0=_R[
M</X?5N[?]:G^;1_PR%\77MI9!X3U4.6:ZS]FGZ$9V_ZOC]1VIVF_L4_&&\29
MY_#6JX:-KA0UO.?E/1 -G8?C7^DI_P * ^$@&W_A#]+Y&W'V>#D>G^J_+\A4
ML?P%^%$0PGA#2U!79_Q[0=/3_5?IT]JF7C/CWHL):-U=<]W:Z;Z>5C"GX 9;
M&$H2S#FO/F;]GKI;E5]]%]^C>Y_FMO\ L=?%^.1E_P"$4U7]U%N'^C3#*J<;
M?]7G';'Y8S5G_AD'XOAU;_A%=5XM1/\ \>TXRO\ <_U6?P_+BO\ 27/P ^$I
M))\':621@_Z-!T^OE9_#I[4QO@'\)02/^$.TOB,I_P >L'3T_P!5T]OR%=F(
M\;L9BHJ#R^WNQ3]].[CRJ^RW2\_NV='P$P&&NUF5DY1DOW;T:V/\VMOV0/B^
M=\G_  BNJ'-N9@#;S\#^[_JL_P#UZA7]C_XP#!_X135=WV?[0"+:;I_<'[O'
M^?QK_29'P#^$C87_ (0_2\&/;_Q[0=/^_73T'Z5)_P ,_P#PEZ?\(=I7"[/^
M/6W^[Z?ZG_ZWM6%+QJS+#SO3PKBE%I+F6EW>_P!VG^5C:IX#Y;7LWC^:S][]
MWHY.W,WYO\.A_FR+^Q_\7@78^%=5):V-P<VT_?\ @_U?X_C]:>O[('Q=,MNO
M_"*:K^\@WY^S3X7C./\ 5U_I*M\ OA+D@^#M+^YL_P"/:#IU _U72D'P#^$H
M*_\ %':7A5V_\>T' ]!^Z]^/QI/QIS%RE)X1N\7I[2WO63YOE=:+T[BCX$Y;
M!*/U]*S2M[*]M5=:_P"?7KN?YM,7[('Q<;[,1X3U,>;YW_+M/\NS/_3/'..>
MF?>B+]D#XNM]F(\)ZF/-\[_EVG^79G_IGWQ[?C7^DLOP"^$JA0/!VE +N_Y=
M8.-P[?NN,_A0OP"^$HV >#M*&TM_RZP<;O3]UWJ?^(SYEI?"O2+4OWF[UL_E
M;SVTZ O O+=/]O6ZM^Z77D\]WS?B_,_S8+7]D;XOR:A;VY\(ZHN\RX;[-.-N
MP$\?NAUQZ]>/>OT3_P"";'_!.KQGXU_:-TK6?&&B7=KIUE>0S@75L_EXA0,1
MEU &=G<5_<<O[/WPD5PZ^#M+#KG!%M;Y&[KTAXS73>'?A=X&\)71OM T"STZ
MYZ^;!%&C9P>ZHI'X&LLP\8\;C,+4P\<'[-RI5(QGSJ7+5E%*,^GPM1=NMCUL
MK\%LMP%:%5XB-62J0D_<M=1DVU\T[?=VN6?"/A.Q\)Z#IV@:;;I;6ME:6\"1
MQJ BM%$BN0 H R4Y/YUV<051Y8(RN,CCO]/U]ZCAEWQI(5P26'N,' Z]?;VI
MJ1$32R9.)L8!SA=O7'^>?:OQ'$XV=6IS2O4G.;E.[UYI133N^K<HKYMG[-@L
MMP^7P=*E%0C2IJG37104X^ZM=;>]*_6R3UL6Z***9U!1110!&RY8>_Z8%.*Y
MW<]<=NF*B>=(R=Y"J!G)]LY_SZ5P6O?%/P3X;9AK&NV=EY>=_G2QKC'U<44L
M%.;FZ=*<U*5_=4FHWCMIZR??7R.>KCL/13=6M3I\K4;2E%.[:L[-[;:]E]_H
ME%?*7B?]KCX-:%;74W_":Z09K="3']J@R#@X!_>9&>.V/P%?!_CC_@JGX$T#
M4FL+'5K*Y :492XC_@Y'W2W7C';UYKZ'!\+9UC:?M</@ZLJ:?*WRR33LM+-*
M^COZ(^:Q/&W#V$JSHU\="-2&ZWNM+._GS+^K'[));LL\\I8XDVX'88':K=?@
M-)_P6*\,1WL5K)/;*9"X?-PGR[>5SGGD=._I7J?A/_@JWX&UMK59]3LHC*'W
MAKF,XV@X[@\]?R%=4^!N(*4'B'@9I3M=WW4;K1?]NO[B:?'7#E6W+CZ=G*RU
M6]K[;ZQ2:OOL?M$5#,>?T_\ KTG/M_<_^O\ _7_2OC+X:_MH?!WQ7H-EJNH^
M,])L[N[,@DMI+J -'LDVC(,JD;ASR/Q]/>-#^./PQ\12I!I'BK3;V5R J17$
M3$@\<8D.>>*^<Q>2XK#5I4YT:T9Q;4[0E)<R:YDGM92NMWOZ'M8+.LOQ]+VE
M+$TN7F:5YQ3:LN67SCRORZGJ_"D9/\..GZT^L])X;M5EMY!(CXVE3D$$=1^7
MX\5>&% !-8>S]G:*33;=XN]T]-+/6_\ 5COIUE4<G&SIJW+44DXROVM_2V'4
M444C8**** "BBB@ HHHH **** "BBB@ I"0.IH8X!/I5.0DJ9#P!U],#J>W;
M_&JC'F]-OGIH95:OLUI'FE:]MO=6[9=SGI4:R;G9<?=Q@^N?2N UCXE^#O#;
MR0ZSK=I9,H^7S947..N-SCH/RXKR+Q-^U7\&M LKB<^-M(,T08A/M5OEB,YP
M/-R>>.1WKKHY=C,1.$*5&K)SE&,;0;4N:W*KVLKN4?,\W$YS@<+#VE;$TX*%
MW5BY1YE9N+C9ZWO&33ZJ/F?3W!((/3/ZTZOQ^^(/_!3[X?\ A.Y:*QUJQNXR
MY&Y+F+& >O#'IW->077_  5^\'Q2W*B]M28?*" 7*#=YF <=.G?'XFO?AP/Q
M#.34,#-N5I-W\X4_S<;_ ']SQ'QYPY"-ZF-A&2<5*.]G*[6NST5_N[H_>#-%
M?B+H7_!63P3J%PL4NI6:+E/F-U'T?&>IXQG.*^T?AQ^W!\)?%\*/=>+=+MW<
M(0KW4(Y?_MH.F?3^5<^(X3SO"TY5:V$G&$$G)];-NUEN[V;6FOS15#CKAS$5
M(4Z>.@YS=HK[KZ[;NU]+VL?<3QEY89 >$W<=CD8_3M[U,#R1Z8_6O*]#^,_P
MWU]DBTGQ1I][(V/EBGB8Y(X& Y/->FV]S%<H)(7$D; %67D$>N<_E7SU2A6I
MN\H3@KZ\T&KZ)):VMT?<^KIXNC74%&K3F^5)*,HMJ_O-:7ON_P#ARQ14:8YP
M<_\ UJDK*#DXIRCROMOZ?>C6Z>J=UW7X_<] HHHJ@"BBB@ HHHH **:[;5)I
M5.X T[.U^E[$\RYN6_O6O;RV%HIF[Y]N.W7_ #_*GTAIIWMK9M/U6Z"BBB@8
M4444 &:*8Z[L<XP?\_\ ZJ?F@2;N]++2SOOWTZ6_$***,T#&.>./7G_Z]5IH
M3(8QNV[75SR1D#L>/S%3C$8<D].3GL/7Z?RKS3Q-\7OA]X6\Q-<\1V&GRQ$A
MDFGB0AAU4[I!SD8_/VK/ZC/$U+Q4YWY$XPBW;;>SZZ:F,\;3PT.>I.%.48RG
MRSE&]EO:_5)?Y['IRC ZY[T[-?F+\:?^"BGPU^'<1.F>(=.OF%SY)$=S$2!S
M_=<^GM7RT?\ @KWX.^V>1]NM<>5OW?:(\;\XV]^?_P!>.]?4X?@[/*M-.E@I
MN"2:WV:4NNO4^4J\><.4IN$\='F4FI63T::OTL]^A^[,R%_+YQM<-]<=OI4I
M91U(ZX_&ORW^$'_!1KX;^/\ 6HM/U77]/L(#IRW?FRW$07S=P'EY9E&X@]OY
M5]U^%_C!\/\ QN81X<\2V&I/D$K;S1N0W!*_)(W3_/K7'CLDS'+I1I8RA.F[
M.>D6THM)WNE_7D=F"XLRO,_:0P.(A7]BX:<RC_$:OOJ[7^1ZVP.<?WOTQ3Z8
MCAUW @CU_P ^M/KPXT^24GKJ]G?1;M?^!-OT:1]*I<R33NFKK[EV\@HHHJP"
MBBHI)1&1[TTFW9$RG&"YI.R5KOU=AY(;*YY[^W>H\ 9^;ICM_P#7[=ZQ]0U2
MQT:"?5-3NDM;.( RRR$*B<X&22!ST_SBOG_QI^T_\)O"MM?S7/C#2XIH8R_E
MM<P*04!(!!DSSCT_&MZ.5U,=5C&E3J5)/DA>*E;FDTN6Z5D]7VT^\\G&9WAL
MOH^UQ,X4DIR7+*<;\BMR3MO[\N2/DWY,^FV?#*N/O4^OP]\5?\%9_!FC^()M
M-M+^TN+2)Y4-PERA4",':>X^8#U[5;\%?\%9_ >O7T4%YJMG;I)(49GN8^,'
M ^\PZ_Y/2OII<$<0PLG@:B]U/NK-)KTW_ \&GQ_PU.;A]?A=U%!+M[J^_77T
MD?MN3@9JNDVY]OKG_/M^9_'K7RCX"_:Y^$?B_3+.Y/C#2DFO%_U?VF#=G( &
M/,_G^%?26BZ[I.NVZ7VD7D5[;D;A)$P88/3H2.>._P"AKP,3E^)P52I1Q5&=
M.I'1\R:2>BO>VU]+]=/1^]ALVPV8*%7!UHSI*:4VFKM/E>V_PN^W7R.BV_-N
MS^&/;%.J-) =H)PQS@>N/\]OTJ2O.C!0NDK7DY/KJSUU+F2DM4TFO2V@4445
M0PHHHH **3(SCO2T %%%% !1110 4444 %%,=MN.,Y/^?_UT^C7?N)--M+=6
MOY7V"HY>49<X+*0/QIS-M!/H,XK/N+F.&-[B=Q''$A9G8\*!U.> /7\*N$6V
MFNZMZW5E_6AE5KJBE+3F6JOHDD]VWHOF7H_E1%R"0 .O^>:D/((]:^??$O[1
M?PM\+B]CU/Q9IMM<VB2,T4EQ"&RG'\4@(Y]NU?!?Q:_X*>?#_P #3&/3M8L+
MY0,YCN8SGD_W6/\ G]/:P?#>;9C&<L-A*E2*:C)N+CK)7T[Z-O3MIW/ Q/%N
M2X2[Q6+A!V<G9IWUL]NM[Z6V/UINKAK=K=57=YDBQGKP#P3]/TZU</0_2OP.
MT[_@L+X3OKRVBDGM@'NDBYGCX4G[X[<>O/?\/T+^$/[;_P )/'^DB[U#Q;I=
ME<.VT1/<P[N0#G!D7\#_ )'7C>$,\P.&]MB,!4ITH12G)7E=3M:UM?A?]7.?
M"\99%B<1["ECH3J59J-.#:BE[J=KO36_WL^Y<?=YZ#CWXIU<5X>\<^%O%21R
MZ!J]MJ*;=V89$<$=<G:[9Z_YSQV:.LBAD.5/0_2OFIT)4':4)0YK.THRB]$H
MK272T5ZV9]12K0JWY)1E:WPR4EK%/==F[>EGU0ZBBBH-0HHHH *,T4PKN96!
MX'Z_X_TH$VULKNZT\KI-_).X^BDR,X[^E+0.X4444 %%%% !111F@"*9S'&6
M R01TZ\FI <@'VJ)W!W+C.".U2CH/I5/1+O=Z^5HM?<)3C)66LDY-O7;16[:
M-2^\6BBBI&&:*8R[L8.,'G_#_P"M3Z!)N[TTTL[WOWTZ6_$****!A1110 44
M4S=\^W';K_G^5 FTK7TNTEZO9#Z*3(SC/-+0.X4444 %%%% !4"1E9II,Y$F
MW ],#'']:GI@(W/@Y(QD#J./K_A2=[QLKZZZ[:/[RE)I27\T;/\ \"C+_P!M
M!GVLHQP>_P#G_)I^<].:YG7?%&C>'X#/K%]%90KNW22NJ 8Y[L/\<?6O _%7
M[5GP>\,VUXTOC721<6JL6B-S#NR 2!@RYY(].,UW8? 8G%2A"C1G.<W9)1;3
MN[+5?GL>/B\WP> C.KB:T8T8M)R;5XMJ*Y;=7=_>SZBHS7XJ_$/_ (*O> _#
M%S/;V&JV5V(GD4F.YC/W20.A/4@8X_.N=\%_\%;O!_B"[TZ'4+ZUM$NW=&9[
MA,*%;&<DCKR/;/7N/;AP=G\X2FL%4Y8[NSTT3>EO.WJ>!/C_ (9BTOK\&Y.T
M5M=V;]5MO;J?N-<(9(F0';DKS]"#3TP $R"0,&ODCX?_ +7GPC\9V-G*OC#3
M!/. 7C%S S*3C&?WG?Z?GTKZ;T/6-,U^W35-)O([RSN%!CEB8,K!>"05+#K_
M #/K7BXS+,5@:LHXJC4I3@I1]Z,N5ZJZOMT[]NY[^!SO!YG&/U&K"O!57&5I
MQYHW@I2?+N[6@NVIOT445PGK#)!E>XY'2GC@ >E,?# @'D$9YQC/3GMFGC@
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MVM\-EY7?9V_MHB_X+:^'Y55E$#9B#G_25X;^[T_K[4/_ ,%M/#RX&(<D9/\
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M&U^KN[:(\?-LZP&3X>KB,56A&%-:)OWIW3<.6.\E)I)M*T;ZGZ5^.?C1\/?
M2SQ>(?$=AIUU';-<>3/-'&YC&?FP[J<9!'2OY^/VI/\ @N/HWPC\5:QX:\/Q
MQ:M;6\]S;1W$%PI5@',0;*JXZ'.<]C@]Z_G9_;'_ ."D?Q%_:<\3R^(M'O\
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MI&"[DG&%'7^G_P"JLZWMY-*@U&3=YS2SS74:KG/S=(QG'/I@\&OR%_X*/?\
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M>'4K37/'24HJ[BX\R:B[-WNE97/KS]OG_@LU#INH^(O@]X1E$R:@[0QZG:W
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MW0,.USF:8?.O/D8!QN[]<?@*PK>"&"C&"C)1ES24W]R@EK9WZ6_EZJP0\?\
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MBN=@_P!5E77.3@_6N<0>6YG,O[MOWP'.-YY\CTSCC'3'--$>QI+C>"LB^9M
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MO*[O?KV%3R!949'? D \WC&S9_J_7&[CJ.:V]AS-MW?LW*,.S7,I-:='9_\
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MXX\2<5F&/Q,'B9>RA6G1HT^;W81=I-76]M+7_P KR):6%R8;Z20+-/$KS)P
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MX?\ $#6T6FS7=P<2O%%YDB1EB%.V1@N #Z=Z_MLTJXM]0MX]3M7$D-]#%*C
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M"XC^,/BG2X69B<6JWK,I&>,>^<=^37RSY,160K)DI<E>W$/=_I[_ ,QT_P!
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MDUE6)BE>U&2<=?>25ET\TU]YABJT)9Q@Y-<L93YYM;+DG%[VW=W;R2/[-O\
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M60Z/C\_FZ>U3+Y9&]6^93]E(_P"F _Y:')_\>Z?3K4'E0_W^/M7EX[>7Z_\
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M'\?U]:6H>G0]/N\=<]?\]^U8U*CI\NET_P!'']&_G8V_K^M?ZWZ'YM_M,?\
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ML///(^[T/I^E/;_@BI\(MQ?='_Q\>9C,.?\ =_U?3WZ]_:OTB'[:'P))8?\
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MW/%M$*?W@W$A' /&3W_#'%;891K8JASIV=1733LI*,4M>TK>]KTCU:.CEE+
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M!=(">:ESXPM(;B/'RE"'QD8Z$8],^G>OF^+\3'"Y?=I:TZDM;I+EDIR7S?\
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M7@GR*ZT<>6'OI_.":OKOV9^IO_!(3]H^3]FK]IZQT2?46@\.>,[ZVBE,LVV
M.ZX5020N3+-C![GZU_H8Z)>1WNFV%S&P9+JRM;M&'(9;F!)P>..0X/\ 2O\
M* \/Z[=^'_$>@^)K>:2!]#UG3KF&9&*L5@OH7DRPZ@*A!(/'YU_ID_L'?&2W
M^._[+WPQ^)-M<+<C4]'BM&E5@P9M-CBLVY!()!C/X]J_B7Q>R)X+&1Q=*FE1
M]LZ+JK><JD(U*:?E'EJ+YG]O^#?$?URG+ 2FI-8:.*AK=*"M&O&/]^2=)VOK
MR-]$?9M%(#D ^U+7X>?T*%?SO?\ !P_XSL=(_9HTSPF]TJ:AXJ,PLK4N ;D6
M5U&\I"$Y;8IR< X_G_1">>/6OY*O^#FG58[>3]FJSCN"' \7B2W#?+)O$0&]
M.IV]?;MFONO#;#?6^,LFHN+DI5JG,K77+["K\7E>R^9^>^*5?V'!&=3NE^ZH
M[NUVL50=OG'FOY(_DPMXU70=5,!+2Q/:F(#J09!YAZ=N<=.G-:4DL,T5J\3@
MS0I@#.6;*@,#Z[?;'3GGBJ-BOV33[P$Y\QQY8)X8%B6]SMR2.WY5*;6*UCCN
M('+NV?+7((;/$GUV@GITK^_:*BL$L/;EC\$4O[L::<7Y<K3U_E7<_P X\>Y2
MS">(:YHR<IQE?XG.4>9/KIR6?FV21B-I4P_$>[RN.6W [^G7:>XZ<5 8E<F)
M3E823;GKOW',GN=OMR*D5579L8-Y>[R 1G?O_P!;]=O]*E810Q0NC\Q[Q'U^
M?S/]9_WSGTKGP\71G=W>JY4D_LRD[:*ZYK<W3WI-;[9/F]K2FG>52<%&*V4T
MHSYGO;GYDF]-GVNH71)_D5L_9\>5WW[S\_3DX[8QC%#HD_R*V?L^/*[[]Y^?
MIR<=L8QBA4CM=TB-N_YXYP=VX8D] VW)Z=.]"I':[I$;=_SQS@[MPQ)Z!MN3
MTZ=Z[$G"WQ/V3C-:?$Y^RO3T?Q1UV_EU\NE._+K\7+-:_P#+]>QTWZWUZ^\Q
M71)L(C9^SX\K^+?N/S].3M/3TQ6?JS(NE7_EMN9)+98L$$MO;# >O/I^76KZ
MI':[I$;/_/(GG=O&)#QPVW)Z<CO69=6Z&>VM%):.YN(BOH^V12W/0XSC_/'E
MYQAOK& JX>TK7IOFL[^\Z<Y1?2\>5I^COY>CE.*>%QM&O&;4>64YV>]3DI<R
M_%/OJ[^7]E/[(?Q+T3]CO_@E3XC\57E['8:GXH6_O=!261(FN]=NM+)MX(PQ
M4O(Y3 5/F/05_(_\1/&E[\8?B!K_ ,6=<N9)=7O;JYM9897W!)I)3,R -\P(
M)Z9K],?VY_VAK:__ &:_@)\!?#^J!+31M(T'QG?QVLP!>]@CFMY+>8+@;2I&
MY#SSUK\H+ZUM]+O+:"U?=%JM@NO2@'.V_FZQ<=/]T\\>O%?F_#'!JPN88['5
M*.N,QTZ]Y*UJ5X0I2NUL[:I[/N?>\1<:SS/*\-A55FI8;"4\/R/3W5=RY5?[
M5ULB:[\JYB23.R6-00%ZF8?P?_6ZU234)+^W;3YAM$#F56P<F51CR\]\YZ=?
MI2;0K[V;C;]H(/'^D?\ //M^7KTHV01S>>A'S1_:"/\ IMG)7VY'W3S_ $_8
M:M>E"%.A!1?+&+C;9N#6FF^J=S\FPN&G.=6O*+5JDYWM>7O-2BK:*UW9NV@%
M(W46V[[H\W_MN.-F.OMMZT%(W46V[[H\W_MN.-F.OMMZT!(XV^T[L[AYO_;<
M\[,]/?;UH"1QM]IW9W#S?^VYYV9Z>^WK66VS>G[^/^)[T_\ AM=SLW^)O7^)
MI_R^7P=/QV I&ZBVW?='F_\ ;<<;,=?;;UIVV)HV@WXV*9C[3 8V<_\ H/7W
MIH2.-OM.[.X>;_VW/.S/3WV]:3RHQYDQ? E0N3Z3-SM';UPO6M*,E&I&ZNG>
MJM+VE)6<;=U]^XGK\4FDVG5T_P"7J:<>E_Z5AZ1POG<XXM_,'_73^[SG_OGK
M5FUD6W:WND^9;%EO<'!!ECY\LYZ@\<'D>]4[A(T\K8_6 .<<?/\ W?\ /2I5
M,<5I,N_Y)(6?/'^N(QLR?U'7O6D&I5;6YG*4))25KI*S3VLX[QZ-(O&QJ0P\
M.6TK\]^EK.+NWW2ORZZV,[58R]AJTL#L3K;S7;D')@FN!G8F,;=O) QG\LU_
MHH_\$=_BG!\3?V+OAE%#<BY;P1H.D>#IVW[V2?3K% R/R2&&>0>?6O\ .X98
MTTR<!MRBU:5>0?WX7B/C]!CK7]J__!MCXD%[^RCXTT62Y,MQ#\1]0N?+=]QC
M1;.-=JC^%1TQ7\Z^.F24X977QE.-Y8>KAK-+2%*;;J2NMW?W7OIV/Z \"\_G
M_K#@<'B:LK8BG5H48+52JJ$52YO6*;O=Z]3^D>BBBOY&/[7"BBB@ HHHH **
M** "BBB@ HHHH **** (C(I8Q9&2".O/(],54939VNR++,&X'4X9LGU^M3-$
M@=K@#YL'![], =N_XUXC\:/C?X5^!G@J[\9^,[R&VL+(%Y'F< !2Q&,9R>>G
M_P"JNG#T76G3]BG4DY0M32NYMZV7=:?<<V-Q>'P=%UJE10C"*E4E.RC%7LW?
M71[1NM79'NRME5/=AGH>N.:!CY<$]\>_KVK\=X_^"SG[++;<:]9\/*GWY.L9
M*MG\0:<G_!9K]EEL :]9\;OXY#TZ].O_ .JO17#6<5;-99BI[\K]FWLT_P '
MR7/&?%610:A+-L"I746O;QOS6IW5N]IR_P#);[L_8?<..>O2EK\=HO\ @LW^
MRRZQNNOV>#OQ\\H^[G/ SG\#]:?'_P %GOV6Y$1QX@M,/OQ\TH^YG/'X=L^^
M*T?#&?*__"7C-'9WI/1ZV7W+\QQXJR#7FS7!)W2TK+=J.FO6\M/)KJ?L-28Y
M!],_K7X]1?\ !9[]EN5$9=?M"'W8^>4?=)!ZGV]Z7_A\[^RWQ_Q/[/G/_+5^
MWX_S_6G_ *J\02T_LG&.TEM1D_>4HV^:DX_-H'Q9PY'?.,$NG\:/6WGVDOO/
MV$) Z\4$@=>*_'L_\%FOV6V"$Z_9X+8'[R3K2'_@LW^RVV,Z_9\/M_UDO7_/
MI^=3_JUGB<4\LQEW?3V3Z;V^7<3XKX?UMFV!^RXWKQU3L[OY/2VOD?L*2!UX
MH) Z\5^/1_X+-_LMMC.OV?#[?]9+U_SZ?G0?^"S7[+;X!U^SXDV#]Y+U_P ^
MGX&DN&\\?+_PF8OWF[?NGJEO;3=:@^*^'];9M@>G+^_CK>U[^E^FOD?L+M^O
MWMWXTQW6-2Q/<GGU/^>E?CQ_P^C_ &6=VW_A(+3/G>3]Z7[W3U_7]*9>_P#!
M9O\ 98$7[S7[,CS/+^_-PQ'M_G':G'A3/(N,I91C$N9*ZHRZVT7G9A/BK(G"
M2I9K@I5+24(RK))R26CW>FG3HM"M_P %8_VV8?V6/A'J5OIM_%'XHUVUFAL+
M3S,2R+<P/Y11 RN=SC P.O3@XK^(*7]JWXCW&L:QXCGU;4D?Q3=SW5XAGE A
MDNVW2* 3\N.V:]6_X**?M2>)_P!L7XT^+-9DU:[U/P_X;\5WL7A%9;F26*+1
M[2X8V2P([G:@4_*   "/P^&KW-W=:48O^0?:)"=8&!M^T1G]_N'?CJ>_&#Q7
M]8^&'"%'!Y?3IXO Q^M5HQ=6I4@K*\4W=M:.":2\[K8_C7Q/XNJXO&U5A,3-
M*G6G&C)U'%1BJB;Y+/5.=W!O5IW/HU?VG?B!$BLNM:D88Y@4/VB3EAT'WL8Q
M_GI2?\-/?$/S/M2ZSJ6?-WK_ *1+_K.R_>.<^G?]*^? 8I3=) !_9[S.+( 8
M E/^KP.W'&<<>U-A!C!4@@*-J?\ 7X.A[<^^*_0_^(?9:I.HO9QE5<[VI1MR
MRM-J[>[:\UITL?GLO$#,Z48TH\[DDE*7M9-74(J4KK[3?WOT/H,_M/?$4S-.
M=9U(ECN(^T2Y\[^[C/KVI[_M1?$=2A&L:E_K@Y_?2_ZT?P\-UKY[02<[L_WA
MD_\ +YZ]3^=..XM@9^YN&,_\?O\ >X[^]7'A/*</%-QIS<?9QA[D+>[J_/JW
MYR[F+XWSBLE_%BWH[SES:25D_75)^?F?0K_M-_$)$=UUK4][L92!/*<3'^'K
MU]03Q48_:?\ B$$\_P#MG4MPXYGDQY^,[?O=?;]*\!1.1N&2.6XR?M>.N2.N
M?4]*;Y"E]N, MYF,#_C]]>G7'?./>KH<,9=R5'&C2<??E#W%[R:B[_/;R?H>
M)B<WS.K-2EB\0W.K&<HN<_=O%15-^]\*5TWO>S[GO!_:F^(]_<%+S6-2B:SA
M^TQ@SRKG9TZGD=>E?;O[ NF?&']KWXWZ%IBW.M3^$+&]MH-3O8GG:*&2.Y"S
M!W&Z,;4/.?QR*_-WX8?#'Q7\=OB'H7P]\&6L]SX@NKVVM[D0QEA]B>01.K.
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MUL7^[&9.O/G="G/M_#][/7V8%A4"Y]?FS_T]=<_7\,<TB_9Q,\A'+1&0]?\
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MW[YV6NE/2WVGK>VNW]7%*J,!7)S&;?C_ )]^TO'7ZG\*;M7.,\^7]G_[=_\
MGK0NTLN,Y\L ?]>7H?;V''X9I$:-_,?))0&-L?\ /H.QZ?B.O-2FIS2;Y(NW
ME:UMO5*Z\_QKD]V4E"$N5J[3?*E9:WMW?](5_+0J"V=R?9AT'[@XQ)ZD^YR*
M9;".([0WWIO()_Z9$8W_ %]SP/3T<L22,CN,A2,9_P"?,'@=>GL!SFFO';F.
M3:/G\\E>W[CL,CM[?E14DE4Y$Y<LG9VM:RMRM7W[RNEJ=6$I>U@I)<K;CS);
M-<WNW?9V;].F@GDQQN8]^-\Q4>IA/\?Z_>^[3WB@&WY^#,(#R/\ 5_WN^?\
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MEW!4C@!CW?ZT^5_VP8XW\^O]X<4*D< ,>[_6GRO^V#'&_GU_O#B@>3/F0_\
M++CCH+51T^@Z8Z\T#R9\R'_EEQQT%JHZ?0=,=>:Y?BO=N/M&N;=<DH6LO+FM
MZ;>8M=>:^R573_EUIR-:_?TW(W@2%'!;&"!#G^,<<^I'?C_]4L1%LL3 @@9"
M\Y!W_>]?NDY.",8IJF.ZR/XH_P#CV]D_BQG@#&>O84K&.0>6@XZ6^,=O];CG
MC//;FG[5PE"J[KEE><?Y8QA!-ZKJM?\ MWU.BGB?8TZF'JJ,HU^6*3>\%",8
M-::M.3;OII/LA)HHC&Z!\HC+Y.#P_F',A]]I/8\=Z_8C_@AAXS?P=^WKX,\,
M+=/'I^O_ &LE-Y"3&'378Y&>=I;\J_'9VA*O&.D/_'N!_"6YD]^3Z]:^K?V"
M_'K_  Z_:Y^$'C".X:W>RU62V24.48"],=LREA@_,'QWS7RGB)E2XER#%N+:
MG"G4HV:NO>BX<[O;WG=/U;1]7X=9K+AS.\'67N?[3"<5>R^%2M_X%))Z:-O0
M_P!.D 2F&8'("[AC_: /KW!]ZGKGO"EX=0\.Z+>Y+?:M*T^XW$Y),UI#(3^.
M[.<UT-?YZUHNG4G3;;]G)Q7R9_I!AJ_UG#4*_2I2A-:W24E?3R;=UY"'D'T(
M/-?Q^?\ !S5XA#:G^SWX?BE.]6\3!H@<[@WE$EE&#PI]NV:_L#&-O'W>?7\?
M>OX4_P#@X2\<+XD_:KTGPD\QE/@G[1Y$)8L(?[0LXW;:N2%W=3C&?J!7Z3X0
MX2.-XNP:FG)4J,J]HZK>$&[OHU-J_8_,/&"NZ'"5>V]6;IOSC[.51Q?]U\EV
M^EEW/P1O+&**RLX(FW8R4 /WRV"^,'G;U_\ U5(J+$L81]QAR(1QF3S!^]YP
M,[?R]J@M#(;VR$F?*43^6#G !4[^/3_/I5@>667RMV 9/LF,\#/[[Z9&?;]*
M_NYP5*E1H<W-[L>6:V]Y1C-R[-.G96^S?:Q_GEJ\1B)2:ES5I-J3LE>K#167
M75RUM9R>MA J((_+?<8MWDC^_P"8#YO/?;Z=J J((_+?<8MWDC^_Y@/F\]]O
MIVH3R\IY6[ \S[)CMD_O_IQG^O-">7E/*W8'F?9,=LG]_P#3C/\ 7FLUK;=<
M[5-:?"X\MY?/6_\ V]V5J27NZ0^SN_\ KQ>_WN_K/L,8+%&AA;>82?)X^_YF
M?-^NWGZ8I24B=2KY$!_<$X^?S?\ 6]QG;R/:D^0>7Y&>"_V3VR?W_P!,\_UI
MC+'*?+4$;3_HO' [S8YXSR<D5K&SH5&UHW!/^:/(TFTMKRYF]>TK;(Q3BJU+
MFM9NGZ.ZA=7[V3<NSOK8?)$D,[2QL6( ,/??O'[SM@A03TZ5H6D47]J^";2)
MMYOO%&A1 9!WB36;19.W.-WT_E6:)(W<+"?FC!%MCC&?]=VR,C)ZU[%\!_!\
M'CGXU?"3P\D/G)/XDL9HD(##=;:A:S2':?0KZ9Z$5XV=2E2R;%R=KQH58N^C
MY73C%:*^B33C:][/L>]DG+5S[!\VBJ5:=G:Z@FH6D]M5%V>MDVS_ $SOV>/#
M%MX,^"_P]T"S14BMO"^BS*JC W76FVDS\#W8U[97'>";<V?A/PS:@86V\.:#
M"HZ!?*TNV0C'3^'M^/I78U_G!BJTJV.Q=2<N:4ZLJC>CUJ2<FV]^9MZ^5GU/
M].LLI^RR[!TEM1HPH)]U1BJ:?:S237XA7\9__!R#XMD?XV^ O!33$01>$=-U
MR.+/!G%Q*@X/&3G'3U]Z_LPK^#'_ (.$O&,7BO\ ;=\/P6DIDAT7X=6VFN-Q
M(6\MM0DRHSP"/_K'FOU'P9PCQ?'>6II>S@I^TD_LJ;BD_6ZLC\P\;L3]7X"S
M%12]I4G3Y')VBN3F<N;K9IVT/PQ-O%YTUP6R/L[2$GH+CDA!QC\.M2;(HQ#.
M&R/)63K_ ,M_[G_UNN.]6(E@DTZ1"#YK3LO(QFYQ_/IGC!]ZK,D)\NUY^6,-
MC_I[Z9^O;TK^Y,6[9I5HMMJ.&A!M:I<S2YO1*U]C^ \).4LOBXJW-5E-K^6.
MBG;Y72_NZC0D<;?:=V=P\W_MN>=F>GOMZT!(XV^T[L[AYO\ VW/.S/3WV]:/
MW,C?9NRY/O\ :AQGZ]LYQ1^YD;[-V7)]_M0XS]>V<XHOW;U7L9?X-+5/R\M^
MZ#_#?_IWI_RY^W^NU_7N!(XV^T[L[AYO_;<\[,]/?;UI5B17\_=R_P"\'_7<
M\B/TZ_PGD4G[F1OLW9<GW^U#C/U[9SBGL8\B$9W( Z]L70XR/?W!QZ=L4O>4
MKRM+E]EK>SA&W[S[K6[W8G=1;@I/E3=/3_ES]J_STT^;&Y"[B6^7<9SZ?:?^
M>?X>F>E=-X'TJ+7OB9\,M&3YSK_C+2-.*C^*>YEP8<<]>R]?:N6 1W\M@2C'
M+ ]/MN<%OKCN17T;^Q3X8M?%7[6/[/>E31K+'!\8?"]Q*C#<-ZWJAL@Y!'Z?
M3BOG^)ZT*&28NM4<K4*4K1C9\UH2E*??6WWVL?0<%T88G.:,+-RE5BN5*_Q.
M,5![/3FLO-G^DQ^S5X?;PQ\"OA-HAC,;:5X$T6Q,9&-IAMPN-O4<]L5[P.@K
M)T2UAL-+LK"%0D5G#';(BC 4(,!0!P.*U <L1V _7-?YT8VLIXRO4YG^]KU.
M6.E[3G*<6^OPO5G^EF648T<!A802M'#T;VZ-4X1:^35A20.M?D/_ ,%COVF4
M_9[_ &2_&::?>K!XA\86-_X=TV(2;9I);^R<Q")0P8N7&%QSGIVS^N1>-T=F
M( C8Y)Z#;SS7\'O_  7V_::G^*_[56B_"K1M3EN?"?@?2H+F>T2>0VT7BC3[
MR2!F,6[8)E0[2<9QQG&,?7<"Y.LVS_"4JD'*G1G&M.+7NRY91<(R\I/5^2VL
M?&>(_$$>'LAKU9VC4KQE1IW;BXJ4?WDI::6CHK=V?A8\MQJ/B'3/%-_,\D^K
MV$/]LF1L[=1F??.),]'!ZAN?Z7M12WBFE-O(&CWLRX/!.?NY'\OSJ"Y,9B:#
M_ECJ5[M[_P#(6EQR,<!L=^GO35@CAWV\HYB!M_K>#C//0CUZ?E7]\Y;@8Y;E
MV%<4E*2<6H]%RI0O_>C%ZI;6]#_/G$9G'%9KB\54M:HJE.$V[J;C-.S=OL\U
MEO<J@*3N+8# ECS\K'D+^?\ .G?9HFCAD:3ARQFY^X5/R#IP3TYZYXJ>&&%I
M 7 ,4:E)A@8,PXSQUY[Y-, B4_9GXR2;C/4XR8L\'...GKS78ZDI\E.',N5+
M16UYKIOR;T>W65]#EK5HUJ=X13E.4^6SUOR)._R3^<EW)/+C>.9I'PSE/-XQ
MMVD;.G W<=N],\E"ZSRL5S_K>VS;CRSC&!NXX/7M3E>&0_O,XN/]?G'/E?ZK
M/'; Q098I<12Y_><3@]]O^JXQVZ#'XXYJZ6$G2;JQ;=HNFH[\ONJ-_G&%UYJ
M/<X8PJ0E-VM*<FX6Z/EFG&*ZJRE->;AW=D,<<D@NG; ;_6]MFS 0]P-V!P>O
M;K08XY)!=.V W^M[;-F A[@;L#@]>W6C]RO^BR9^;_7CU[Q<=R.,;?7GO1^Y
M7_19,_-_KQZ]XN.Y'&-OKSWK7_#TYO9^=^?G^Z^GI$O7[#>G-['S7O\ /ZVT
MY?2'?0,<<D@NG; ;_6]MFS 0]P-V!P>O;K2%D<LY8!9^9CTV>5]SJ>"Q'ZTN
M(1_HDG\7^O![XYB_$>WX]Z39"F;=Q_K!_I XYV_-%GZ<8P?K3V4I)74$W3?1
M:RYI?]NNUGK>T.Y%2/.E&+NN;]VM'>*]HYV[ZQ27ER]]%#1R9+-C[3C>/[GD
M_=[\;L=Z"4<ERV$GP)CV0Q#$?J1N(]>:8BV^8-_./,\_(ZY'[O=V..,=<>U"
M>3M2%ONR%O.XY.TYB]<\]/UQVXJ&*C.7LX1<G"5X7W=W.FYO?WKPB]]HQ=^K
MZ,1@N2#<8M2;MI%:-<TN3=Z-)Q6F\5T;2D 5E=Y&P9L><,8V>7_J\'H-V!_*
MF&.*9A.[[0W^NP?N;,!.W&[W/)Z5(6A,WDSY_>#%R#SDJ!Y.<#MQCG\:B_<1
MYMY.-Y_TCW .8<]<XXQ@_6NE23J-04E**;II+W6Y6YVN_+;EAIKRKN<\:<J=
M-2]UM\\4TW=QC&ISOINFM/\ #?5BM'%,_P!H=\!O]=CC9LP$]<;L=^O:AHXI
MG^T.^ W^NQQLV8">N-V._7M1_H\>;:3(W_\ 'Q[]XLX]..GXT?Z/'FVDR-__
M !\>_>+./3CI^-:=N2_7V7F_>Y_NZ=[0[L;>]DM%/DUE_"_?7>_DK?\ ;NNN
M@T<4S_:&?&__ %N.-FW 3Z;L#J>>U20A95F>5MKR8\P?W0GW/]W=P><YZBH_
MW$6;=\Y?_CX]\?-%GKT..GXU8A\DO,)P=Q"_: 0><#]UGUZ#Z?6N/&2LJ*5_
M9NJN3LWSIR3Z^ENBCW(DFYT^5N*]I3C!PNY<LJ\DI:_95GS:VY6NY#)%!)';
M,SA2Y<R$<%2A^3D],_\ ZN>:^W/^";GA>;Q7^V)\(I3"9%TSQAISR\$[$VG!
M/IU'7C//I7PROD;\39,>3D=L@_)T]/\ /%?NW_P0>^&4?CGX]>(]9>U$]QX3
MU#2[MW= QC!6 JP)4X.U_P#(Y'PWBM6^K9#4=U9T*FL7K%NG>#6GV9-1?FU9
M6T7Z+X?4U7XQRU5(\ZE4HJ?,G]JKKUZ]?1='8_O M(1;6T$"_=BC5!] .*L4
M45_ DI.3<GJY-MONV[O\3_1J,5",815E&*BEV459?@@KF?$^MV'AW2=3UO5)
MDM].TNREO;^9V"+#;0KNDD9FX4*.YKIB<#-?A[_P6T_:P7]G_P#9UO/#6DZJ
M]AKOCEY-#G2WG>*:73=1M71U81LI*%A@C.#UKT<IP=3'X[#X6FGS5JD872^%
M.2YI?]NJ[];'D9]C89?EU?%5;.G2A*<UUDHK2*OHW-NVO2Y_,/\ \%:/VM)O
MVF_V@O$OA1=39_"/A&6ZM]#>&8F"YNK&Y=;=0V3&[/&Q^[SQQ7Y3R6L,<-G&
MK$R;(TG!P3&/X\GM@XYZ#OWHOK)M3U1/M1:2]NR->MG<EF\US\C[CT;UW-D]
M>:I0-\]V)<FY2XD%UGDF)?OCTP3Z8_G7]T\(<(PRW)<+BJ4>5QI*/+RZ-U+7
M;L[II7NM#_/OC/BN689QBJ*E*/-4=3E;NDN;2.EKI1]W7K96U'PPQHT[*V06
M>$]P(3U?VZ#YN@/:IP8Y "K=%%M[&$?\M/\ Z^,5"AAC8(>D[<\<_96[=#QZ
M_3THC>")F"C"&8QGC_EV/\/?CVZ\?G][3JNC25*/,TXQM=?&H6U:OI9K3IL?
M!NE"M*511YE.22=OMNW-=6V2T35]K60L:0I [>9EEF,:CKF/ ^;MUYY'K@#M
M4*JK_.&PY/EN.NV#D[\>W<_R/%32QV\;\@ &3>H];?T_^MU^M*1!#*H(_P"/
M@[3QP;1\<=QCU'6FL.Z4OKTFY-JUVMT[._5;OONEV-J]95\-' QV]HFG?XN1
MI=OL[[DB ,"<]OLXX_Y=_P#GIT]>-W^(IHMK&X7SWGVW$#^0D88#= H_UFTY
M)!]:=YL2C QQ)Y0]?LG]WUQ_G%9[P6@O5NMIV [2%!),.>1M )[\<?6N;$9E
M&*YG[L:4+RL[IVM'5:7E?^N]X7*JE12@FHU&E[UM=;.25NBVWV6QJ7=_-=1F
M!5^2*#R@0,$JO&_\N_\ D9=KI]PEU#>DMLCC5&/0>6#G=TR>._MCKP(&U^WA
M:6"*TN?,:5@"+:?!M#Q@83[OMCCO[78K[47M_-,<\=BTGEMYB2(/)ZD8<#C!
M_+TKCP>;0Q&(A3C;EG&25WK-Q5N>*ZMR>FRZ=COQ>7+ 8=UVFHSM%NUFTX)M
M_>].[?G8TXXK74))YG<"2$,JC/\  .=W\CGWYQQ6?Y9F/F2,<QMY0SG'V=?^
M6G3CMSG'K4U[!#9Q6]U /EN-B/M&,P,,G.,GZBI+N6!3 J@ 21*K<8S;$_=Z
M?Y'Z>DI24E)6:2^!:\J:2:6_K?\ (\+GYI4XTXRCR.7L[KXI<OQ2[-MM-7_,
MK-&MP?,4Y:(B)5'>(8P_'X\__KJ0B.6&2-&R;?;Y0!!+[C^\Z9) ]@,<9J-C
M':_+']]_N=C]G/ Z=B,G'7VIP2.(@P@YDS]G]O\ GKC\R.:<](6YFE2]^$_Y
MU>FW9O>RU^7<WA/E::^!N5KZ6K2Y(N_EJ_\ R;M8LQK%(RX;(C!\K_;W?ZS.
M!SM]O2H"T-O%=3!@3:%5M<G 83';-CN<9.<=,<^E,9XX NWC;G[-[;O]=@CI
MDY],T@M8KBYM8.L$JRM&,<9"EG]_O>M==+%?NG%.2O'E323O/G?,XKNVX<RO
MLVUL>=4PLYU/:^ZO@4O6G%2:6EN>ISN+7G+>R-"_T^RGL]%T^*09OHKQV8'G
M<JE\\'L>GIQTQ7]HG_!N9\9I/%/[-6M?!R>[-Q)\+)4V*S[I%76+V6<!ADXX
MQC@#%?Q))(\5MJ5X-P;298$L#W19Y-DVT]@1G.-N1@5_1E_P;M?$J'P?^TCX
MT\%"Y:)/BBFFF" 2,!,VDV;RR_("%.TDD[A7XIXMY!2K\(9AC'=O#\F(I-Q7
MNRC5YI6?\W)&I!:;.Y^Z^#&;U<-QCE6"4H\F)>(H.$97BE.A)=4K<MX.W\SM
M8_N!4Y48]!2TQ  HQ3Z_BA_U<_O*/PQ]%MMMT$R,X[U_$[_P<B^+QX@^-_PK
M\+1S;Y/"W]L[H@02@O+>.3D?GQZ"O[792!@\!ADC/^?K^./:O\^S_@N9XFN=
M:_X*"?$;21,[Q:#_ &7]G0MN$0N-,1I-JDD)GOQD\5^K^#5-RXXRYJW\.LKR
MVC>UW_X"G;T/QOQQQ7LN!L?332G*O045=I2C9MN5ME&33;Z>Z?CV@WV3>;\O
MDD"(?W]Q ;ZX]NG?-7C"D4%HR/N:(/Y8Z[]_WSCOM&:SIW1Y/+C^Y&?W8Z ;
MN7X]S[?3MF2.4*A//[O_ %..P;B3&>F>2>F?>O[<I2ESJG=->TBE'5*\K)OT
M:C_6A_"=;#RJ4J=915HMR]FNJG*UI:=)<KFELI^HZ,!7^5LK!N^SG ._S?\
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M)PY*^A+#W_K_ $M2.(U+'H,?KQ7\??\ P<<>.+4ZUX6\&K,#>0W-EJDD6?\
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M24?AZ:<UEZ_EI[."MS1^&5ZFG_+M_"UY]]NHZ22.%D!)SM"#/>U/H/?T&#2
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M&,I_6HSI75Y.G1Y8V=_LMZI)[:G\D_2%XDF\SP&0PE>E*G%UI-Z7J1<G%/\
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MIZ<T$02#[3)DX_UY_2+IZ\=/3FC]TA%L_1O]>._K'T].#P>O6C]TA%L_1O\
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MW731KYB9BG0=VBF/X6P^G\C\W]3,4Z#NT4Q_"V'T_D?F_JJ+#&[;>%=O-/\
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MW9$KQN#(/X/DX_Y]1^'X'O2L5)S\V2@)_P"O+_/X4.D4&4'"R28'_7LWY_\
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MK@E$Y\O'V?'_ )%Z^O).?PH;RK<;X^/,_P!1_P"U<=?4CG\*&\JW&^/CS/\
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M4A^S=D'0?\_(X_\ K==M'[J0_9NR#H/^?D<?_6Z[:/W48%SW8=3_ ,_)Y_\
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M8T8*"7+:2?Q7ORRT76VJ\FMC,B\/W>NZYHGAJS1Y=1\17EOIT4:Y+M=W3;5
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MB_T_+%=761H$/V;0M%M\8\C2M/AQZ"*TB0#\EK7)QUK_ #HJO]Y4;?VY:_\
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M^#_[*G@"<6:6^H>*='TW7K@F(*[O>62%F8D9SNZ\\=J_4W:"S;ASC ^G^?\
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M#@?ZQ93Q_P!,?_U?B/YP+''(S1J#M'_'M[=Y>I]C][J.:EWKOE2WSYGF$_\
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M_7[XZ_Y_GTK^-<VXRS'%XVI4HXW$4:?N*A3C4:BH\J4VTK^\^NOS/[2R'@7
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M&,H49S<VE=Q:34W\FM^FA_2+1117\5G]YA1110 4444 %%%% !1110 4444
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M[_89)[?U-?Z-,"A8DP.JC^5?Q?XY6_UN<K-.>$I;VV4YM6ZVU=O*RZ7/[=\
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M>*_<9NF/4@#ZU_G[XDXVKF'$N:595'>E4C1A)/=48Q23;WW:>W0_T(\)\##
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M"R5.*M;FHP=2_G*ISN7]]R?4PM> ;1-75AE&TK41(#_=-I,#^&.O>O\ ,_\
MV];32K#]L;XT6]AL&G3:I"3MY4R 2$[<'KYAY_+K7^EKXSN!9>$/$]P<9A\/
M:U*3_P!<]-N7!['C;^AK_+M_:/\ %:^,?VDO'NJY:5;GQ!JL3GKO-O=7,:_7
M:5''; _']B\ J-3Z_CG\$:5/"RE;=V=5\MD]'I>]OB1^+?2$G3>6Y?!OFO\
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M#_[/;8SX,TOAPW_'A;=1W^[_ /7]J?\ Q&G'/?#.\DE*W+I:WPZZ*]]KZ6[
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MYPFH? GQW)-X>N;;0-43S]2M=&N_]&D^>1\[V;@Y'KG&:_OJ_P""6W[-5O\
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MFF/K33YJF*K.2?E-I?.R1_I/PWA?J>38"@K-0PU))Q5D_=OIY:Z$4SA H/\
M&P7\_6O\YK_@KGXV3Q_^VIXZU3S#*OA#5=1\-9.#Y;6-^YQW"XXX[?6O]%;5
M[A;6U,[' B.\GT"@DG_/Z=:_S$_VUO$?]O?M3_M19)=T^+_C"UMSUQB\;9C'
M3 _+K]?U7P7I2_MRM7NHQC"C=OJE67,EYI-?UO\ C/CQBO\ A&P^%2YY*LY.
M,=)*$Z-N;S2DV]-=CY?MIXBUW 4.Z[N6F3(XW/PK]>>OWN>^*E#QO*;<KE5!
MA [>>#C?GZ_Q=<5&\D*BQ9(\/%IL5O*=H_X^A]YCZ-UYSGO4A>-(Q<!?F8"+
M('_+<C._'T[]<U_;->JZJIKD<7""<;_:JI1:[WNKNU_)ZG\14J;I.IS7<74=
M]=7*:BH2TZ:*W7=]0#QO*;<KE5!A [>>#C?GZ_Q=<4!XWE-N5RJ@P@=O/!QO
MS]?XNN*"\:1"X"_,P$.>_GD9WX^G\77-!>-(A<!?F8"'/?SR,[\?3^+KFL/2
M_P#/'_K_ -8^?IY>>NVWQ<WN^Y4\ZC^&7]:CB5QC;D(_V<#/_+<?\M.V?J>:
M>LR+(T;C*^44.>AFZ%Q^/&[&>*CRIC1]N0Y$?_;P1_K/_KTD[QEU 7#)%Y;'
M'WI0>6X]3GD^M<R7-6L]-+O^ZU.+;?>*>EM=UL;82%ZK522O%I-]>VO=]%KN
M]NI#/( D,0&%C=?./0/EP5^N"/PXZ\8];^ VCGQ#^T/X%T*-/.&M>(=$D$:K
MG>+&[M9<@8YV[2?;D\<"O([IT:V7:O[P<O@'))Y!XS7WM_P2Z\%Q_$#]NCX"
M://$)UCO=5FN%8;MWDVXECX/]W;GD<>U>3Q_.-+AS$5&N5^PJ<TG97BK2<D]
MDDU9?.Q]'P5"=3BC+Z:BO9U,2ISYM91_>/V:OKKRQ278_P!(7P7;K;>#O"MN
M%P(O#>AQXQC!CTNU3''3&*Z>J.G1+;:;80 86WLK6$#'010QQ@?AMQ5W/)'I
MC]:_SDJ37M))R]YR>C>NK?YV?W'^EE))4J:2LE3@E9:)**T^5_Q/*_C1JD>D
M_#/QS>RL$2'PGXA!8G W/I%XH],?-QU_&O\ +*O93>?$/7]4N?WAD\5>*][]
M=^[5KX1G)SG QC)XZU_I5?\ !1/QT/AS^R3\6?%7F&(VFCFUWAMI!OEEM0"?
M<R 8_$5_FEQW"$WMVXS)'J^LW,S$?>^VWT\D9R3DGYQS[&OZA^C_ );[:GC\
M5'>==4)WV2I4HU$]._M97/Y.^D3C)4Z^%PTJB<98656,5U=64J-K/?2"TVYE
M?4K/^[O)A*-ZNQW]PV<E>HYQG\_2G,\<<BV[+E4_UHZA]XRG/?;D8R..U/$B
M&VCF=2S0%S*2,EO,8B/KUV]\]*8KQ^7]H=<M%GS3W?><1\'KM]SQ7],S34I*
M5E>]VME4CSJG;33FBD[==3^6Y6]UN-K4X*M&.BO*#Y5MHTY6TUO*+Z68SQQR
M+;LN53_6CJ'WC*<]]N1C(X[4,\<<BV[+E4_UHZA]XRG/?;D8R..U"O'Y?VAU
MRT6?-/=]YQ'P>NWW/%"O'Y?VAURT6?-/=]YQ'P>NWW/%2];WTYKRE_=K+GY5
MMI?MU$]+\_,^6ZJ_WE+G]FUV^)6W?OQ[:J'AAN$C=<^2'\S/(;S%^7D]=N0.
MG'8&D26.)45DRF7$@_OEL[,^NWCKTQQGK3,"6+S<?/&3YI(Y8,3LZ]<#UZ?R
MLQF'R$=T!^S;O-! ^?S#A/7[N>IZ8XZ<U0;EBZ6]W*7/#M*.MTNF[2W=T_,Z
M)Q7U*I*H[RC*4;O9-I\M_*:FG'1I6U[MD,B1O'#(HX60S'J'W F/Z[0>X.*_
MIW_X-J_#,&H^./CIXADB5I=!/AT12%<D"Y65#M; QP<<'Z5_,!=.L-K)-M_>
M6RGS,9)829V8..=N>_/85_7O_P &S_A=[/X>?&#Q++'@ZX^B$R$<R>1/*HYQ
MS@8Z'O7Y#XZU?JN2594[6<71F]%=572HN*ZV<&W%66NNZ/UWP*PCQ6>X.I#6
M="2J3:LH^XG53MI9:1D]/A77<_JI!SS36[$]!U'\J4=!]!2.<*3_ )ZU_#M9
M\M*I)[1BY?\ @/O?IMUV/[UCK;SMMY]OT/S<_P""M'B]? _["GQE\1"0Q&&S
MT^WW X(^UW1@/Y[L>_;O7^<;<-%=2W5ZPW-?Z_<7+-_>2>620\YQGYN?7GVK
M^]W_ (+Z^+DT+_@GS\3=&#[;C7&T40CH6$6J1EL?3/O_ #K^!K3V5] A+#]Y
M#,ETS8'W%4DC.<]??&:_KSZ..#G4P%>NTU.6*J.3:LE!T*,6O6\)66MC^+OI
M+8]1S;!TE&RCA:=!2=K-N<ZO-ML_:1CKU3&F(0ZI-;J!AH3<L.WE%ON?B#TZ
M?E4TCI"4C"X$A$Q'4>2Q^YV_+I_*HD5I+H71.=T>_/)_<'G9GUQQMZ?3-3*T
M<OF.RY,3&4'OY"_P?R^7I7]"5=<3B82?N^T7-_=T3@]^KT\C^<Z+OAZ%1ZQ]
ME3=3E71IW3_[>UOO9"2/'"RQA<"0B8]_W!/W/;W7I1(\<++&%P)")CW_ '!/
MW/;W7I1&\<RO(R\QDS>G[@#[G^"]*(WCF5Y&7F,F;T_< ?<_P7I4[_&K<_\
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M=/--;+NNIOAJKE1D]%)RC%12LXN34%)VZ-Z_U<(WCN6= N.GDYXV;,E_7&X
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M:4N>+\W[U[)_GY'^BT(I6CK9*R]$K+^NY^1'_!;_ ,1?V'_P3Q^-K*VV5O\
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M24;==5;[]'I8RK4HJFJLTVX3Y9:V;A-+DLT]UMZ7[D%Y+;V=E+*\890K7+#
M/[C&2AZ<]>.!BO[R?^""'@.;PC^QTMP\?EQ>)_$O_"1VPQC_ $>[L8R@^G '
MMZBOX,[J2*?3=0B:/<SK*R#&3Y!'" <X]@/Y5_I%_P#!*WP@/"?[%?P5'EB/
M^U_!.@:HBXP=D]@F/Y?SZU_-GCSB(X3"0P<5+]]B*<U*^CE'6VNKLON6Q_3/
M@!EU/&8WZW7_ (M&G4C%-?848MVZ)O37_AS]%F&5QZ?RI4&%^O-.HK^3/9+V
MWMOM<G+Y[_E;IWU/[&OI;I?_ "$SSCVS7^?]_P %T_%$/B[]M[4+Z!@T>B>!
MI?#KXY'GV^H2$CC@'GV_'%?Z #L$5G(^Z"?P%?YK/_!33QK_ ,)7^V+\90',
MG]C>.M=TQSG.(X+YLQ]">^,<"OW3P$H.MQB^:W*J"L[=>=<JO]]^Y_/_ -(F
MLX<&T84W^\EC.;DZRBH6^YM_U;7X,BN+:2WM$$?SP%#*<8R% ##CU.!^?M2S
M2)'(%"X$K"8\?\L6Q\AY_3I4\$,,%IY[*/WEWNQP/W9_AQP.W3]*A#1RF5RO
M^J=I1[0+_P LQ_1>!7]DU%_MF,A*W*JSB[:<MK.*WWYM+K3]?XJ5G@<%63;C
M*+E46]XI\OX7U\QLCQPLL87 D(F/?]P3]SV]UZ42/'"RQA<"0B8]_P!P3]SV
M]UZ41O',KR,O,9,WI^X ^Y_@O2B-XYE>1EYC)F]/W 'W/\%Z4]_C5N?^+Y2C
M;D?S[^?D9;?%S/EUJ>=*7P].G?\  64I;@;!@W!!B/\ <7C()[9'''\J9)<(
MN41<#Y3&1_!CF0>V[GH#GO2Q,MT60CECF$G^ #DCKQD9X'K^%/A$4OGQLG[Q
MB/+)Q\H3[_KC(';\:N,85(S]HOWCY5./:FG23EY+E?2W8TC3O"4Y27-3E!QO
M;6E)0E]R5-Q?>[5G<69U==\*[3< >7QC9Y>/,]<9P>AP>_OZ#\.K%-<\9> -
M,LTS<7?BO06BVC)'D:Q:-(<KR,@'/Z9K@('1I'7;A9%80=/D*J=_TWD'\_7K
M]'_L->''\;_M4?!SP?Y1E?4-;EGCC(S@6,L5PQV\]ER./3VKQ>*JT,)DV(7,
MXWH5+-/6+4&HIZZ<J@H^K>FIZ'"2GC.(L+*7O1ISI2TUNXU8QG"-F]=OG?H?
MZ:?P]A$'@3P:F,>5X4\.IC'1ETBS5OU'?V]*[!I N/?_ #_/_/IA^%H?(\.Z
M' 1@0:/IEO@^L%E!$?R*FMFX(2(L1]WV[=Z_SBJJ<L5.[O%RDN7[7.Y:.]_/
M77?\?].*#C3P-.5.T8QHQDG;W>513NDMERK1=%:VUW_#Y_P<8_$"'6_VA/!7
MAN/+OX-:^$RC^'^T+>)AD9.,C/IGO7\^,H5V$D8VBY5&@QQY>Q1YF>,?-T/.
M#GOFOUR_X+A^)[?7?V\/C#HI(D_L5]!\L#GR_.L(F8>@S[>O(K\B(I!<%XD!
M4NJ?9^PC" ;^^%W 'ZGK[_WGX+T(X/(,)5IJSG@Z-U*[7,Z<8SLO_ T_-6V5
MC_/3QAQ7]H<38^S4XQQ-><)KX4H5Y132[.=F^Z>I-/-&(-P3Y9"HA''R;"!)
M[KNP>W/'J:2XEC0^9&NW[0%$>!]T(,2=#QGV_'UIB21W DB5.N!#G&(]AR_T
MW8[9SW]"Y2D[O'MQPODYXV;!E^F<;@#TZU]Y&2J8O%.2:4JD.;^[3E&BXO2^
M[2UZO7KK\&N:.&H1Z*-.I.VW)S1TVW:WM>_*QLKQQ*'C7;]H_P!7C^'9Q)TQ
MMW'/3J.M$KQQ*'C7;]H_U>/X=G$G3&W<<].HZT1O'<LZ!<=/)SQLV9+^N-P!
MZ=3UHC>.Y9T"XZ>3GC9LR7]<;@#TZGK6RUMSW7-RPK?W8+V7LY;:7TU6CT^>
M2TMH].6:_P"O#]CI\OOT>FH2R1PJ'C7;]H(\O'\.T@2?[NXD],Y[U4FE%Q->
M+",)8^02 .GFX+<8QR?S/>IGFCE5SL^4,@BR,;=I^<>V['..O?TJ?31$UQK[
M[,+>);",8'!C7#<=LGTZX_&L*<G_ &G@5-74VX271**IM2TZNFK)]&[^85IJ
MAE^)K<K<HNE[*754YJG"R=MTI[OL^[9UOPZTE_%OQ$\%>'K!&^V:GXJ\.26Y
M53E5L]5LY9NF",JIR!VSWK_4Z^'EH+'P)X,M0,>3X4\.QD?[2:1:*W_CP-?Y
MI_\ P3M\'#Q_^V7\&?"0B\V6]U6ZN(TQG;]B"7!.!G'"<5_IGZ)!]DT;2+7_
M )]M,L+?_OS:11_^RU_*?TA\3.?$6#PZ?[JA3K**N]7;#IR2OL^73YV\O[+^
MCG@*5/AW&8]P3KXBK3C[2WO<D/:QM?>S>K6E[)]C3J!I"#U// J>JCL%V;A]
MY@H..]?SE/F=;#Q2;3E*4DO[J5K^6OS/Z,J24*4Y-\MN5)ONY)?>]EZG\'7_
M  <1^)HO$W[;'@^VM3N&B> K&&<#G$EO?R;L@<\#^G2OPYFF26%Y(UPOG$$8
M_P"6@'WOZY]Z_3#_ (*T>.(?B#^VY\3)5;S%\+G5_#Q)((26SOWR >V#Q^@K
M\R(9XMDBA/D,!3&,#SNF[KU_VL9Z<U_H1P#@*. X3RE4E)VP]"4M=XRIQJ-_
M?-].S]?\XO$+$SQW&>8UYOWJ..KQB^CC3<EMY].]GL11M$IV;"6F&Q3Q_K3G
MYO;!(Y//.:G8I"AEVX8'[.2/^>P&3)_]EU]*C#(S1C;@M"(U..!-_?\ PSUZ
M_K4B.DCFW9<D#RSGO/T\ST_'KV'%?>Q;G22:LFDHWW<4ES23UT:5O4^#K.4\
M6YVM-TXN>U^56NM^J5]4[WW!GCCB%P%Y8"+/K-C)DQ_[-][VH9XXXA<!>6 B
MSZS8R9,?^S?>]J<)(Y)#;[?NCROK,,CS/3_@7WO;F@21R2&WV_='E?689'F>
MG_ OO>W-+E3O:_O148_]>U:Z]=/4+M_"G[S4H:[4U;F6^E]=/,0O''&+C;RP
M\K([S8R9,?\ LWWO:G0PM?6,EI_RT\\S]?;KW^O8G'6F&6-O,B*_+$A0\=9E
MS\X' ]?FZ_G56*XDM9Y9 " UH8@!Q^\_O=,\<\^]*,%+$89->Y*:49/K"*MR
M>O\ 5S>%EA\74V2I<U%-K6]DDM=+.[MYKT/H_P#9*T:+7_VK?V;M)$7F*WQ6
M\)VLRXW98W@#.PY!!]2!T]J_T^/#NFQZ-H>FZ=&FQ;*TBM54# 41KC'&.F/\
M\U_FV?\ !,+PM+XP_;4^#(6)I1HWBK0=9; SL:WOX\RD=L>N>/S-?Z5:G]WC
MOG!^OK^A'_ZZ_C/Q[Q=1Y['#)_NZ%*I-?X[J&O\ V[9>KN?VG]'_  -*EP_/
M&74ZM:5./-:[4>52E%O77FU]'8<7P@/?I_+G^7YU_ Y_P<">.5\;?MX>')+6
M3-EX>^'UKH,L>?E%_:ZC)F3 )4''\6,^W>O[W\_NL'KG'XC S^?^-?YN/_!4
M;QS#XU_;F^*6"7C\/Z[K.AGD$+/;:@W(YR,<>_M7!X$Y?3S+/9XZ<7*IE^$I
M5Z=G]JI4]FT[];*U][W[B^D/G&+RWAG"8/#-*&98V5"K=7?+3I>U279O?TTW
MV^ A)!%<7]ZZ B2.6RC]KDD$-R/;KUJDI41*54AAC/'64#EQV_'OZYQ4C.H5
M(W7B76A$,C(+-_%VSZ=<58F>);BYC5,*@>(?]= 3\W'_ .O^O]MRI_79X>O5
MB^>E9IRVC**44FK]>WYK;^+<NKO!4ZU"G>I#$J2?5-IQ;NGWYM=-=>K*TDR[
M#.%(!7R0/2XQGS.WY]:<71(EGV_,P$)('6<C)DQ_[-UHBDCEVP[, KL _P"F
MW3?Z#_>Z_K0'CDE,!7(4&(#''GYQOS]>^,XK2M.4WK\#T:_EI647Z6:N<M.D
MH7Y4U.=YIIZ<ETYK5[Z):]!V8EC%T5X0;9!CEI#CYO?GN::KQ^7]H=<M%GS3
MW?><1\'KM]SQ3?.C\WRBN8H\QR+C.YQQN]^<\GGFG,\<<BV[+E4_UHZA]XRG
M/?;D8R..U<[NO6*Y4N]%\]WYV[^IHTW;EO[ZYJ%NEN?FCZM.W:\H]M1'0Q_:
M&7<T1_>GN^\XCZYSM]^F*D+P+.B2IN>.*9I",'=NC)3Z[0>_3WQ4;.D4BV[+
MD)_K1R0Q893GOMR.O3M4UI&HOK=9E^[*D,C=0QNF$<6?^^QCTX%98NJZ&7YE
M44K*EA*G);XI0<FKIV\VGYM&V#Y99GET91;H5L5".JND^=W^4I.^B^U'70_O
M3_X(&>#K?2OV"_AWXICA5)O$DNLB=]N&<6>J2JFX]20.GX^U?N"0#U%?ES_P
M1[\-3>"?V"?@CX=G0QR)%K<^PK@A;F^,Z\'U5@?IS7ZCU_G3Q1B:V-SW,ZV(
M?/*6+K03[QHS=*/K:--:_KJ?Z9\*X.E@<@RRA1BU%82A-WZRJ4H5)-+HN:<K
M" $  U7EN!%+#$029=V/3C\*LU5NE7"RL 3'DC/OC\/7K7@)6Y8I.6L(VZVN
MHW^2U9[U2?)"<W]F+D_DKW/XD?\ @XM\=V/B/]H_X<>&%R7\!C5A=K@'G5+2
M-HCC/8\\XK^=TND3F(KN(+-*1_&&YCZ==H(Z].U?KK_P78\61ZE^WQ\3]+C(
M<:!_8RN!@\W.G1D8&.2,9YYXK\A[6XB80/(F]E63S"1][( 3KUV^_P!:_P!
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M[2>NKM;2]]78DAF6\-E+>+O^Q:2ELQ89^2,\KSSWZ?B*GAGM 6:WB$:HAE(
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MGENM?9L _)Y-HS\],9QZ8K_1TM8S%:VT1ZQP0QG_ (!&J_TK^1_I"UZ=3B7
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M8S_PA7A[/VGR?NWO^K_YZ?\ '[G'OTK^/0W6I,[RBWD G7R0F,",_=W ^O\
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MC/.FI-PC5I4TDW9<E"G&27;W^9M=&W?6Y_H5X38?ZMP'D<90Y:CAB7.ZU?\
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M%I-KI%I)+9W>]R-G "RJ@4W#*% _Y8;6 ;'_ %TY)S^!K].?^".?A^U\1?\
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MG0_O#P(PT</P/1DHV=3%5->O*J=)J/HFWZMN^H5G:C<1VUI)<R86.%6=F/1
MO);/&,8S6C7DGQY\1#PE\&_B1XF9M@T/PGJNH^9G;L^SP%]V[MC'^37Y!AJ?
MM,5AX7LIU84G_P!Q)PC>^^FNG4_7\==8/%.+LXT*LT[7LX0<OT/\US]L?6Y-
M;_:T_:;O9)/,:3XR>+M,MG/_ #[?;6*LN.W3#'(_K\Q,BQPRGRQNC!MR.>6
MQYW7.[MVY]*])^,FN?\ "4_&OXF>)4.Z/7?'6KZLS;LAA<SES*2!T/=N?YUY
MS)=[I[H^6-IC:%>.#DG#@8_6O]%>&J<\-PYE])>^EA:<5*R5H4XP@W_V\DO-
M-:^7^:G%<_K'$^,FY64JE9R2]UO]XV]NKEN]Q-R-%!((U5CMMN_RMC_7\GAA
MQSR!T[42[;=/-50S$^02,\OR?/Z_>..,8'7&!4:R$F)"N T0A'^R3_RT]O\
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MV/[W\%,(\+P9A*G(E[>LVTK1Y532BFOD]MW^>-K^H)I.@ZIJ;D*EC:37)+<
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MHT:<6FYP@HIJWO4E&:J.UN]W9[7^_P#S.QC<\37E=MU9RG3Z<OQ.2?9ROO\
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MEJN-.S3]Y-.^JM;W;=-U;T3?H7@(U)R;A[]Y>X]E=2E)VOY-2TWNET1_<?\
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M#$X>EB*;O"M3C4BUKI)7^=C^,O\ X.2O%#-\8? WA)E++'X.T[6>O5A/+'C
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M  KX32 ;ON_;[**<_+CC.WUP:_N9U"416TSDX$<;R$GL(U+9_3GVZ5_G(_\
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M ,OE['W]];6]/=WU$6Z+QS@H )2H4'G;Y9^@P#[_ /ZYHIM[S1L IE52I/\
M!Y8R<?[WT[U%.X"H0@S<D9'39Y1'7K][D]OQHN':1VF5"FX*#CMMXYZ'G_/2
ME;X%".CDI0;_ .?EJ%U_X%&WSZW.JA%5(-/W94H.G??7DAK;J^>R7?4?87)@
MUBSOMI^[/%L_YY[D,>1SU;/MG-1QR-:WYT=@3]MN8HRW7RFN) JKZ?,7 '()
M/KFIH7#7$,FP?Z1EBN?]7Y(SG'HV,Y_0\5L^%M-F\6>*+>.VA9Y]6\3^%(;6
M-!EMD.K6D=QM R?N_>QC@G/K7G\48R."RN7--.,:?-*V]X3:;OW5N7=733*X
M1HU<1G]&E/WDZD8P6CU;4^77:UTOQZ'^A?\ \$;O!$_P_P#V#/@_H5U T%TL
M.K3RJR[6*W-\9D)''57!SZ5^IH&"3ZX_2O$OV>?"%MX$^#WP^\-VD*P0VOAC
M19/+4 !7N--M99. ."78D]\_6O;J_P [N(<3''YWF>-B^:.(QV)K4Y7?PSJR
M<?\ R6RL?Z7<+X66!R'+,))<LZ&$H4ZD;6M4]G"4U\YMOYGYG_\ !6_QE)X#
M_85^,GB*,G?!!I5NN#M.+N]$!P?HWX@XK_.<>5;'5_&5^Z!O[6GAG5&/W"[L
MY&,=R_)P.1UK^^W_ (+M>*8M'_8.^)6D2,H?5GT78"<%OL^IQL<#O_3J>.*_
M@1O6%Y/?R*,"Y6V.WC">4HQ_WUQ_]>OZ1\#,-[/+:M:JN3VN+E6I35WS04:4
M$M-O?HS7EOU1_(_TB\U@L\PV#4G:&%A3GN]8UI5[M=-*J\[>A%&I94++A;S)
M''^KV<9S[YYX'UIJ2^9.8RGR &W&>G7_ %G]?ZU+<W>ZTMD5 K.&!(ZIL./U
MZ]L_2HWEVPB8)AV_T?WY&3)_3I^-?TK-RD_>BXV;4%?_ )>IQY5\H\L5?>U]
M#^=L/'EI)ZN"?(HM[.48<DNGX=K]6(DF^=HBGR*#;#TZX\S^O7\:$DWSM$4^
M10;8>G7'F?UZ_C0TFR!90GSD"V]#TR9/Z=/QH:39 LH3YR!;>AZ9,G].GXU'
MI?NO^PC2Z_X&QO:WQ)^Y^[GKO4E\,M^GEVU&&<;Y$*_*B- O&0<=' _SVY/9
MJ7!:2-&0!67[/_L@'CS.F?Z<=<4,Y; V+E8@A/T_C[?GZ8!P:M.XDAC=4 8I
M]EZ9P<']YTZ],>XZ]:J*3<(6]Z;Y[W^&JEKIYZOMI8JK%4L,JKE[ZC+G7=II
M1DM.VOD'FXCN"%!&UK0  DL/^>G/8_\ ZJ_J%_X-LO!;7GC'X@?$)HRJVVF:
MGX9''!*R12[L^I].>?I7\N9G,4$SE>5C-J>Q)QGS>GJ/?_#^S+_@VV\,K'^S
M[XZ\6^5M9O'FHZ7G;RP-M&^[)'?@U^)>,^/A2X>QF&>KJQ]G%W?OSE.-_P %
MII;8_8_ _#QK\3Y?B)+G=.I&I>WP1=^:ZV?Q*[^?2Y_32G3Z$BG4@.<^Q(H8
M94CI[U_%T'>*;=[[NUNO;RV\[']Y[+1;+1;;;(_F _X.7O%"K^SO\-/"((\V
M3XH:1J;+D9\HVTJ$[>../\.G'\=,ACECC^0 [1: =-HP,2?0?Y..O]-G_!RI
M\0"WQ$^'/PV5B^W2=*U\Q!LXQ)+%YFWGI]/K7\QL;E]C%< J+;:??_EM['M^
M=?W+X*8!4^$</6IP?-4A.O47\_/HO6[BGTMZ'\#>.N.E+BNMAY7LI*C&=V[1
MT=K+M=]_Q$0XN! R@CR_(W'D$YP9/USCZG/2G))OG:(I\B@VP].N/,_KU_&G
M2R$.V%^:.$V^[N<8^<' _P ]_5K2[8%E"?.P%OQUZ9\S^G]:_4,.Y.FDTU:3
MY%?:K=67S6W3[M/R6K3]DX.UZ;IP4=?B<HI1EOT?;RN"2;YVB*?(H-L/3KCS
M/Z]?QH23?.T13Y%!MAZ=<>9_7K^-#2;(%E"?.0+;T/3)D_IT_&AI-D"RA/G(
M%MZ'IDR?TZ?C6_I?NO\ L(TNO^!L96M\2?N?NYZ[U)?#+?IY=M1IN=KR)L!5
M%, SWP>''Y?A[TMM*4FVM&,21>5],_Q_7Z^_;JXN! )=@W%?LY&.>GWS[=.W
MXTYI=PBD" $JMH>.1G!W]./3G/2G7FW1H+;]XTWU<])6MTM*-OUU-*4_8PKM
M[KV<9:?:[WZZZ^F^XV6;R6$*Q[O*1U!'_+0NN/3M^M?Z!'_!"301IG_!.SX/
MWDD7EW%^_B!I<K@L$U679DX^; _^O7^?V95@N;%6&_9J%A: ]3*;VYCA^AP7
M]_3FO](__@EYX)?X=?L5?"+PP\?E-;:?<W>PC:<7\JW.<?\  \]*_G;Z0^,J
M++LLI7Y(^TH^U=_B;I.H_P#P%\J>GZV_HWZ-^&I5\WS+$37-*E0J*G*V]3VD
M%?R_=U)-K^]:^EC]!Z8Z[E(_'\J?4-S)Y-O<2G@10RR'Z)&S?TK^3HZN-M;M
M6^;/[&G;EE=77*[^EC^ C_@O?XKE\1?MS>(_#NXF+PM]D 3)*G[9I\;=,\8Z
MDC/]*_%U%-G=(-GF* V..#N7!Y'&1FOTN_X+">+4\3?\%"OC->P_O([:;2(U
M(.0Q&GB,CJ?NL/?U]Z_-=;GY;=M@8PB3D?Q;_P /X<^X].E?Z \#X6I@.!\K
MH58)0^JT%.'>:H0YKM>:^:?8_P YN.\6\QXVSJM%IVQ-?DULG&=1U-KV?+RO
M;UL,+^4X4*"("?\ MIYH_P#9<\?TI6E\N=8@FY(?0</Y@]/;./\ #I42S842
M% 3;EN#UD\PGIP?N]1U]:E27$'G%,O!TS]Y_-/'_ 'P/8U]URN-##QFF^:BI
M<R>\K25*^[W4O_ K=+'YS3NJN*<I.<85N6<;6NW"W?75W[+G;^R#2>5.L(3<
MD.<XZ/Y@Y]>F<?X4-)Y4ZPA-R0YSCH_F#GUZ9Q_A0DFV#SBF7@SC/5_-/_LO
M7O0DFV#SBF7@SC/5_-/_ ++U[U+5[\RE[U_:>6(7M.3II?R[Z^>[TOS)RY+J
MI_?YN?D];7\E'F_NZ#W/V68(J;E@#'@</YBYXZ\J3[]#4D'-E;WH&2CR!T_O
M[VVC\L\<>M0AQY'FLN6@R,'_ ):>:3C_ +YSSUXJY!)]FTF-67YRY 0YR=[]
M>G.T&JI3Y*KJ234X\W,OYY72=^UN9M>C>[,<1[3E5-N\8R3E=_:DYM/H]8]%
MHMEL?1W['7P_/Q,_:=^%G@I?G_M#7+>[^[N!^P3PW6,9YQL[?6O]./PK:?8?
M#F@6N,&VT32;7_P'L+>+]-G\_:O\ZK_@D+H)U_\ X*(_!31V7S$M9=7E<XR/
MFT\S+G.>G&/<>M?Z-=HOE00P 8$4,2#T^1%7CUZ?Y%?QMXY8E5L_P\'*]6,*
M\Y+M3E*E&'EO!L_N#P#H^RR'$-ZQD\*T^6R=5TZC;3\HRM9;>K9:K.UBX^RZ
M3JEU_P ^VG7MQ_WXMI)?_9:T:Y3QW<_8_!7BZZ)QY'AK79<^FS2[IOZ5^'TD
MY5*<5O*<$O5R2/WRM.-.C5G)VC"G.4F^BC%ML_S:/^"C7C4>,OVV?CKXM*^:
M=>U'3[9'Y;/]FQ-:GGGIMY]/I7Q8["&..-5W[9%N"W7/4[./\CC@UZ?\;O%@
M\7?&'XCZTPWF'Q+J\*L3N\S;J-U#Q_N@=><'/K7E,%QB'81O*S>=S^>S///I
M[CI7^C&289X7A++6ERS>%HN44K)QY$EVM:W,O7<_S4XBQ4\=Q?FM27O1^LU8
MRUZJ4I1ZW>]VUH[^5QSDY!51RPNSWP3_ ,L^!^=-EEV-&JKPY6Y;'J3S&<YZ
M?Y'>I8;SB?='C!>9=V<_]<Q[?Y S4<,GF)([)RA:X7/M_P LQ^/3^5?007+A
M<)&2;A*C%N2E=W:T5NGOVOV^9\='F^M8MR?-&E*#DK6YHM?HFNX32>6\:*G#
ME;DX]S_JS]!_^KO1-)Y;QHJ<.5N3CW/^K/T'_P"KO1#)YB2.R<H3<C/? _U8
M^I_ET[40R>8DCLG*$W(SWP/]6/J?Y=.U3_C4M?=K?XO^7;_+;SOY[VY=U?V?
MORU^*E/X8_(DWA+FVB"C;+*DS>@W''EGKG ^GTIDLF)9 J_*M\3D=\?\L^G^
M<<BEMYBP:5EPT;&Y4GKQ_P LQ]?Y=JD'6V5EYN;Q;LDYXW\>7C'&/PS6E!?O
MHRE=3BI\U^LDERKL]-?5O<&XJ+HS]Y-<_+>WNJTHN_>WNV6NE^Q]1?L->''\
M3_MD_LY6R#Y=.^+GA759E X\N*_4,I]CW_E7^G1:1+#&410J@X4 ?=7H%'H!
MCI_^NO\ .3_X))>'#XL_;D\#6JQ;QHFJZ;K1P,A!;ZB@Y&!C;TS]*_T=(UP"
M?[QS_G_/3%?QGXYUW4XCPRLXWPLW*-V[R=;7YI)?*R/[=\ Z*7#-6HHI+ZPG
M!6^&$J*45?=[:=KOYOHHIB/OW>QQ_G_/X5^''[VVDTGN[V\[;GY^?\%0/%\'
MA/\ 8H^/AGD6)]8^'7B72;;) WS7%@Q51GJQ[ >OXU_FR6%R+O2-+5T DMK6
M&9R0,NZ#E/J<_G]17]W7_!P5X_G\&_L>6%G:R,DGB+Q=%HTJHVTR075C(&0C
M/*GC([\5_"#9?+;+%MQY/[_G^+:/]5TY]/>OZ^\ <N]EDF(S)0Y95<1-RF^L
M:35-)+S3MTW9_%_TBLSC5SFEE\)NI*E1@G%:<CG9R5NZ>_R+MW.WVJVN57Y?
M*0LO;.<[#Z>_MVZ4VXFV2JJKQ(PN3CW_ .69X[?G38I/-C=F7'EL;D ]\?\
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M=[1/35].Z_SK;2^;4$N-0E.9;N5K1RW7,F"9?SR2>0*5\+#*P4,8U-K]0/\
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M!90GSD"V]#TR9/Z=/QH:39 LH3YR!;>AZ9,G].GXTJ2;YVA*?*H-N,CY>O\
MK/TZ?K0DF^=H2GRJ#;C(^7K_ *S].GZTE%^[IO>.^]!6\]]/7;Y7O\*:YFJD
M-=H*W-'Y^?R$>39 LH3YR!;>AZ9\S^G3\:=<2DVJS>7SL^RGU!Z[_P"61_DH
MDF^=H2GRJ#;C(^7K_K/TZ?K5IID$*0% 29A >,87&/,(P?\ (Z\5$_<BIO=*
M:CUO2C';R?KNM/0<FUR15E6J4FM?A@Y)6\[/[EK;M_7)_P &V'@07O@?Q_\
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M7Z]/:D_X0;XJC_F3-3^_]M_X]Y^G_/'_ %77]/:O]'.7]@;X3N8_^*4TSY)
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M_!<O+R\W]WF/ZW2O\=+??VT-O2Y[]D>OO3688//:O E_:6^"@S_Q7>D=,?\
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MZ+V<;K5RC?E:M:5)^T]IWO9WWV_ _P S:DI5)SD[\U1RY+.W*X<\9>G,NO\
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M0;J?:J&U*V@(W")9OF_O[T+>W*],9[5+83%+O1/W6Y1J]JG3[WF7L2\?3/\
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M<D.<XZ/Y@Y]>F<?X4-)Y4ZPA-R0YSCH_F#GUZ9Q_A0DFV#SBF7@SC/5_-/\
M[+U[T))M@\XIEX,XSU?S3_[+U[U#5[\RE[U_:>6(7M.3II?R[Z^?0]+\R<N2
MZJ?W^;GY/6U_)1YO[NC9)O)F6()N6!ATZ.9,?7[N??IVJ6ZN'%_ -N(;?;D
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MA4YKJMRQ]Z]K0M32ZK>#;_[=-L);ZSAXN]IRA."\KT)16_V>1[]%M=G]Z_\
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M)IWW>D6O5>9K64HY]E$(_;J4*<GK*RFZ?/IWN[WW5K=;'^A3_P $0](.C_\
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M_P#X8"_:;^T74G_"!:O^\N7A4?V;> "-CD$?+STX_I6=<?L"_M13-.#X#UC
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M?EVC^$-WP1GOUIEW>2FZMU*X\WB7MM\L?+D=L_\ U^U6]1N6GMH=B\C_ %H
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MI;G?J?;O_!-[X5K\<_VP?A7\.[JU,VA>(-2GO-6= R"%]%5+V#$J8,6Z6(9
M8;NASTK_ $G/#]A'I>BZ5IT0VI8:;8V* =DM+6*W7\<1C)ZY[U_$-_P;G_"F
M;Q;^T+XQ^(%[:%X_ ,MN]G.5)"#5H)E;#8.,Y R#WP37]QT0(0#&/\XK^(?%
M_-\1F&?TZ%6I[2.&I7B^:]G4=G>VEW&E!KR9_=G@SD>'RS(?K%*DJ<L1927*
ME=4U&4)7ZZ5Y+U3[$E?R0?\ !SCXLO\ 3V_9QT"W=OLFI'Q2;Q1]W]UY+Q[C
MQ@$\"OZWZ_C*_P"#F77EO?B'\!]&#JQT]O$6\9R4,B0NO';../S]*\7PNPT,
M3QCEJJQYH4_:3:?^'D_]N/3\9,77PG V92H2<9U'&G>]K:2G=OR<4S^9U 9D
MDD(V/<A#<J!AD\H?N\ 8*[L#_>]*@:60PAC& 9VQ-P 4\IODQQA<X'IN-36T
MKK)(LXVK<HO)S@>6OR\$XR>.WY]*9%+(P59P%1RXD." NT_NSD],_J>GO_=E
M;VL<?AL+/FGAX*,I4WM?EC.T/YO>3TU=DM.W^>UU0CA:R:YZ]2:K./6*?M.;
M3>3LT]=XV$GEDE\[" *_E;R%"[=GW<$?=ST/KZ&EG=U1=J!6FQY^ !LV_P"K
MZ#Y=^,G^]4L4C%IHV_U<@!=MO"[.4YZ?,<?7/UJ*!Y)'E\Y=JO\ ZS/\&S.S
MKG&[ 'O7HUI+G5.UJ5!J,EWI2]ERO>U[V6FJ2[:G15A&-:3CK*ZJ-O=PA*G'
MV?J[<W+Z7"=W"*54!IL>?@ ;-OW.@^7?U/\ >HG=PBE5 :;'GX &S;]SH/EW
M]3_>H@>21Y?.7:K_ .LS_!LSLZYQNP![T0/)(\OG+M5_]9G^#9G9USC=@#WK
M%)+EYU\/+[7SI/V7L^O^37RTS72W]VLO\'[F]/Y6^'R6NHEP[JBE5 :8?O\
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M?DVMUTZG\[X=-TUK?VK<4[_ T[I^5^^VP0/(T<A=>03*OO/CB/GGG^[U_G1
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MTT*R/&N5BF9$XZQ#HV>,\'KFFMYLA48SY</!P?\ 5C^//]?? S5FSDDNHKF
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M+CS^VS;_ *OZ;L9YZ^U$#R2/+YR[5?\ UF?X-F=G7.-V />B!Y)'E\Y=JO\
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MCX:-N^<]5X.?SKJOBE\2?%/Q@^+VN?%36);FZ:[N;G6%CE,CQI?O.9A H8G
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M^<WYV_NA,RA@,_7IQGIGT]J#,H8#/UZ<9Z9]/:OX7A_P7Z^/9Z^&+7YOO?\
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M(WNU#, %&9)<#(!],FOC2(7MK+;Q7$15;9G.2#@K,<@_]\D]O\*_?+_@O_\
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M(;LD8QT]O#)XA/IL9O28H_$3(UXT?SO;36C!K-4'&1-)M5N1@$\,<"OZM?\
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M]?:GH\F)T<8B;89&Q\RE?]7M'&<G&>F.?2FQ-*6F\]0H./-QSMQ_J]N0<[N
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MDW*3;Z.6MNLXBFI1E"FG.$(RA"*5Y<]X1IKEZ^[^%FPN&ANM5^V0L&2!?].
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M CV%1_U[?W^F-^.V.M"-*9FW*!'L*C_KV_O],;\=L=:-M];:OSP[V7G;MNM
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M5R"?WXQB/U&?3K4N9#T7^$/T'_'Y_P \_P#=]SD^HHS(>B_PA^@_X_/^>?\
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M,XFABYX;GI0E&=2H[<L:$;N3;TU=DNNC1_0OI>FPZ9ING:="H2+3[&ULXU4
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M1GU[X:[WLY8X]TB0:E=1I=\C)_U*MU[?2OXB;.XL;J"6SM@!;8"HIXQ/%Q<
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M#P7H]C-=V$&KZ/+"%C)C%JEQ%-/AL!<>4K9R0?45_I#_  "^%6B?![X7^$?
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M:I(4/_ 5\S.1]>I^E)(9C-;>3]SY_*Y'7'[WK[Y^]]14DD<VTP19 T](Q#W
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M^6NNBU1TY5@:E7$T,-/GE'VJ5H*\G&E&4I^OM%=KHY19[C\'_A#K'QF\5/\
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MH_Z.E.4\ZG6:]R&&Q4(VV4E"*E\GI;KIO96/T0'WCG.>W^[[?Y_K3JB^;?\
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M''(BH68W;<'A0>XYQQ^-2+JCV?DP6"M)<*[&YV(7;#%B. &_AZ<9/M7ZK_\
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M!T*="G#$^SIRQ$X12<JJ]]J_57:;\^Q?HHHKXP^T"BBB@!",]1[U6N;:.=)
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M:>+:A2(AT/0-]_&<\_I7]PWPR^%OACX0>!-&\&>'K."VTC2H(XE$403&X+W
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M]*_KAE)"''T_.OXE/^#COQ/'XJ_:$^#_ (4DD\Q/"*:^UQ&&_P!4;VUCEC)
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M]$4EG=3P1E0=JNS)GCY@V3UZ\],X'UK^DG_@V]\$7/B/XV?&'QCJ$6Z?PH-
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M?I1117\T6MLK7=WIU[^I_5@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'F'Q!^(FD> 8%O]4E$5NH8REL@>W3W_ *?2O'(_VNOAL8)93?PXA*JY
MWMP6.!Z'_/3M5?\ ;!\)3ZW\,-6O;,N)K6'+!,DG+<8P1BOP+$>K6UG?V\\\
MN^*8K.NZ12X,IV8&\_=[Y)^E>[@,#1QM*G=3<E)P:CHVU:3?RB[*^]O*[^8S
M+,<1E]:I[-)^Y*I9_P -)V<6O.\9<WXG[]?\-@?#++?Z?#\NW^)N_OBC_AL#
MX99;_3X?EV_Q-W]\5^!$?VG"EY9N!^]S(XWDC"\ECC;Q^/I3E%RI^>6;Y?\
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MP/AE_P _\/$>_P"\U?@1_I0_Y:3]?[\G^J_N=>O^<4QVN45F,D^%^8_O)/\
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MF:[TD>1N L58K 08P?3J>W:OE73+:/7M,GGD4K>1;FVN"C>>%R!@^_MUK_3
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MUOTZL_(C1-'U;Q9K]AX5TFTNI(M6E\N<)!(1NR/(!.TC!8@^O]?W^_X)V_\
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M^Z.3_G_/MWK_ #X_^"Y'Q 74O^"A7Q(T&Y9WMO#ATE(E^9E3[;ID><=AD^F
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MNY6VLN\?*?\ 5^G&>3^>.E?TVR?\$%?B4SQ_\3R+9+D7*_V4WS!.(]I^T<8
M&>*23_@@G\290N_6XB5D"<:4W_'N/X1_I/7G@_I7JTO&[(G!2J8J%^17C&,K
M\_+3BK7CKJM?7=A2\">(9**>!J1BI*6KBY6>JCH]E+?K[S[G\RDEY?QNI96V
MNOF ;3_JO3CO^M$EY?QNI96VNOF ;3_JO3CO^M?TUR?\$$_B1(%#:W%\KB,?
M\2IO^/8?P\7/7G@_I1)_P03^)$@4-K<7RN(Q_P 2IO\ CV'\/%SUYX/Z5?\
MQ&WAY;XN+M32=HOWJCM9P]W9:<WJ6O ?B#W;X.>LW.7P^7+%>]MJK]=^ZO\
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M_,F]Y?@1R*K!),[/E/&W[^?KSU[T/>7X$<BJP23.SY3QM^_GZ\]>]?TUR?\
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M%0#MT4 =.O\ ^NOC>(?%#-<YIU</3E[/#2GSTFFU5BTFH^GNMW?R7<^JX?\
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M]L;_ ((V_$+]H/XTZQ\0QK,:17FHR/$O]GM)MM6<.%W&XZYZ$ #IQS7S4/\
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M\$84\G!KM:**\24G*4I/>3;?JW<]Z,5&,8K:,5%>B5D%%%%(H**** "BBB@
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MOT1^!O\ P2!\'^&3:_\ "5Z!9793/GF2V23?UQG>GTZ_TK^AD(V "<]?P_\
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M[=J=114Q2BK+:[?WN_\ 2*&E02&(Y7I_G_/O3J**86M?3=W?F[)?DD@HHHH
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M^'@_PT2+S#J-B=T?G#$L6,'H#\PYX_STI%_X*"_#5XU;^TK'YL/_ *Z(=?\
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M7=AX+TN"_B"2&5;"V4^<.=V0N3S_ )]/K?PUX.T/PG;+:Z/:1VT0 &V-%0=
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M*&[NX0BH145TW\WU84444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D(SP12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 C E2!P:%!"@'DTM%%^G]=/\A6U
MYM;VMY;WV[A1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **09R?0X
MQ2TDV^C6KW\G:^G?< HHHI@%%%% !1110 4444 %4]1G%MI]]<L<"WL[J<GT
M$4#R$_@%JY7,>-KC[)X-\6W).W[/X9UV8'I@Q:7=./QRM735ZD%:]YQ7WM(B
MH[4YOM"3^Y,_SBO^"HGB]OB!^WK\;O$%I,&MY[S388&5LJ#9VIAE 89ZE2"
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M4(VV]V,=%Z*2"BBBF,**** "BBB@ HHHH :S!<9[G%.I" >HZ4M'Y_\ #?\
M!$KW=]M++MWN%( !T'6EHH&%%%% !1110 4444 %%%% !1110 4444 %%%-8
MD8/8=1]:F4N6+DUHK7]+I-_):_(!U%(,@#/6EIIW2=K72=NUUL 4444P"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBWW"BBBOE#[@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJX9@222>W>OO^ >)GD>/<<5/EPN)2A)J[=.LY14)*[^UHI=M[GYMQ_PE3S_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,8^SGA:5FK).;W<N;FUZI_+\#CQ/@#ELYQE2Q<[-+FTBE=-).W>WY'^<.O\
MP3N_:+D*2'P5JV^*58L'3[KE%_B^YW''8&OM+_@G'^P-\:O!7[4W@'QIXJ\(
MZA:V6D>+=-NGFN+*=$2*"\63S-SI\N #D\#WZU_=/_PK[P?'R/#NDG/&/LJ8
M_P#U_P"?2M&T\(^%].D6[M=$TZVFC^998K9$92.A!'(/IW![U\]G?BMF6;4*
MM&>'A3A5ISBVIMVYHJ+TV6EWKMZ:/Z'ASP?RW):M&2JN4Z-6%1+E33LT]'_-
M=)VZ/K<VX& 8*Q DVYV]_P CS_GZU<JJ(4>=;D'GR@H Z8SZ?_6JU7Y)S.4I
M/2VEK>FOW=#]IIT_904%=\NC;W;ZM^84444%A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !3"H;*%049>01P<\8/;I3Z*3N[6;5FGIUMT#Y'Q3^U9^QQX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ,9ZC/X4QE#8_V3V_S_GTI])T!Q[G\:3;336RNV^JLM++
MK<32:::W_';<I.[M=B+'[KR\[N@#9Z=NG6I?*5GVLH9"O<9!_P ],U-L!'.<
MGD_X4$[>.VWCZBHC5G%7DE&+2LT]5)]^VGGN3*E";4FES73=TM4K:.^EOT73
M4S)="TB;<9=/M9"2>6B4GGKS_G\*JMX4\./][1K!O<P+^?UKH!T%%;JK4:3Y
MYZZ_$UT6XE1I+:E3TT^"/>_;OJ<[_P (EX:_Z FG_P#?A:FB\.:!%A8M*L4V
M= L"C&:W*8J!69QG+8S^%#JU=/?FU?6\Y:*W3\ Y(JW+3A;K[J5E;IIKK;30
MKQV-I" L-O%&!TV(!CZ58"JI)&!T_#_/:GTA7.>O.,_A43G4:T?,_P"])]M-
M_-+JM"E""=^5)]U%7[>71L0L,CD8[_TH"@,6[FFE>P)P>O&>E/&<#/6L*4ZC
M<E-6;U\E91NE]\7ZW]2FD[.U[.ZNM>NN[UW7I;N+1116X!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44447 **3
M(_3/X4M)-/9I^FOY %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "C&?P.:**&KZ-779JX!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444$XZT7MJ]$ 449Z^W6BA.^VOH
M 4444 %%%% !1110 4444 )@?IC\*6BBDDELDO16_( HHHI@%%%)D?IG\*7,
MD[-I-[*^OW +1113 **,\X[]:*+WVUL[/U[>H!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !132P! )ZTH8,,BC7L+F5[75UTZ]/\ -?>+
M111G'YXH;MJ]%W>@PHHSG\\44)WU6J[K4 HI"0.M .>E+F7-RW7-:]NMO0!:
M*:S!1DTH.0".AIBNKM75UJUU2]!:***!A1110 4444 %%%% !1110 4444 %
M%%(6"C)H"]M7HA:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)P"3T
M% "T5&L@8X'7_/L*>2!U-*345>3Y5IOIN*,E)7BU);::BT4A( R>E .0".AI
M^?1[,=];==[=;=["T4447UMUWMUMWL 4444 %%%% !1110 4444 %%%% !11
M2%@" >IZ4 W;?35+YMV7WO06BBB@ HHHH **** "BBB@ HHHH **** "BD+!
M<9[G%+0%]UU6Z[7[A11G/YXHH3OJM5W6H!1110 4444 %%%% !111G/YXHOL
MNKV7>W8 HJ**9)=^PYV.4/L1V^M2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "%@HR:.H]C00&&#2T-)JS
M5[W37EI_P1>]?I;IO>XU1@<]3U[_ $IU%%3&*A%173\7U;\WNQA1115 %%%%
M "$X!)Z"@'(!'0T$9!!Z&@#  '04"UOTY;>=[W^ZUOQ%HI"< D]J8)5+;<'.
MW=^%)M)7>BO:X.232;U=K+O?1?B244@.>/;-+1&2DKQ::\OO_)H84444P"FJ
M,9SGT'TI3G!QUQQ_GBJL:S@G<1]\D<?P]O\ /\Z7LXR:FVDXW23ZWMY=-UKH
M]C*=1PE"*ISGS7O**5HVM\5VM[Z%NF)NYW>O'^?\CTI2P'!S3@<\TE.+<HII
MRCHUVV9HUJGJK7TZ.^FO>W3L&.<]^E%5]LN_.1C/I[>O^?3':K%79+:VNKMW
M=KW\_P#(F$W+FO"4>5V]ZVOFK-A1112+"BBB@ HI,\@>N?TI:2:;:6Z=GY:)
M_DT 4444P"BBD#9QUYSC\*ERBFDVDWM]Z7YM(!:*0-G'7G./PI:<9*2O%W7^
M:3_)I@%%%%, HHHH **** &E02"1TI,;5(7KV_S_ (?SI/,&0.><_I3P<C-9
MPKTYMQA-2<=XZ^3^?Q)_/U$X+5VLY)^\M'K9;_)?<@7.T9Z]Z7&?P.:**T:O
MHU==FKC6B2U=M+O=^OF&,?B<T44@.<^QQ2T5EHKWLEIYL!&!)]L<?6D0,.O3
M^M/HK)T8^T56\N9-O?=/[/HNP[NS71C'4, #Z\?6E&  !T!Q^/I_GBHIY!&$
MR#\SA1CL3TI()5F#X!_=R%3GNP[U;=5RDH*+C%)MN^E[))^;?;H+DM:=DG.Z
M3ZM1M?[KK^K%BBBBK *8'!8J.H_7_/\ ^O!I],"*IW <T^_X?>OTN3+GO'EM
M:_O7O>WEYCZ0,&SCL<4'.#CKVJ.+&#CKGYO<_P"?\]@6T;[6_I_H)R:G&-M&
MI-M^5K)>>MW?H2%@N,]SBEIK '&1WX_S_DTI.,>YQ4N45>[V^+ROM]Y2YKN]
MK:<MKW\[]-]K"T4F[@GG@XH+8SUXQG\:GVD/YE_5_P#)_<RK/L_N_KNOO%HH
MHJQ"$X&331AUP>?7^GM3FZ'--3H?7O\ TK"4Y+$4XJ44N63MUW7XZ:>5QV3B
M[J^J6VG]?\ =T'L*13D>XZTK=#FF*0 3SVS_ $I3FXUX+FBH\DFT[WW6K\]-
M/*XTO=>CO=)66G]?\ 4NHSSTZ_Y_Q_"E# D@'I2%%.>.O7_/^.?:DV$,"O [
M_P"?_P!?\JZO=:^7Z+\]?ZL97J*VD6KI.U[V;:OKVTOY79)1114EA03CK12<
M'(],9_G2D[;-)O2-]F_^&#\NHM(&!) ZCK03@9I,!<MCKUHYHJ_,TFHIORUW
M]-Q/FTM:U];W_#S'4444QA3'W<;?7G_/^1ZT^B@35U:[7FM']X4UP2K =2*=
M10G;4&KII[-6^\KP1[1D]<G'^?\ Z_\ *I'4DY [4]FVC)I@<;2Q^H'M6-:5
M.M/V$F^>7OV71+J^FHJ<%1II1TC%6;=M7NV^MV* 2I5O\BG 8  Z"@'(!'>@
MG''MFK5J<(Q<G:/NIR>OI^GR*T;YDEJMTNCZ>@M% .>:*I6>JMJM_+??L 44
M44P"BBB@ HH)QS2;OKTW?A_C4N45HVDPU["T4F>,]L9I%8,,CUQ5+576W?UU
M%=7MULW;R5DW^*'4444#"D*@D$CD=*6B@&K[KJG\T[K[FKA129Y ]<_I2TKW
MO;H[/R=D_P FF 444F>0/7/Z4-VW[I?-NR^]M(!:***8!12 Y&:6DFFDUJGJ
MF 4444P"BBB@!CKN7IR.1]:<N=HSU[T$XQ[G% .<^QQ2YE?ENK]NNJ7Z(7+[
MSEKJK/L[=7YJ]K]M! "&/H>?QIU%%$8\MTKV;;MVOT79>0Q"P7&>YQ2TA4-C
M(Z'-+3$KW=[6TM:]_._SVL%%%% PSC\\44AQQGU&/K4%Q.(%4X)+ML&/4BB"
ME.;BK/:R5[[7=[Z>E@;LFWLKO[MQ)KJ.';N/WGV#OD_Y^OT]'22! "& YW,"
M1G'K@G_ZWK7A?QT^-7@[X'^#;[QEXMN;<VVFQRW)M7NEMI)/*C,GREE?&0I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^";NX=(I.VR9WO[7W_!/3QG^R%K-W^TE\-9!:Z!X;=[V0:670 6I:[S^Z14
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_&7P)^)7A'7M#U>YTSP[;^,['5M1ACGDACET))5:6V958(5*@ H?E/?BO\
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MQ.*AS3::U7+.,5+>RE;N?BM8C3M4LO$VJ2VX\^>2S;0V*?-#)(__ !,6C/\
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M\LV. <^O7BO[/H_^",%K*EA]HTJU8P6L2N/(_P"6Z=6Y3D]\]?Q-?'_[0/\
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MS75^"/B1KGPHUEO%OA*ZGL+NSW0P-;L\4B3(V]2"G/!'&.>F!GBO[</VJO\
M@DEX+\6:+=#X9>'K'2I?*D+>1;1PG&TY \E.I/'?UK^0K]J3]F?7OV6?BG+X
M&\8VDCVVK3&XMI71C //F,:J#(!@D#IR..*]_A?C'A_/J%:CS4O;SPTN:F[/
ME3BE*$N[MO\ GN>=Q5E.=<-U\).I2K0ISC&5&;O:45-1NWZ-Z/5+7H?VX?\
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M_P""-4WB?2[O4?AIIMOI<5C;2W+);P^22(8_,?B),Y.QO7ZY-?RM_$KP_?\
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MKQ'_  4ATFP^&'Q'\-_"BUA6%OAEH-C+=1HH50_B#1[>Y&%&.2SD\C.?>OZ
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MHN/VZDG%<RO;X4];Z^1_.%>W&K>)?&.HB7SKWQ%XVUV6=IDW2RRW6H2<OO\
MO,S-WZY]:_N4_P""/G[!F@_ _P"#_A[QMXST6"7QMXB-KK]E?2VZM<0VMW D
MD<9ED42*5D&=O3N.*_FL_P""/O[*5M^U)^U5I/\ PD%K-=:!\.5@UJ[XQ!>R
MZ5>)YEO,=I&)%/S!"IZ[3FO]"C2O#NE:'I%AHVE6D=G8Z7:1V5A!'G;;V\*[
M8HDR2=JCH"2?4U^E>*W%?L*6$X:P_-'V5*,L2XNST@HTU=-;[ONM.A^.^"/
ME2KC<9Q3F5I*IB(2P?/K)-5'*4VFK? [+71ZLTFC0[6D&3NRN1G'ICTZ_CU/
M6F-;1B.:.(;6D+,>/XCQGC/Y\?2K2)A$5OF*@<GN?4_7N*B,;+<>;D[2FW;V
MSZ].OX_AWK^>:E>K34)Q;45-.HNBCH[VV?*S^HOJE&7M8M1]Z,HJ?*N>5URN
M\N\EMV/YD/\ @OM^RQX9U7X0VGQ@TO1(FUS2-50ZE?16Z^:+:""2:4R2 ;MF
M[ELGW],?R-_ _P <+X2^(_PQ\26Q:!_"?CW2/%1<?*QBLY0YVD$?AT'6O]'C
M]OGX?:1X_P#V/_V@=*UFQ2_DB\!>)KK2V?=FTOEL2(;B/!^^F<C<",\X-?YH
M>HPKH-RJPQ^7-X<N1:7:]3<):GYVE'!&_OMQ_.OZA\-LUEGG"N.PE9NK_9<9
M4I5)7DIT9TO:4[7;V?N.Z\MK'\K^)N H<+\497C*EH1S&K'V=.&EIWC&:;T5
M](S3?6[T;;?^IK\!?&:^./@S\+_&^6?_ (2OPEH^J[CU+7L DRQR<D_X<U[$
M"CL5(^XVX9[$?YZ^WUKXL_X)W>)4\7?L<? .^,*QK;_#OPW"B)D* MBI&,DU
M]K-'RS*<$KC_ #_GVQ7\X9IAU1S'%4JL>2M1Q%>+M:R4JB<5OLH6WV['],Y5
M7=7+,OQ.'OR5</1JR3:YFG25];VNY*_S/X@?^#CG47O_ -L?P%I1ES:K\+M-
M=(\@J+D7TJ[P">H'<=NN.*]D_P"#;/PK/-\0?B9XW,3?9[6RU?PV9"O'G++%
M)C=CGUQUS7P5_P %V_B'<>.?VXH61E7_ (1'PRND.B<^8EEJ#YWY+<GOC;QR
M,5^VW_!M7X7LY?V8OB;XO>S6+4+CXM:O:K-R&:W:TC< #^Z3R/KUX&/WC-\%
M_8'AIA5B4_\ A0P<*%%QO\564:BBU9:I:M]?0_G'*\;6XB\5J\J"YWEN)=:M
M&VE-4[TG+K?DZKKNM#^E:.0/&W!&UMN#ZC\/QJC>6D5[%<03J'MY(6CD0C((
M;[W'?/3GBM/RU (7C)S^-(L6,Y.01@CKGZ\"OYOE5Q-/'4IT8/V.G//F2<=4
M[K^\I*Z=M$?T]7H4J]%TI)-)*R>M_=46GWB];KL?SX?\%0?^"</A/XO>%_$?
MC'PQH-K'?6VEWEW-(EL@D>>&UEG=@44DDF,\GG(]AG^&>72KZ%-=\.[9+;4O
M">M,JA\I)FTU%BI7C(QY.>W _/\ U@?$_ABS\1:+J>C748DM=1L[JUEC).&%
MQ!)#S^#GZ>O:O\X#_@I=\';'X!?ML_%/P5H-J;32M-NHKF2$?=O&U6V>ZRY(
M!_=M+D;,<XR:_IOPOXG>;86KP_B9RK8R$(K!Q>LJM%)IQ<G]N$IWO+OY'\N>
M)G"M3(\?'B&%-4\!**6*G3:4(5X-U'*$--*D8**MLT[Z']EG_!%GXPS_ !4_
M8E^&AU*^-[K>@V]Y:ZFSOOE"K=>3;JY)+<(GRY[#':OUSN9#$JS<[%(R/]XC
M![_I7\I/_!LC\0-9UK0?V@? M_=/-I7A.3PX^E6[C"P?;Y)I9MAZG)SW/UK^
MKB[8) 24W@%1MP?7L!CI7XGQ]EU7*^(<XP59.G4IU75DWTE6A"NW\I3>G;0_
M=O#W'TLXX9RG&4Y^TI5H4X*SL_W,HTH==+TX4[IK>]]W?\T?^"O/B5?!_P"P
M5\:-?5O*9+;2(=^2#FZO! !G/??VQ7\ '[-_AV]\9_'_ .'_ (4MU:2XO_%=
MK>L!EC(J:E#=DXZG:O/K[G-?V^?\%\O%QTG_ ()__$;PS$56Y\22:(T1'^L
MM-4AD8(,X(QP>#7\F_\ P2*\+VGC[_@H-\%]-U"V#VML^HR2*00MR\6G>8"_
M(SL9<Y7OZXK]J\,95\O\/,_QU2+A&M+%RI5.9745A:=.[L[VC.E+3J?S]XPT
MJ>8^)W"M&*YUA(X6G7[QE*I5JI);^]3JQLTE9M;69_HJ>$;0VGA#PK:D8,/A
MW187'^U%IMJASD=BO<<>F:Z<19VDD\\MS^7U]O3O4$,:V]E:Q(N%@@AA51R
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MI3<,1B:M"I!.SFX.*G+WEVB^7YJQ_,O@[AZ?^N^:P2ERX.->,KNZ4[**NO\
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M_L7XE?%C3]G[K3_$VM:4!C 'ERD>9SQVQTK_ %)_C$ZK\*O'9? 4>&]2W$]
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M6:"BBC-?.'U9_)?_ ,'-?B;[.?V9O#4;?-K(\8F4 ]/LHC=>/<C'Y<&O@?\
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MI;W?LXT8.+^<F[]5L?SU]':%?'9MQ1FU:3?/5GHX]9UK1C?RCK??\STF1B
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M=<]!ZU_:%+G8<9ZCIFOX#?\ @O!X]EUK]O;Q%H,JF:#P&+3;"?F#?VEIL;9
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M"STF50Q'F17-E)NC('4$=CP>X-?NY]I:*5X@A(6W,H/OG&T8QSGH.M?S0?\
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M7$K"?5/$F@3&0+DK]@U&TN')X_B"<G/3K7^I-\.[&/3? _A"QB0(EKX8T&#
M&/FCTJS1C]25/\J_:_&3$?5<KR3*87]FZDZO9)T*<(VM_>CB>O5/S/P;P,PT
M<5G.?9M&:?)3IX?DY;\_MZLJDJO-T<94-/5=$=EN!;;U]?RS3J@2(K-+(3D/
MMP.PP.W]:G/((]:_G?WES==6XK:RLE:_FU>_GY']02235M?=BWZN*;7R;:^0
M@.<^QQ2TU>F/0X_*G4J;<H1;=VUKI;7JK>6WR)/RQ_X*T?$0_#_]B[XKAW\M
MO%.E:SX;B8DJ<WEBY &>23C@#_"O\^GX.>'O^$G^)OPA\.R+YC^*O'6A^&6&
M,E_MDH4Y'S$]>AX/!/M_:Y_P<4>*IO#7[''AF&V)!U?XD6FG3!/E)CGL9,YP
M,D?7C-?R'?L*>'SXR_:G_9QL2F1I?QH\*7\J$$YAAO%!)&>AZ>F./4U_3?A6
M_J_">;YBE9TO;5GYJDD]?51_&Z/Y6\7*RQW&^6993G9R^IPO>_O5'RVL]N63
MUVO?R9_I'?L\>$AX&^#/PY\);-A\/>%=*TL)@# M8 G3V_GTKVNJ5E;I;PQ1
M1C;'%&L:J!Q@# Q^'Y?C5VOYRQ^(>*QN*Q+5OK%>K6MO;VLW.WRYC^F,IP[P
MF6X/#/>AAZ5-O^9PA&+E9;:K\+]0IKG ^O%.J.5ML;-C.!7GUW:C4=[6BW>U
M[6/1O;7MK]QX7^TUJ8T?]GOXOZH3M_L_P+KEQN_N^7;$[NV.OK7^7Q\8-5;5
M?$GQ5UH*6%]K>M7&X_\ 35RWFYP<CGK].:_TQ?V[=4;2_P!CC]H>_7Y6C^%?
MBAU/(P18L>W^2:_S*9)QXATK4<INF\07,FE 8R3)=+PXR"2<D?X\U_1G@M[G
M"O$U6;7*JE!\STT6&73R3VO?2]C^4?I#3IU\]X,P\4YSA5E/DV5ZE6/)=]?=
MUL_S9_I-_P#!,[3DTS]AO]FMXU ^W?"OPI=.1_$TFGKEC^!Z_P Z^B_VBM>/
MAKX&_%+7E8QG2?!^LWF\'!7R+<MNSCC%>6_L#:2=#_8O_9HTEA\VG_"/PE;-
MQSNBL%7)]Z;^WQJW]B_L=?M$7X;8\/PM\4LC#((86+$?Y_\ UC\4;EC>)(-;
MU<VBFK7<E]9C%>EDKZ;]3^A?^19PBY3J\JP^2*7-:W))X6_G]J5NQ_FM_%C5
M#XK^+7CJ0#>_BKX@:C=L<9\P7DQ_>>^<_>_R?]*S]A+3$T7]D/\ 9ZTU4"&#
MX7>&$8 8RRV*@D_Y[U_FJ?#_ $QO&'QO^%6G(OG/XL\1Z-9NH()+7L^"Y'))
MS].O7O7^GO\ L[>'SX7^"7PO\/L"K:)X-T?3B",?\>]N$Z8]J_9_&JHX8;(\
M&]/8KFY-/A=&"3[H_$? JE[3'9[CU:4JLW&4K+WI>WO-KM[MMGVTV/:J***_
MGP_I<C9\*3Z'%?PZ?\'$OB1;_P#:8\%:1MS_ &$=04YZ?Z7:1'G/ ]>AK^W_
M .T,\<Q*D;)"H]".1D9S^'\A7\!__!?#Q,=3_;7\2Z0!EM">QQCK_I=E$?K^
M0K]@\#HN7%+KKWG1P%::O[MVL1AH6?2WO6OKW=C\,\?)?\8K3PDOBJXZCI>R
MY94*[=FMV]-.FES[&_X-H=)^U?%O]HJ[ R-&_P"$6.X#.[[3!+^H_P ^E?V=
M5_(A_P &Q^C&WU[]J:^9<L5\$LLA'WMT<F<?0GG_ .M7]=C= W3'//O7B>*F
M,EC.,<QFFYN$J<'?O.U25NUO:MGO>#F&G@^",#&H_=G*=6#::_=J$*;??XZ<
M]/*_4_B5_P"#B[QM_;W[2WPD\)EMZ^%%U_,>>AOK*-\XZ<?YYKXA_P""7/[>
M]I^Q5<?&>[?3TEN==?13;R%@C3"V:3<!E26V[AZ=*[?_ (+P^-7U/]O[QIIJ
M@NG@T6"HH/!_M+3(]Q'N/IS7XYBUNIH([FUC;_1B[SJ@_P"/CS>5W8Z[,\9)
M].F*_H[AG(L!B?"_+<-F$4Z6)CAY2A>W.ZE#G2TL[>]%OORVZMK^9.*\YQN'
M\2LSQ6%F^;"8[$JC5BKJG[/%O7EU4M+Q6GGUN?U>V?\ P<0S2W#POHA"(R@N
M9CCYC_USZ]>_\^+-W_P<,_9]0>U71=T?[O:XFX;(RW(B[9_I7\G-HM]=6&H*
MEBXEV@HP4Y)4DG'REOQ'2LZ(ZA+I<3BS>2]MEN 4VDN^[*C^')QUSR?R->3F
M'A;POA:<7'!IR>%IUI6JM>_RPYM;W^+F?9==SZ=>*G%KQ]"F\2_8+EB[TT]-
M%*6NS>NG]VRW/]$?_@F7_P %!T_;CN?B@T=N(%\%#1<@2;\G4 W^R.A'XX[=
M*_6JOY/?^#83PEJ^C>"?CQXDU2&:(^(I/#_D^:".+::96 R,GWY_I7]8).!G
M^=?R_P 482CEV<X_"T4HT:$XQ@EK[JI0ETWNFC^J.%L;7S')<'B\1)RK5U*<
MKZ;SE%+_ ,E?WBT5""<9XPO]:FKYVE5]HKV:V=M=FE=_^!)KY(^B::_K^NX4
M445J(*_C;_X.9O$:ZQXX^ &D(0S>%G\1>;&#G/VT0E21ZCKW_K7]D3-M'OVK
M^#W_ (+^?$)]>_:]U3P8PWKX3-NT:$Y'^F64<A..V,<_0]J_5/!W"1Q/&N J
M25UA8NNE_P!Q*5*7W1JR?R?8_)_&?$RH<$XV,9\OMJU*G-6NW"TZC6O_ %[O
M\O,]Q_X-R/!@U[X^_&3Q4\66\*)X=VR;<D?;K-U(!XQZ?7TQ7]J=?R8?\&RV
MCL9/VEM?DBP+X>$A%(1U\D2HP7CVYP?2OZS@<C-8>+V+6(XZS.G?F>'C2I1>
M]XJG"H]?[KJJ+[V#P5P;PO .6S>^*JXBN]-G[1TGT[TW]PM?DI_P6;^(J^ ?
MV-?&2M+Y2^)(+_03\VWS!=V+Y3MG/I]:_6NOYV?^#C[6I;']D#PU90RM$]WX
M^M(R%)&]7LI1M.".OI_]:OGN!L*\9Q7DE!1YN;&4Y6>WNW>O]>9]'XAXY8#A
M#.*SGR.>']C%]Y59)65^K2:/XP_@AX8'C/XT?!OPWY?F1Z_X^T'3&7&0\5S<
M!/+]PP.,?C7^H?\ !'PU'X.^$GP]\+QQB)-"\+:7IJQ@8""VA";<<8QZ8%?Y
MNG_!/#PS_P )3^U?^SOIKIDZ3\0O"VLRY!.Y8+U 4.1QGKGDY[=:_P!-.T18
M((8D7:BHH11_".P_#IVK]-\=,3[#%Y1@)-\M.G.I%ZZ.3C3Y+=EO<_*O *AS
M8;.L7;WIU:=+;[*7M+WZZWC:]]--BW1117X,?T4,?H/K_C7SS^U;J?\ 8W[.
M?QEU7_H'^ ==O,]OW5J6Q^'^%?0S]/Q_H:^/OV^M4&C?L;?M&WI.'B^%/BEX
MQG!++8L0!QUS71DT9SX@R^,8N3^MX2UNC=:FKVZWV_$\CB"4(Y%FLIRY8K 8
MOF?DZ$E:_35I?,_S.OB?J4>M^+_B!K*#<;_5-3N&(P<^:Y;:3_GKCZ_Z37_!
M-+3/[,_8F_9X&W;]K^&7A>ZQZ;[!/S^M?YG$/GWEK;7"H9;GQ'KR6OE8)?;=
M#(]3P>.@&<U_J ?L):<VD_L?_LZZ<Z%'MOA5X5C=<8PRV(!!';']17]*>.F,
M<<HR+!Q]WGFY5:?9TZ<7%_>WMH?S3X#81U<\S;'.5_9T79V_Y_-0<?+X;=-E
MH?6U%%%?S&?U:%?R\_\ !RW\0I+3X&?#SP%;S%))/'.EZW.BM@O;_9Y8W5E'
M)4\#TK^H:OXM_P#@Y4\;R3_&OP7\.L_NXO EAXD12>#*+B6+A?7&.1_C7Z'X
M6X*GCN,LNHU(\W)&K6AY3I\KC*W6UWH?F_BOC_[.X*S+$\_)[]"DY?W:L^5K
M_M[8_)W_ ()H> )/B7^W7\%-.2W,UIX>ET#Q-(NW>BI;:BH8D8QCWQQ[5_I0
MV\26L*6\:A(XD"QJ.  !@ ?Y_.OX0/\ @WY\*V_B']L^?4+B$2'2OA*UVCLH
M.R>"_C. 2.".O7CG'I7]X8._8>F5!P?QKZ#QQQ$EG^!PD&U+#890G'2R=:IS
M05GI=1UN?(^!%"DLBS+%6M4Q.+A.+MO&-.S7:SD[JWK;0E!R ?6BBBOQQ7LK
MZOJ^_F?NP444A. 3[4 <EX]NC9^"_%=SG'D>'-<FSW!BTRZ?@]NE?Y;_ ,?O
M$,_C/X_>./$!+2G6O%EY:G)W8%IJ<]L!WZXQVXXK_3F^._B!-!^#/C_69CL6
M'POKL>2>AETV[C')[DXQ]:_RW-6OY?\ A.;[4&C,K7/Q*>WP1R%O_%AAX..>
M)<\YST[\_P! >!].4'GF+22BL,XQE=+WH4JDN5=M)+TMIN?S9X\5W+%9-ECA
MSRE*-51OU=:$8Q73WI0U?IW/]%W_ ()%:$/#O[!OP9TP0^3Y5MJDFS;C'G79
M?./?.:_2ZOF;]D+P&OPW_9W^&7A-%"K;^'-.O.!@#^T+.WNSQ]9#[&OIFOP_
M-ZZQ&;YI5BO=GCL1-/I[]64K?)-/YG[WP]3]CD63TK<KIY=@X.-K6<</36OG
MH%,<;E(SCO\ E3ZAN)?)MYYCTBAED/T1&;^E<$;MI+=M)>M]#UI6Y9<VUG?T
M/\_O_@O%XQDU[]NCXA>%3*6_X1LZ2T W$^3Y^GQ2. /X=_0X[],U^MW_  ;4
M>%FL/#/QW\5-#L'B)?#2JVW 8V;21D@X&>A]_P J_"+_ (*ZZD?%/_!0S]HO
M7_,_=QR: L:9RH\C3MC8)Y^8KZ<>M?U ?\&^'A'^SOV.M%\=&'RF\:O=JWRX
MW#3-0EA!W8&[VZ>AK^D>,*53+/"[*LOG^ZE6PN$<J7\]2$\-*I\U;1>3\S^7
M."ZL<S\6LRS.,>>DL5C%&HM5&+I2I4WULI^[VUE?S?[\U^,?_!=WQ-#I7[ '
MQ/T64A3K4FB;2>/^/?5(F(]P?\YZ5^SA. 3Z5_-E_P ''GCJ32?V<O#/@M&*
M-XOFGS@X)^P7L,F-O)/3_/2OQ[@#+*>;\6Y-@*L>:G5Q#E)=O94IU4^^C@GH
M?N'B)F4LKX.SS%PG[.<,(XJ7:-6I3HR_"H?R[?L'OHUO^V3\']5UF6&#2K"[
MN9)GF(6*(BW1E8EOE4E@#V[&O]!/2?VK/@]%IND1R>+M)1[>QMXFW7,&8MEO
M&@&6DR.G'^37^9MIVIZEX6UW3]5T^ZEL[S8IAN$+*\)2)<X9=I7/U%=]J7QY
M^+#KJ30^--5 F6!8U6YFQ&$X_P">H(W#^O7O_3'&G N%SZCEJE5]G]2]O%RM
M>_M53Y=.\>1/;IOJC^.?"_C;-,JK9W[.;7UJ=&3G9/FE*$O9KRL[IN^O-KT/
M[M/VR/\ @IIX"^!'@[4M9\-ZS8ZU<W%M-&([>YC)1F4Q+]UGY);\_P!?X=_V
ML?CQXA_:$^(VM_$Z_P!1N+@ZI=,^F6+RLYM ,HXC#'@.,9PH]SBO&Y?&_C[Q
M3+_9?BKQ'?7]EJ"LT!NI9&1C$I=@H:0Y^88/<5]S?L$_L*^,?VI?B/:VUWIU
MW;>&UGB%O=/!(]O,OF(&(9@%Z]>3]>IKR:/!.5<-9#//'R\]'V<:E66CE)6C
M#E4NJY>9I:V;[,]_#<99OQEF&(X8JU)5:-?GY8);\TO:S;?G4L[MV6W8_2#_
M (('?LB7WB+XD77Q?\4Z9(UIIP>2R:YA8J+B&:.5)49L#([8R>O/.*_MXM0J
MP1HHPJ*%4 '&!P*^.?V2/V9]#_9M^'&F^$-.LH8KE$3SKA(U1G)3:V[ SSUX
M:OLE1Y<2J/0#/KQU_+_.*_"/$+BE\19A3K\SEA<#AU0PRO=.*2<Y[7O.5EKL
MC^B?"[A#_5++L1A912KXFI[;$.UFJDK<D?10M=KJ)</LB=L=!^7O7^8S^WEK
MC^,OVOOVCM5:0L?#WQ6\5Z2O<@6MZS  \'_/KQ7^EWXZUY/#7@WQ%K\GW='T
MNYOFSP-L";N37^7?^T-K!U7]HC]I/5R28O$GQ?\ %FJJ>RI=W3,,'TQR#D<F
MOO/ 7+?[0S?%XB4+X;V=*G4;VU?,XZK>VM^MCX#Z16(JK)\#AJ3O44YU5"VW
M-:GS7_N]O/LS]@_V!_\ @KI'^RA\')_ARNCB28Z@VIMA]AD'D+%YNW8>N!SZ
M]_3[>TW_ (.'VNK2[GDT3:;>1UP9^R=^4R.OX_2OY1K-+B7Q"LSVC16\7A<0
M1@J0LS*_$@X R1W&?K6.XU+R9(X+&3%U=&U;"'A''^L)"GC\,>^*_0^(O#WA
MS%Y[B*E2*E4K5I3J)2WF[6UOUMJUUN?G7"7'O$>6Y%@\%0Q/+3I4U3I)TU^Z
MC%<S3;WNW97Z;']9T/\ P<0M))8J^BE8+N]CMFD,WRA7/+?ZO''3^HZU_1_^
MR)\?(?VC?A%I7Q$@4*EZ(1@'=_K(%EZ@ 'KUK_+RO8]0ETPZ9;V4OVBT8NKJ
MIW H,;L[<CZ]:_T:?^"17@W4?!7['/POM]0\PRZ]X;T?729 05^TV*#;R.H]
MC7Y)Q_PIE>281U,#3C3E&=*WOW;4I-2=GJ].UUI?8_<O#[BK-<YQ<:>8U74M
M3G#X+)_ X2;6BUNOQV/U(IK#<I'K3J*_'S]D:NFFKIJS]'N9.IZ58ZG;&SU"
MW2ZMY 4>)P&4@C!R"",8]O\ "O+)/A!\-M.NH+JV\)Z>L\UZNZ18(MP=CGS"
M1'G@]3GI@]Z]IIC1H^"R@X8,,C/([\UK&K)6NW9=G;M_6GZ'-4PRE\+C'WHN
MS@GHK)ZO75(S+2SM;&)+>SB6&&(A%B0#"@#C &,8^G2M&(*-VU=OS$GW)[^_
M3K2+%M<MV)S^?^?;\>M34I2OU;NE=OOH]>]K?\-L.C2E!N3M'WG[J2M;9--;
M7WLE^84445F=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!',XCBDD;[J(SL?15&2?P S7^<Y_P65\46VJ_P#!2?\
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M\FO?M9_LT6LL9D0_$#PG9E&Y&S[: 9>^5_7'YU_J!:'8+I>E6.GJ %L[>.
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MQA_8@LYSC$YL)9(I..OR'CD\]J_ITOY_LUE<W':*"24^RHC.3^ &?PK\>?\
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MB_\ ;A\&645OD>'[>PU^8YP(UMK] 1CN1D8X(K_18R/DP..,>G7I^%?P2_\
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M^V_X]'Q(_:J^-/BFQ#R6^K:U%9[O1K*66U*MDGJRX&"?SK^XS_@B5HDFB?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?B?=+9_#KQQ.S;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@5"=&OFN+ORPJ0]C%Z74Z=-SD[/M&HFO/0_E_P"DE-8G+,KP"C><:]*O%_\
M7RO&%K:MMJFWMT\S^_[_ ((>>!&\$?L9:.6B,7_"1ZE!KP!7&X75A'AAZCMG
MI7[(U\(_\$U=#71/V*_V?<1B*74OAKX8U"Y4+M_?2V";L^YZG/-?=U?CG%F)
MCB^),YQ$).<:N/K-2:LW9J+;\[Q9^Z<"8>6$X/X=PTH\LJ.68>#CKIHVM^Z:
M9X)^U)H__"0_L[?&31-F_P#M3P#KUGLQG=YUJ5VXP>OTK_+V^*-I+H'C+QYI
M5NFTZ#XCU*R"J#E9;:0KY6/Z>OKUK_53^(6G_P!K>"/%&F;=_P!NT>\MMF,[
MO,C(QCOFO\N[]I;35T;]H+]HK1F4+]A^*'BG8O/$D=R4$>#Z#(QC(_E^Q>!=
M>%*MF\7\;A*2LKV7L&E+RM+KYV/Q#Z0].4X9')1NH/F4OY91Q$6K>>OS/]&'
M_@G9JS:G^Q/^SS<+\TT7PL\+QRJ>JRBP7*$'I^/2OM1R[VJMT<IR!USC../I
MVZ]NM?EU_P $>?&B^,?V+/AR5D$AT31]*T=P"3L>WL$RGJ,9Z<=:_4U<X8=L
M$_C_ )_E7XIQ-'ZIQ1F5)-R7UVMT=FY352[^<FGKLV?N?"$GB>#<F51OGEEU
M'FF_B7N<MEMM:^O7>Y_GZ?\ !<_P:_A']NVZMD@$=OK_ ,.GUV-MN!)J5UJ,
MF%'9G;'3[Q'/K7UE_P &]WQ@L/#'[06O?#B\O%@L]4\ W-[Y)D"!M;FN8XO+
M*D_ZS'4?>]N:ZC_@Y$^%NH6'Q1^'OQ?L[-C$NF:7H,MPL?RG$TL[1LRCN.V:
M_$+]AGXT7/P _:!\%?$>]NFL8=5\6V&G74C2&)!9370E=225 0X]<#T]?Z:R
M>@N*> ?J//R5<1@?9)+6SC!<FZTO*"3\GU/Y>S;%RX4XYCCI4N:6'S"<W'57
MBY:RTU;Y9RFT^J1_IRP1J(\J<[FWD>AQ]<_A^>*FDD8(Y4 D X YY]*^=?@%
M\=/"_P 9?"FFZ[X>U*"_BGMX1,T,J2!9F0,5^4\-SG'Y]J^C2JHK-Z9/^>?Z
MCZ5_)V:Y3CLLS"IAI4W1GSM5E+W7>#LI*]N:^MGJFM?,_K3(L]P>>8"EC\/-
M5()1OY6BG9I;:+KYD?FJL$;2G:7"C_@1[?A_2OY"O^#@K]L%;RXT3]GWPKJ*
MS6HNK>\U5()B2+T&2VGMY IX'3<I'UQTK]^OVS/VR_A]\ ?ASXOOKS7K2T\0
MZ9HM]/I-K)<Q(\VI0Q$P1*A(=BSC&!\WTK_/&^/WQSOOV@?BOXT^)/B.\DDF
MD?4-0TY7D+*U\9S+%;QAB?7A5P>WO7ZUX?\ "^(]M_;&,I3A2PRO152+BI57
MRM35U?W87::ZNUS\A\3N+\-6H8C(L!4BZU1NE6J0=^6,TGR)W2LY>ZWY+T/9
M?^">?P0O_C9^TY\-O L-DUW:Z)XNTGQ9J:K&7$=O;W:QS;\9 C&><@#ZU_I8
M^#-%M_#?A?1- M45(-(T^WL(D4 !4@3:% ' '7 K^5C_ (-[_P!DO4-.M-8_
M:*\9Z2]OJNKVD]EI0N864/87 BNH)X@Z[N6R%93_ /7_ *P[,8C8]V;<?;(Z
M?I6/BCG4<TS#"8:$^>& PZCS=YU6FXM+1<JCY_(/!KAZMDN&QF*K0Y99A)^S
M[^RA:3D_.51Z;::F!XIU(Z5I&L7[X6*STN>Y+GH#&N?Y5_EY?M;:D_B+]J/]
MI%R2\=[\5?%=W >3OD>\.T+CU]/YU_IA?M-:Z?#/P$^*^OAMATKP5K5YOSC;
MY%L7SGM]:_S%O$K2^-OCEXNU-1YK^)/'-]/$1SYL]W<;@O7YL^P_E7O^$\*2
MR_/,3;EK)0H1E97:]DY.W6[E\TKL^5\?/:5\QX9PL9.,>?GM'5\SK15VNFB2
M_JZ_T0?^"6?@R#PO^Q[\';R.,1S:KX-T^688 .X$]>,_P]">*_1K.%9CUZ].
MF.GO7R3^PEIDFC_LH?!?3IH_*FM?"%E%)&0058%L@Y_S^=?6TB[D8>Q_E7XW
MFTY8C-<55JMRDL35B[ZWM/DO\E&RVW[G]!Y!AOJ>1Y?0C:\<'2E_V]*"F[V5
MOB>NA_);_P '*>A.UK\"]>$68T?Q 97()"?/$J\XP,X[D?ES7XI?L#_M+W7P
M TW]H.\@F%K-XIT;3[*R7<4^T?Z#<6TFT @MM$G;./3T_HK_ .#B[PM+J/[/
MWA'Q&D!== >]$L@7.S[5=Q1KDCIG/'K7\7EQ>WEA:VB6[O''&I&J[#@ 2@>1
MYF#CG(QG\.:_JCPOPL<VX6P]*<5-4X3HS35TX0Q53W=7UC&*7_ /X]\6*D\M
MXCQ'L;\V)=*M-[>]6HQJ33M;>4]?,]-_9Z\ :_\ '/XY^%_",=O-=SZSXSEO
MY"%9Y'C;6?MLF>"2JH3VZ=>U?Z?'P4\$67PZ^%W@OPC8Q)!!I>A::@B50H61
MK. R<#@'>#^/O7\//_!!WX*S?$3]JE/%MWI_GZ7X&=);B5HMT<;7]J_EESR!
MEA\N2,G]/[TX(E2*!1P(HT10.FU%"C'I@#'X=J_-/&3,XU<;EN54YIPP=&I4
MJ)=:DY.,.9+1-<DVEH^6:=M4S]<\"LI>&P&:YHX:X^M05.4MVH14J\M]FZD;
M=W%KH/7CS&/![^W7M7\ O_!=SQ9+JO[;?Q$TS=N_X1G^S0@!SL^U:?&QP>V2
M/3\2:_OSOY/(M+J;./+ADD/TCC9O3VK_ #C?^"O7B,>)O^"@/Q[F$@>VN)-%
M16!R T&GA<#WW  _7\3X_@[AW1S3,*S7-3A@JU*;W;=>O"KVW?))NR^_IKX_
M585>',)@I2:YL5'$<O2?LHJG;S?[S1=KNQ_1)_P;?^#9=,^"'COQK+"8SXN.
MG#<1C?\ 8;B6,<]3C_.*_I:K\4/^""7AK^R_^"?WPQUJ6$1W>MOK7GG;AF6W
MU258BW?[O0FOVOKY'C*M3K\29G4I.\/;0A_V]2I0I37RG"27DC]$\.*-2AP7
MD-*K'EFL)=KRG.<XOYQDF%%%%?,'VX5^&/\ P7]\&/XC_87\;:O##YLVAR:4
M0P4DHL^IQ!NG/W17[G5\:_MZ?".'XV?LN?%+P%<0^<-1T.XNT3:"3+IL4UY%
M@$$\O&!T]*]_A;&_4>(<IKIV<<727,](QC.<:<I-^2G?Y>1\UQAA)XWAO-L/
M!-REA*DDEK)RIKVD4DDV^:45%V6B;/\ -%\(>(]0\'>/O#6H6FY+6V\0>'9/
M.7< J1:A:&X(88QA0V3T&.<\U_J$_LY?$32OB;\'O!'BO1[I+NPNO#>C1)/&
MX=6FMM/MH9AN7(RLB,#Z'@XK_+IU."XTJ-]&U6/[/KN@:]KL&I0,-LL"6VIS
MK9,RL-R[DB5E)Z@\8[_UW?\ !#3]O72-1^'=A\$O&FMQPW&A8@TP7-RHEF^T
M3,V )&!;'R@87C^7]'>,>15\_P"'\!F>#A[:>%H5?>2O)TW"+J.-MY?NTTEW
MO<_F3P?SJ/#G$>-RK&S=!8JHX-2:C"5>$I<C;VY8^UE9[6<G;2Q_4L(PSK(>
MHZ#MS[]?\]*E60<LQQ@<\]/Y55MYUNK2&[B.4EC$B,.0590P(.>X.<^U>6>.
M_BKX8^'UA=ZGXGU"&PTVVB>2>>:5(D5$Y<EG(&%'/]?3^3L#E^-Q>(]B_:3>
M#Y8*,8MNI>S<FOYT^9*V]S^IL?G. RRC1K2E3A''24H3G*RE.<8J%V^CLKO;
M8Z[Q7XWTCP5HNH>(]?N4M-(TZ*6XN;F5Q'''#$NYV9G(4 +R<X'IBI?!7C#2
MO'?AZV\1Z%<I=Z7J,:3V5Q&P9)()%#HZLN005P00?IVK^1K_ (+ ?\%7+BVL
M+[X8_!O58]3T/7=)EMM2O+"<S- EP'BE;S+=]JE5QC(X_&OZ%?\ @F)=:MJ'
M[&7P4U+5S*\^H^!_#]XLLI)>5);!"');EL_WN:^HS3(ZF682EB,0G3K5)1Y:
M;6\6HM-[.ZB]5T]3QN'N(8YUB*]&G*<Z<%44IM;58MPG%-:.">L&]S\G/^#D
M?P5)J'[.'PX\30PEI+;XFZ3:7D@4DI9):RN[,1T4=?0=Q7\N?["?C&W\"?M6
M_!O5KBY%HB_$?05D?<$W:5]L!,A)ZQX&2<8K^W'_ (+1_"R[^*/[&'C*&TM#
M<W/AEK_Q%"%C+LAL[!\2#&2,=SQU[5_GQV5YJ6@ZYX9\7:5O_M#PNEFEQY9(
M,5Y9MO8D+\P=3C//'UK^@O"O#TL[X1QF7R<75I/$4TKJ\(5+1CIT24G;3=>6
MO\Z^*N&>4<687,X.<8XB=&?/;7F5FY/7O%+_ (<_U;O#NMVWB#0K+5;:17L-
M1L([N"93E7AE4%6##J"#G('K@UTEOQ''LY3: #C@KTZ\_P Z_'3_ ()<_MF^
M&OCQ\%?!OA>\UBWF\3:3X:L+*]M_/1IU,%NB2%T+;P0QYST_*OV#BD"001Q'
M=MVJ.1G9CKQ_3KS7\Z<3\.XK)\WK87$0=*="K)4YI>Y.G>\6I6LU;5V[]MOZ
M/X3XCPV:9/0J0KNMRPCSJ27M?:<L(OW$]KOW>^N^AH9X)8< G\A]:_*W_@JU
M^UC8_LV_LY>*KV"_BM]9U;3;VQMXFE"R,LUJY4J RMG<N1_G'W_\2?B[X,^%
MNE3:GXPU2WTVU1&9I)YDA 4#.<O@= 37\%G_  5N_;:N/VH/BUK?PYTS4S/X
M.T74[E(+B";=$]G;SO"LA*DH08SGIC'-?2^'G#DLWSJE.M%RP^!MBJDI:*5I
M6I_^3V^Z_K\OXF\:4>'\HC0H58O$9E.6#2B_?I\\;3YETM%N^N[/R1@E\1_$
M?Q_<:J\4MSJWQ.UIA%&5=G>/5Y"5= ?F.2?E/()Y]:_TE/\ @FS\%+;X)?LI
M?#'08[86MW?^&M(U#48]@1C>R62+,9!M!WY'4C=W)K^)K_@E!^SAJ7[0/[1W
M@]I=,:X\,^ ]2L MP(2T+1:;=)AV?E#E&Z\<>E?Z)OA_1;;P_HFEZ+:(L=MI
MEI#:PJ@ 4)"NU0 !C '0#''I7W?C7FM&M2RS+:$DL0J*=3E:_A**2D[:*3DM
MK+34^ \#^$)87%X_B#$PT525/#MZN<I^]S?]NQ>]]]V:9CP_F'C$>S_/X]Z_
MAU_X.-]<#_M?^ =,CDW"+X<:;/*F<A0+V4,V,G'IG_\ 57]Q[C*L/:O\^K_@
MN=XJF\>?MP7_ )3><WA[P=+H>U26V"UU!_3H03CM]*^4\*</4JYY7G3O)T,!
M4@TOBY:KA36B]-?\C[/QEQ/L\FRNE-*4:N8TVG)V2=!<R7R4KGZ3_P#!MKX)
MN'O?B1\1S;GRS<ZMH$<^WAH\Q2CYN.3C('3KWYK^NI9,(SOP%R<GTZ_Y_P ,
M5_-A_P &YVG2:/\ LL>,[Z[@$=U-\1=0B5RF&> V<1R">2"><Y_45_1J=5M&
MMY(Y)5!\HLXR!A,8.?3ZYXQ7C\<T*SX@QJ]FY2@X4I63;YHJ[WOI9KK^!Z/A
MSF."IY+1H?65'WZM1P=E%.3BM'?7JV^_S-Y6#*&4Y##(/UKY4_:\_:%\+_LZ
M?!KQ=XYUW4H+"YMM,OO[(\^58A-J20%X(5W$%F;'W5Y.*V?BA^TS\+OA+9(?
M$NOV=B(D!8S7,46$4=3O(X^IYK^*7_@KE_P4+UO]I#Q=JWP>\,:H\O@G1[^?
M6A>V<SE)8('> !Y$8QE#&0>!W_"KX-X)Q?$>9T74I2IX?"25:<YIK3F2<4GH
MW/;TV-..^/,#D&!J4*-2%;$XF,J4>22DHJ4=))I[QE;I_F?DY\9?B]XA^*'Q
MA^(?Q3\2R2R1:]XHU:ZL6G+,GV;49CY9B+9^3&-H!/Z9K^DS_@W4_9=>'5_&
MGQDU:R8P1O83:%=S)D2F;S4N!&[##;=W.T\8Y]!_-KX,^&VM_&O4O"/PZ\(V
M4FH:KJ-WI*)%;1M+++;"[@2:4A 2V(WR6''?I7^C1^PM^SYIG[-7[/G@SP9I
M]JD5^=*M)+OY%69Y98XYI5? !)1W88(XQVK]=\2>)'EG#\,CA/V=6I&-)07N
MODCR4]4MO<7*MMM-;GXEX6\,UL[XF_MO$T_W%&K4Q$Y.+M*:DFM7H^:4G9=I
M-]C[FP,!>P 'ITK\K_\ @L]XPG\$?\$^?C3KMJ2)X8]%A7J/EN=06!^G)^5S
MD CCO7ZFEF"!@.<#/XCFOQ&_X+Z^(8K7]@+XC^'?, N=>_LIX8]W+_9-2BD?
M"]3M SQG_'\&X7LN(LEG)<T89G@YM=^2O3DT_5']*\7U'#AG/(Q^+^S,3&VJ
M]VI3E3;3[I/\C^+7]D#P_P#\+#_:2^%NB7$6[[;XA2]@3&=YCNX;I\#!)P0#
MT/U[C_3G\+0+#X:\.1#_ )=M#TF ?]LK"WCQ^&VO\Y3_ ()!:)9>-OVWO@!:
M76TPQ7&O-+R,;HK0L,Y]&7@]?>O]'33VAM["UMXV!2*WBC0YSD1QJ/Y#_#)K
M]E^D!5PF-S3(E0IM2C@5.4>5\JBITU2Z:<LJ3:[I7L?AGT=YU,+EV?4JU2/L
MY8N,XW:YHRM.,HI6VLFWM:\>YI!]S,IZ=O\ /\\]_P J>J[1@5EQW,7FX#9Y
M^7D=NO\ G\\4DVH*KMM;*+CH>/?_ "*_G]X5NJI1A[_)RIM6=FXMKYM+7NF?
MT+',\/&ESU:L=:CBE%J7G?IHE?U7+W1KT57MKF.YA26-@RMD CGD'!Z58J&G
M%N,DTTVFGT:T?XGHQDIQ4HM--)IKLTFOP:84444BB+!:3)'"]/\ /^>_X# [
MOKC'\JEI,<@^F?UK*O3=6,4M'&4?N35_PN_P""Y+VUYFVV^[V[;62]$?GG_P
M5"\<3?#_ /8O^,7B:-_+:SL+.W1LXXO9'MV&001]\CKZU_G1_#?1;CQ+\8_!
MNF11&1]9\<V-Y$N-QEVZY#=.<#DE<DG'<5_>U_P72UM],_X)V?&J*!B+FZ?P
M\L*CAG U6,28[G )[<5_%;^P-X4F\=_MB? ?P_Y'F[]2NKA$*[O,,*QW#YSU
MV[2>!QUK^E_"7$?4^&,Y<_W4:KQ+<GHO9_5\/35MOMJ5[=8ZWL?RKXR<N,XG
MR2AS2F\/5PTG'>3E+%5I6M_*J?*D^RN]$?Z5WP]MOLG@;P?;$8\GPMX>C(]"
MFDV:D?@0<UV=8WAZ(P:)I%OC'D:7I\./0Q6D,9'_ ([C\*V:_G*NW*M4;W<Y
M/\3^H<'&$,+AX4_@C2@HK6R2BM%Y+8*_EV_X.7O#AMO@;X \;1Q9N(/&>F:?
M"^W[\B6\LBQ9QDY],\^_2OZB:_%+_@NQ\')OB[^QGJSVULUQ/X!U"?QJH12S
M#^S+%R-W!^7/4#GTYZ_6<!8I87BG*Y2Y5"K4E0J2D[*$*L;.5WI=-)+U/D/$
M;!_7N$,VH\THRC3C5@HJ[G*G)/DMV:O=]$C^-G]AOXJ7'PO_ &N/V=?$5N1"
MGB7Q/X6T37F!*K#;7=ZKW)?'W<#@[LC'7UK_ $K?#U];:EIT&H6<BRVU[&MS
M;."&62*0 HX(X(/8CM7^4YX)\0S:-XDTOQ/&Q2[\+Z7#K>FD'!&OV;;XH$QR
M']%'S=O2O]!G_@F-^V5X:^-GP \ VVNZO;_\)A;:3ING7EFTZ>>+E+9 X:-F
M+[O,.,=0:_4_%_*)8_!X/,<,I5(4J7U:HHJ_NU&I^U5KW:G&S73UT/Q'P8S7
M#8''XO+ZDHPE4K.O3G4?+\,%"4)-]HZVNKO31'ZTJS#MVY^OT_K45Z[1VSNH
MS(JDH/5@,X__ %T*Y:0!?N&/>&]_K^F.O>O%_C3\9O"7PG\):KKOB/4H+%+.
MUFDA::6.,-.B$JGS'DG'3OFOYZRO+,3BJT<+R5,0YU*<%22OM*"V2O;FMY;G
M]*9CFF&PF$K8B=2-+EA4<92:2GR1YVX:J[46VN[L?!/_  5@_:MTO]G_ /9A
M\96\>I16WC#Q'X<O]/T>T\U4FFO+JS;[.D:!@[,SCY=O)/3M7^?&MKX@^(WB
MBRT=X)9O$?CN6/4;B+#-.VI:D^UX]O+EMW&.IZ>M?IE_P5._;-UK]J7XAPVU
MM?R/H?@SQ0LD"6\K&">SL)&V[P&*LC*><=?:M#_@DQ^S;JG[1O[27AWQQ/IC
MW'AWPMKUJ\D@B+VRFSNDD,9)!7 4D]CC-?UWPYEO_$/.%IXS$NG3Q5>C4KUV
MFM)3VA&75TH\L4O/Y/\ D;B7,X^(G%6'PV%A*K2I5HPI.2?,XP48PTV]^7OR
M_P" C^TW_@G)\%X?@A^R7\*_#R6HM=1N_!^C:CJT6S8_]I/9*DPD7 (?<.=P
MS7WE#GRD+##%02/>L_1=*M]%TJQTJUC6.WLK:.VBC085(XUVJJ@<  =,5JU_
M*6:8N>99GB\PJR=2KB*]6HYRO=JI*ZW[*R/Z[R?!PRW*L%@(4XT_J]&E&2CL
MI1IQC)+_ +>3?]:%%%%<1Z 5_%/_ ,'*?@Z\M/VB?A;\1UMV%E!X7T;2!<;3
ML>X2YEE\DMT.1_#7]K%?S??\'%GP@F\8_L[^%?&NG69GN_#WBZSDO9D0,T6G
MVUK)([,P&50=<DX'X5^A>%^)HX;C'+Y5Y."JTZ]"$E_S]J17)?I;1[GYAXP8
M2KC>!\?2HPYYQQ&$JVLVU&G5O)_<[?._0_GS_P""/GQT'P=_;6T._NYDM+/Q
MW%;^&Y&+;%)U&_0F,'([ $#VK_0QT^1&LS=6K>9'=I]JB8$,&#KD8(&,$'\/
M>O\ *7\%^-[SP9XS\*>.]&D9)?">L6>JP21G&Z\LG$BQ94\YX.WKZ=Z_T3/^
M"?G[9GA+XX_!/P'<:EK%LWB:71]-M[RU\]#*MTUNN]&4L7!#'&#W-?;>+F45
M<7*CF6#@]*?L*SIIN3@YWHST5^:+4E;HMV? ^#F=X7+U5RK%U%2J2J4ZE)U)
M<L6X0M4@[NRYEKI?5'Z812.8T+#!*@GCOCGVX]JK79WQ2*/O;&;CU497I[C&
M.O%3"963?G]WC(/;H>_/3WS7S?\ '3]I#X<_!;1[F[\4:[::;<2P3-;+/<11
M&1XT.  Y!)W8'0=SFOPC!9=C,3C*6'A"==.T=FVI-*-W9:<O7ROIH?O699OA
M<#@ZN.E6IT84DZO,Y)7C&TDH7>O,[*-EJ[<IU?B3XO>&?!,6A67C+4(=-N]>
MGFAL8YYDA,S12A5"!SSU4?+ZXKV"WG^T64%S'\PECCDC(YS'( RD=L%""#[U
M_#A^T5_P44\?_M#?MP?#_P"%NB3S#P[HOB6%-'DLVDV7<,T\$DYRK,KJJC)V
MX&#]:_MY\)72R^'=#@)!N8-!T?[0G4AVT^W)R.O+9ZU]%Q%P_6RA488FFHU,
M0JDIQCK&G[.:LD_6</GVT/GN%\]HY[4QE7#UISI4%"E"JU9U.=RLW?2\73FX
M]^>6Y^ 7_!PSI]R?V<=)UQ86?3M(CN1?R8)2)[F>-( YZ#<YP >_:OY9O^"5
MWCR'X;?MR?L[^-]3E%NEG?:_!<22,$5?M\'V:#).,;]X Z=?I7]H7_!:_P"'
MDGQ"_8&^+EE#;F:_@BTJZM]J[I$6VOTGDV]\;4R<<]\=S_G[>"/%G_"+:CX=
M\;Z=,8K[PYKUFKM&V#%]GU***3[O(R(SGGK7[[X98JGG' &8<,V4Y56X>SF_
MXG[WV]I;?\_%;T]3\ \5*M7(^.LOXFA%PG0=*4)1C]AP5&3?9NT'ZI=S_54T
M'4!<PR:H3B&\L[*YB;C:PG@612#_ ,"_&MV&XE=K<%,!R^[C[H[?7</RKX/_
M &%OVBO#_P"T7\"?"6J:=J$-YJ-OI&G0:FD4JN\3P0PPH'"L2N=A^]U-?=C^
M9%<VT:+F-E.XC/RX48_/OV%?S/Q/A,;E.9RPM6FZ<J&(6%G"*O=TW&*>WPR4
M%9[6E>]C^E.$<YPV=911Q=&2JQJT85G)[QE54I2BTNL>;9W=TE;5HN74_D0R
MR=HH996/IL0OW'' K^)__@X4_:-C^)?C'X8?"C2+\3V^B7&MIX@@ADW"'<R2
MV_G*I.W.W(+XSCCUK^GO]M3]K;P/^SG\-?$>HZOK-K9:NMA.EK#-<1Q.TCQN
M@ 5F#$Y8=N_XU_G;_'_XLZW\;_C=XU\<:G+)<0^(=0$>B%R[(Q+/"/(SUWED
M&5]:_</"+))8:I7XHQ-/DA@90AAIR5FYU(2IU;7W4HUDDTKM7MLC\8\7.):.
M-IPX9PF(<IXF4GB84W>FU!T94X-J_O1DN=K=22NC]?O^" ?PJ;Q;^UE?_$![
M/[3I7PV2W6&X=-\:-JEB\1^;HI+@=QS7]UMN[O;QEAMSGCV!^7ICMVK^>W_@
M@1^R_>?"?]G;4?&WB/3WL_$/Q#-O<7)GC*RK%8W+_9R-X# /$Z]<\=/6OZ&@
MF%1!]T#&?H/ZU\'XGYFLUX@QDT[R@J%*Z=]X0J6ZV:G5E3E_@78_0/"W+9Y9
MPQA:4HV4YSJ7:2DY1G*F^VDH4X37=R9SWC&X-MX7\0W .#;Z'JUQGI_J;"XE
M')]-E?YCW[6GCF3QW^T[\3O$[OY@U?7+FS:0'=S:33V@ //H !GOQZ5_IB_%
M*\6Q^'_C2=V"JOA+Q)R>/F_L>]V\D@#FO\KKQ7>W>J?$+499,M)??$75;9SG
M)P_B>:%,_P"\K <GIZU^D> 4_JN9YI7G[L(X-VEWFZ=9)+N]8OT^X_,OI PC
MBL#EV&C)^T6*@Y)?9A&KA9_B^:W=IVN?Z"O_  1/T>?P[_P3T^!NG-#Y;-_P
MDDDBXQ@2:G)(AQUY!^O.:_6P?O$(/7/3Z=/\_3\?BC_@G?X,?P)^R1\)O#LL
M/D/:Z0;CR]I7 O5BGR5('W@^:^V@H#%NYK\1SRHYYWG$Y:N68XIQEU:]M+5_
MC]R/W?A^ER9%DT$HJ*RW"*I'6S<L/3;=G?7F]-V?.O[57AI?%WP"^)6B.GF"
M?PWJ4NW&3_H]C<RCL>FW\\5_EU^(K0QWGB"'85:#Q7K$<H Y00:U<JN1CC[O
M?&>]?ZM'Q&M5N_A[XVMW4$2^%/$(VD=3_9%YM&#[\U_E;?$NUN-*\?\ C?29
M8RGF>+=?:1>AC']L7;H<= ",=_0]Z_<_ 2<J^4\398[*I6CAJK;^USRDTGVY
M>1NZ[MI=OY[^D%1JTLTX8S"G90IPQ%-)NR:C:,T_*U2-O3[O]$/_ (),?$ ^
M/OV0/ #F02'P]86>@C!)PMO S\\X!R:_3CD'D$@<=,<=/Y5^"G_!OAXGG\0?
ML@ZY',Y8Z;X\NK"/))Q'%:)@<_Y&<>]?O:Y^1\\8S[<#O7XMQK@XT>*,SH17
ML_98ZI&/*M++E=EI:U[M;7N?MO %?VG"&45+\S6#BI)ZVDM7\]MNVVFG\JW_
M  <P^+%?X7_"KP>C_O;;QWHVO^3NY$:PRQ[\9SC..?Y$U^>O_!O!YOB']N3Q
M;)) &M[/X4WTXDVY FCU"+YLXQD#MU_*O9_^#DOQ9++\>/AMX+5RT!\)Z3JD
ML>3@+]HE0R8Z#C/..W7I71?\&W?@G3;7XL?$/QN,&Z_L#5=&4Y!_T<S12Y'&
M<9SCGZ"OW[*,'3CX-YMB(TU[199*:WTDJ\8R?^*2>O6_IK_.V=XEU?&K)\/S
MNG"KFCYJE[/2DII:_9NK:=/N7]E(8[PO;;_3_&JM]++"L/DKNWSJ']E/4^OX
M"E6XA!+E@-JENO\ #SST_/\ "F_;[=E5BRE2XVG/;L1_]?\ &OYF]E.]U"36
ME[+1NRO_ $S^KUBJ*IOGQ$(<S?++F6B5M/6Y:?;*C0D_,Z'/T/Y=?\FGQ)Y<
M:(.BJ!^54OM$(F61GP9"(D&1SDY [<_Y]:O;QOV9^;&['?'T_K4R;BE#6UU)
MI_S-)?\ #=SHH3=6#DK22<N62UO!6M)[V;W8ZBBBH-0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)WYW91;7-JNG?\#@Q'%7%LJ:<\15E'GC%**]VSLN9Z7NI))V=DK6/VW^$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#"8^"IXRA2KP@W*,:L5))O1M7ZO8_..\_P"";_P.DF#_ -BVF0-I_='[OO\
M+_GMZUL:/_P3I^!VD74=_;:+9B90,'R>^<YYX_G7Z!R*200.^#]/_K_TIYX
MQT!&?IWKTL1Q!FM6$'4QV(G[._VVVMEM?:R^[7='C4.&,FHU*UL!0Y)VLG3C
M97U]UV^3\SQ;P9\'_#7@=(K?2--M$AC C'^CQ'Y1[E">@Z\?G7LL,,4"K'%&
MD8"CY40* /3Y0!_G-/&XX/\ M>WW?\_C1@YSSG=C_@/^?\YKS,5F.)QKA.JZ
MM6248\TDW>"22MKNE:W0[\NRC!Y7[;ZI34%6GSR2BE9^5EZ#Z***R/4"O!_C
M+\"_!?QPCT^U\5V<-W_8HG^S>;&'V?:0-^.&QG'MZBO=SG''7_/K4*QI'*S#
M[TF,^^/P_P <>U.E7Q-#$4ZF'E*G*FW)U%HU=/X7O==?)^IG7H8?$T*M#%0C
M5I5(J/)-)Q;YX6NG_P"2^9^>#_\ !-WX%M#*#HMH3,ZLV8_1L_W>?3G/MQ4\
MG_!-[X$RRI*^B6>Y5 _U1XPNWTYK]"?G\WV_I_G_ #FIJ]BIG^<3Y.?,<3)Q
MY7%NK+W>5+E2UTY;*WR/$PW#F1T>;V668>"M&FTZ44FJ;NI6MU;_ *TM^=:?
M\$VO@1'(LHT6SRF['[D]P<\;<?3GZ56M?^"<_P "=(U-=3@T6S%P9HY$/D_Q
M1,&_N\D$<9SCDU^CM9]PD33VR/U._;QUXR>G^<>G6JCG^:R7)5S#%2A:UG4E
M:R3LK;:W[;7,L3PWE?(Y8;+\+&JY0]YTUOSQC=V5](N379I=+F)X3\.6/A;1
M[#0M,18['3XQ'"BC"JN .F,]L?Y%=7FHPH4-MZX_$<<5':^9Y(\W[^6SUZ9X
MZ\UY-23JN564KR<ES7?O2<KMO[]SW</2]A3C3LE;915HQ22C&,5T7*E9>I8H
MHHK(W"JZ>9YL^_/EX79^7S?_ %JL4TE0<'JWZT??IKI_7S&I**DG;WDHZ]&Y
MQ:^;M;YV/F7X_?LU^ _V@H-%M?&=E%>1:']I^R"5-X3[1CS,?4C/X<>M9GP$
M_9=\!? VYN7\*:?!:Q+M\EHXMISAMW) ;N?I7U0(OF;(X[?Y]_;]*7R_+CVQ
MCOZ>O7_/]*]!8^O&A/"QJR]E42BX?9LY*;=GU=OQ?=G@PRC#_6XXZ="#JTVY
M1:C[_-!1A34;_9Y8W^2Z[.0DLQ_A/0_3_/\ GBI*:HV@ #_]=.K@;N]-NGRT
M/;@FHJ[NWJ_5ZM+R73KW"JG[[[9T_<^5_P"/Y_S[YJW3<C=C^+'^?\]*15[;
MZ7=EZ]O4S[NSMYXY(9XHY8I@0ZR(KCYNO!&/_P!7O7Y[_%W_ ()O_ OXN^(K
MKQ+XBT:TDO;LN6/DE>9&+'A>.237Z,,H<8-!7*X';I_GW_G7?A<SQN YI83$
M5:,I*T_92<7)1LUMN]%]UCQL=D> S*\<9A:%>"5J:J0YN5-WE&ST4;ZV\S\7
M(?\ @BO^S"-2^V-H%IN\_P _(24?,2#VX_#N?RKZ3^#O_!.GX'_!/Q!#X@\+
MZ+:17L$BRH?*+8=7W*0'!'4?3TXK]##N Z ?@/Z4* <,W7('XX_K_P#KYK=\
M7YSB)NC5QV+494FIJ51J$D[)Q=W9W3[]3S:'!6182+=' X=S5124W!72TT5M
M=-XJ^C((((K2**.&**$! N(XT0$_\! Z]:GAE60/MZJQ5O\ >[]SS3V&XCT_
M#\<=\XIL42Q;]H^^Y8_4_@.:^?BJTL55J2NZ=VES;\S2<G'R;T5NA]9"-.%*
M,%O&,8Q](^[K\DK?\$EHHHKJ$%%%% !322&'H>/QIU&,_@<U,U)KW79IIK>S
ML]4[=&@.;UG3+?4H)K2]ACF@G0Q,)(U<888/# _A[#M7YR_$G_@F#\ _B9JF
MI:IK.B6;RZC>RWTY\HC,TI+-T&!UYX_G7Z=21K( &_A.1]:I1"=8KD-G=YC^
M5_N]AT^O]*]7#YQC,OHRCAL15HQM><83<8R<4N5NWVNG7L?.8WAC+LTQ#GCL
M/1KQYHNE.I%2G"^\;M?#?7?;\/R7T3_@CQ^S-H+++::#:*XE$XQ')]\$$'\"
M ?P'7O\ <7P;_9K\ ?!*&\A\,:7:1#4E@6X(@0DBV&(\;E)' [8]23W^B$:7
MRTW_ 'L '/4'_(]*?'(DSO%QOAQN&.?FYKDAQ9F>82J8.OBL5*DTIN%23:;7
M=>6C7^&Y?^JF2X9QJ8? X:-6GRJ$HTTK<KBF[K>ZC:_GYDUO$L,2HBJH'0*H
M4 >P%3445@VVVWJV[L]Z$5",815HQBHI>25D-8;E((S6%J^A6>M6,]C?0131
M7,;Q2"2-7^5@5_B''7GIFM^BKIU9TI1G"3C*,E*+6Z:U3^^S^1G5H4ZVE2*D
MK.+36Z=KI^5KKTD[GYB_%7_@EM^SY\6;ZXU#Q#HEH\]W(\LG[IERQ.?X OZ"
MO(;;_@C%^S)IZO#;:!:".]93<8CDY\DY0DDY'/7'H*_9&3S/.AVYV?-O_+C]
M>M*TH1HU?[S[L<=<>G;I7LTN*\]PUE#,\5&$5>WM)<JY4DM.Z4]-.AX.+X-R
M#&R4Z^7X>K4:4N;V<7*/)*,M=--8-O\ QR^?R7\ OV/?A;\ (?L_A'2K2':$
M!/D D;?]]>#S^GUKZX5510J*%51@!0 !]  !2*-N6/!/7_/^?YT^O+Q6/Q./
MFJV*KU*U3E6M27-**>K6NN[>_4]; 9=A,NI.EA,/2H0;U5*/*G;:_=V>OGJ%
M(<Y'ISG^E+2$X&37)*UM79)IM[?"T_N=K/R.X\S^*7PUT#XH>$=9\&^(8%GT
MO75B6\C<;E<0ME<CO@]OU%?*?PI_8+^#WPI\2KKOAO1[6&Z,WG2.L."K*2RD
M%E.,GKC@U]ZE=P!8<C/8?A_G^M-BCV9;'S-U]\=/\_\ UJ]'#YEBJ&'J4J5:
MI3A6@E.G=I2TBES*_P!E17SBO(\;%Y50QF)I5*M*$E":FI-7:C!PGRZW^*HM
MOY6Q\:+%''&HPL:*BCT5%"C]!3Z**X#V5IHMEH!YX]:^%?C9^Q#\)OC=XNOO
M%/C#2[6YOKHQYD>+<S;$"<LHYP,#T%?=+9VG'7!Q]<<51@@:2%#<?ZP%L_3=
MQ^E=F#QE;!5'4H5)TI2CR\\&U)*Z>C7I8\S-,NI9E2IPJ0A4]E4]I&%57A)N
M+B^9>2=UYH^=_@!^S9X!^ -E=6?@VRAM(KHNSB)"H(<#/H>W.:^E!NP,9^]W
M_N_Y_P#K<4WR@N-OT/T[U(N0,'UX^G:N+$UJN*Q3J595)2<6G4;]YOW9).6N
MFFG]Y^9T8+"PP>'A0IPA",+VC!66N[Z:O\K'R9\6_P!D;X9?%O7V\1>*--MK
MB\-N8#(\66V;BW7![D]\\^F*\0A_X)O? ??*4T:T!D#!OW+#Y#UR=OOVY_&O
MT:96D&&Y&[!^GI_GBA88XLD==OOT_EU_'WKUZ.<X_#TE2AC*\(JT80C4:C]E
MI6OOY=_N/(Q618'&UU.K@L/.GS.<Y5J:Y[R6K3:U2MU;W/SS;_@FU\") A.B
MV?RQ"(9B/W1ZX7FJUQ_P39^ BH7?1+(").3Y1QM SW _.OT=7[HQZ4R6)94=
M&&0ZE2.V#_G\JV7$>=I./]IXM1=M%5E;1Z:7Z=/,O_5G(G!)99A-D_X4;/KH
MK6U=F?#O@?\ 85^#O@G7=#\4Z)I-I'>Z1=6UY:2)%@J\#;XV!*]B/4^U?;EM
MO_>[^OF''^[VJ:.-8XTB4?*BA0/85%;AQYN__GHVW_=[5Y.*Q>,QE>-3$UI5
MO=DG*HW*5VTUJ^_^9ZV!P&$P%"=/"8>E0BW"3A3BHI2V;BEM?KW+-%%%8G2%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIY?U^HDK*UV_-ZO[PHHHH&%%%% !2%02"1R.E+10#5]UU3^:=U]S5P!STHH
MQP**2O9<V]E>VU[:V^8!5658S<6Y8?.-VS\OFQ^%6JC:,,Z.1RF<>V1S^?>F
M[].Z_/7\"H\M_>O:SV[VT_'<9'YGG3;L[/EV?ES^O2IZ** E+F=[6]V*_P#
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M .K_ #FI*3 SG')J9J4I4W&R497DM==-&O-/6_?U!)*/*[O2VNO7K\KH ,
M=!3<G..<[L]/X?\ /^<T^C'.>_2B<92Y>63C9ZV;5X]?GV]6,****L HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432881360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPUGEN LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651427966448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,877<span></span>
</td>
<td class="nump">$ 13,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">47,439<span></span>
</td>
<td class="nump">25,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted short-term bank deposit</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">32,688<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">4,796<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,133<span></span>
</td>
<td class="nump">114,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayFundNonCurrent', window );">Severance pay fund</a></td>
<td class="nump">3,023<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right to use asset</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">8,034<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">110,167<span></span>
</td>
<td class="nump">121,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred revenues</a></td>
<td class="nump">11,252<span></span>
</td>
<td class="nump">11,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,218<span></span>
</td>
<td class="nump">7,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,769<span></span>
</td>
<td class="nump">26,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses', window );">Long-term deferred revenues</a></td>
<td class="nump">21,028<span></span>
</td>
<td class="nump">25,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term operating lease liability</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">27,058<span></span>
</td>
<td class="nump">29,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2024, and December 31, 2023; 89,531,937 and 89,237,465 shares issued and outstanding on June 30, 2024, and December 31, 2023, respectively</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">542,032<span></span>
</td>
<td class="nump">539,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(483,917)<span></span>
</td>
<td class="num">(474,527)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">58,340<span></span>
</td>
<td class="nump">65,559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 110,167<span></span>
</td>
<td class="nump">$ 121,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432801568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">89,531,937<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">89,531,937<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432792928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">3,654<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">12,593<span></span>
</td>
<td class="nump">15,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,670<span></span>
</td>
<td class="nump">4,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,511<span></span>
</td>
<td class="nump">20,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(11,904)<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial income, net</a></td>
<td class="nump">2,528<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(9,376)<span></span>
</td>
<td class="num">(18,651)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit (expense)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,390)<span></span>
</td>
<td class="num">(18,615)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (9,415)<span></span>
</td>
<td class="num">$ (18,615)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">89,518,778<span></span>
</td>
<td class="nump">86,903,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">89,518,778<span></span>
</td>
<td class="nump">86,903,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $ 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651424311888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th" colspan="2"><div>Accumulated other comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 533,213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (455,773)<span></span>
</td>
<td class="nump">$ 77,680<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, (in shares)</a></td>
<td class="nump">1,609,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other comprehensive income (loss) from marketable securities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,615)<span></span>
</td>
<td class="num">(18,615)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">536,145<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(474,388)<span></span>
</td>
<td class="nump">62,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">88,233,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">539,837<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(474,527)<span></span>
</td>
<td class="nump">$ 65,559<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">89,237,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">561<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, (in shares)</a></td>
<td class="nump">292,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other comprehensive income (loss) from marketable securities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,390)<span></span>
</td>
<td class="num">(9,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 542,032<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (483,917)<span></span>
</td>
<td class="nump">$ 58,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">89,531,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,531,937<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $ 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432775760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,390)<span></span>
</td>
<td class="num">$ (18,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfDiscountOnMarketableSecurities', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain on sale of marketable securities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Increase in severance pay, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances', window );">Exchange rate differences loss (gain) on cash balances</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement', window );">Increase in interest receivables and exchange differences on short-term bank deposits</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease in trade receivables</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in other accounts receivable and prepaid expenses</a></td>
<td class="num">(2,267)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="nump">311<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Decrease in trade payables</a></td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in other accounts payable and accrued expenses</a></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredRevenues', window );">Decrease in deferred revenues</a></td>
<td class="num">(4,261)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Decrease in deferred participation in R&amp;D expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">39,703<span></span>
</td>
<td class="num">(18,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">25,011<span></span>
</td>
<td class="nump">51,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(47,086)<span></span>
</td>
<td class="num">(23,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">15,825<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="num">(5,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(42,287)<span></span>
</td>
<td class="nump">23,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,033)<span></span>
</td>
<td class="nump">6,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">13,910<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">11,877<span></span>
</td>
<td class="nump">17,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction', window );">Purchase of property and equipment</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceExpenses', window );">Issuance expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfDiscountOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of amortization of discount on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfDiscountOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Issuance expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase property and equipment as non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the Right-of-use asset obtained in exchange for operating lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432307424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
        <div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL<br/>&#160;</span></span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. <span style="color:rgb(0, 0, 0)">The Company</span>&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from the Company&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trials. The Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced <span style="color:rgb(0, 0, 0)">early-stage </span>program, COM503, was licensed to Gilead Sciences, Inc. (&#8220;Gilead&#8221;) in December 2023, see also Note 12. COM503 is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#8217;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
              </tr>
              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $9,390 during the six months ended June 30, 2024, has an accumulated deficit of $483,917 as of June 30, 2024, and has an accumulated negative cash flow from operating activities in the amount of $39,703 for the six months ended June 30, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
                </tr>

            </table>
          </div>
          <div></div>
          <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and additional aggregate milestone payments of approximately $23,000. </span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902. Rilvegostomig entered the clinic in September 2021, initiated a Phase 3 with first patient dosing in the first indication Phase 3 study in December 2023, and first patient dosing in the second indication Phase 3 study in May 2024. Compugen received a $10,000 upfront payment and received or accrued $30,500 milestone payments out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb Company (&#8220;Bristol Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></span></span></div>
                  <div>&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.<br/>&#160;<br/>In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 investment in Compugen, see Note 7a.</span></span></span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 7a.<br/>&#160;<br/>On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div></div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On December 18, 2023, the Company entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate (&#8220;COM503 License&#8221;), and additional products that may be so developed by Gilead (together with COM503, the &#8220;Licensed Products&#8221;).<br/>&#160;<br/>Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60 million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company is eligible to receive from Gilead $30 million in the form of a milestone payment upon clearance of the IND for COM503, see also Note 12. The Company is also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti- PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.<br/>&#160;<br/>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.<br/>&#160;<br/>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gilead withheld at source 15% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.</span></span></span></span></div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin:0pt">&#160;</p>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">
            <div style="line-height:1.25">
              <div style="text-align:justify;line-height:1.25">&#160;</div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="font-family:Times New Roman, Times, serif;width:16pt">&#160;</td>
                  <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:40pt">&#160;</td>
                  <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                    <div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, are applied consistently in these interim consolidated financial statements.</span></span></div>
                      <div style="line-height:1.25">&#160;</div>

                        <div>
                          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently Accounting Pronouncements</span></span></div>
                          <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></div>
                          <div style="line-height:1.25">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></div>
                        </div>

                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428629936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract', window );"><strong>Unaudited Interim Consolidated Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock', window );">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating results for the six-month period ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ended December 31, 2024.</span></span></div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of unaudited interim consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651427554656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">MARKETABLE SECURITIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following is a summary of available-for-sale marketable securities as of June 30, 2024 and December 31, 2023</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amortized cost</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized gains</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized losses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,711</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,740</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_xbrl_20230728101905592">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="text-align:justify;margin-left:58.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2024 and </span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">December 31, </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023, and the length of time that those investments have been in a continuous loss position:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less than 12 months</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12 months or greater</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized loss</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Gross</span></span></strong></span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>unrealized loss</span></span></strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">992</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_xbrl_20240730224858104">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>

        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company had no significant unrealized losses related to marketable securities (which were accumulated in a period of less than 12 months) and determined the unrealized losses are not due to credit related losses, therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, all of the Company&#8217;s available-for-sale marketable securities were due within one year.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no sales of marketable securities during the six-month periods ended June 30, 2024 and 2023, and accordingly no realized gains or losses were recorded.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432206160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FAIR VALUE MEASUREMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

          <div>
            <div>
              <div style="margin-left:63pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="3" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;text-indent:2pt">&#160;</div>
                      </td>
                      <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Short-term investments:</span></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. government bonds</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
              <div>&#160;</div>
            </div>
          </div>

      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651427879856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></span></span></div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $286 in favor of its offices and car leases in Israel.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the six-month periods ended June 30, 2024 and 2023, the Company recorded royalties to the IIA as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ 278 and $ 0, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $8,870.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2024 and 2023, the Company did not incur Contingent Fees.</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to 4% of the cash considerations that may be received under such transactions.In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the six months ended June 30, 2024 and 2023, the Company has not paid nor accrued any expenses related to the May 2012 Agreement.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div>Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2024 and 2023, the Company did not incur milestone payments. We also entered into a CLA in February 2024 with the European cell line development company for COM503. Under the agreement the Company is required to pay an annual maintenance fee and certain amounts upon the occurrence of specified milestones events.</div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2024 and 2023 the Company did not incur milestone payments.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651527939600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 7:-</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS' EQUITY</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>a.</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Issuance of Shares:</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants were exercisable at a price of $4.74 per Ordinary Share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).</span></span></span></span></span></span></span></span></div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div></div>
          </div>
        </div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of 3,955,696 Ordinary Shares were exercised with proceeds of approximately $18,750, and the remaining warrants to purchase up to 297,469 Ordinary Shares expired in June 2023.<br/>&#160;</span></span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 equity investment in the Company.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of the Company&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $7,788 (net of $91 issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $14,958 (net of $42 issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#8217;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div></div>
          </div>
        </div>
      </div>
    </div>
    <div>
      <div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of June 30, 2024, 2,905,550 shares were issued and sold through the ATM, with proceeds of approximately $3,643 (net of $530 issuance expenses).</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share option plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions related to the grant of options to employees, directors and non-employees under the Company&#8217;s 2010 Share Option Plan, as amended, during the six-month period ended June 30, 2024, were as follows:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate intrinsic</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,373,745</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.65</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.61</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,912</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">40,500</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.08</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,744</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.84</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(282,455</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.55</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(140,000</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.08</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,990,046</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.58</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.19</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,205</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,245,345</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.68</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.99</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">124</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month period ended June 30, 2024, the Company&#8217;s Board of Directors granted 40,500 options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $1.80 to $2.09 per share, with vesting to occur in up to four years.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92.7%-95.9</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">75.9%-76.4</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.9%-4.5</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.3%-4.2</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.0-5.1</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">Weighted average fair value of options granted during the six-month periods ended June 30, 2024 and 2023 were $</span><span>1.41<span style="color:rgb(0, 0, 0)"> and $0.53, respectively.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2024 and 2023, the Company recorded share based compensation related to stock options in a total amount of $</span><span>1,633<span style="color:rgb(0, 0, 0)"> and $1,782, respectively.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">As of June 30, 2024, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $</span><span>3,405<span style="color:rgb(0, 0, 0)"> which is expected to be recognized over a weighted average period of approximately</span><span style="font-weight:bold;color:rgb(0, 0, 0)">&#160;</span>1.85<span style="color:rgb(0, 0, 0)"> years.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2024 and 2023, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,002,799<span style="color:rgb(0, 0, 0)">&#160;</span>and 7,460,568, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>805</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,002</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">785</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">821</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,633</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,782</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428654656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL INCOME, NET</a></td>
<td class="text">
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">FINANCIAL INCOME, NET</span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
          </div>

            <div>
              <div style="margin-left:90pt">
                <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                    <tr>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td rowspan="1" style="vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
                      </td>
                      <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,770</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,671</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">796</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(38</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,528</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,697</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>

        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/720/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651526859984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 9:-</span></span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">REVENUES</span></span></span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
        </div>
      </div>
      <div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following represents the total revenue for the six-month periods ended June 30, 2024 and 2023 by region based on the invoicing address of customers<span style="font-weight:bold">:</span></span></span></span></div>&#160;<div style="margin-left:63pt">

          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2024</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unaudited</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue from sales to customers:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>United States</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,261</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Europe</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,000</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Total revenues</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9,261</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      <div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Contract Balances</span></span></span></div>
      <div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Of the $ 36,541 of deferred revenue recorded as of December 31, 2023, the Company recognized $ 4,261 as revenue during the six months ended June 30, 2024. The Company had no deferred revenues as of December 31, 2022.</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Remaining Performance Obligation</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#8217;s remaining performance obligations are comprised of revenue not yet delivered. As of June 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $32,280, that the Company expects to recognize as revenue. As of June 30, 2024, the Company expects to recognize 35% of its remaining performance obligations as revenue over the next 12 months.</span></span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651434049072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
            <div>
              <div>
                <div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">
                        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                            <tr>
                              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></span></span></div>
                              </td>
                            </tr>

                        </table>
                        <div style="line-height:1.25">&#160;</div>
                      </div>
                    </div>
                  </div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balances with related parties:</span></span></div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="margin-left:63pt">

                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade and other payables (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>22</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>

                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <div></div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related parties' expenses:</span></span></div>
                  <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                  <div style="margin-left:63pt">

                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>74</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>

                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:56.75pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                        <td style="width:28.3pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></td>
                        <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428661760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSSES PER SHARE</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="line-height:1.25">
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25">
                    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                        <tr>
                          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 11:-</span></span></td>
                          <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                            <div style="font-weight:bold">
                              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">LOSSES PER SHARE</span></span></span></div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div style="line-height:1.25">&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share for the six-month periods ended June 30, 2024 and 2023:</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="margin-left:63pt">

              <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>9,390</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>18,615</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">89,518,778</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,903,741</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.10</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.21</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>

          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432674720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <div>
              <div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25">
                            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                                <tr>
                                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 12:-</span></span></span></td>
                                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                                    <div style="font-weight:bold">
                                      <div style="font-weight:bold">
                                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>SUBSEQUENT EVENTS</span></span></span></div>
                                      </div>
                                    </div>
                                  </td>
                                </tr>

                            </table>
                            <div style="line-height:1.25">&#160;</div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
                <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On July 29, 2024, the Company announced that the U.S. Food and Drug Administration has cleared the IND application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead. The IND clearance triggered a $30,000 milestone payment from Gilead which is expected in the third quarter of 2024.</span></span></span></div>
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                <div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On July 31, 2024, following recommendation of the compensation committee, the Company&#8217;s board of directors increased the total number of shares reserved for issuance under the Company&#8217;s 2010 Plan by 300,000 and reduced the total number of shares reserved for issuance under the ESPP by 114,146 to zero.</span></span></span></span></span></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651553249632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text">
                        <div>
                          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently Accounting Pronouncements</span></span></div>
                          <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></div>
                          <div style="line-height:1.25">&#160;</div>
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></div>
                        </div>
                      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428756656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amortized cost</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized gains</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized losses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,711</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Available-for-sale &#8211; matures within one year:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governmental bonds</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,740</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730211801692_xbrl_20230728101905592">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of unrealized loss on investments</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less than 12 months</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12 months or greater</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross unrealized loss</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fair value</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Gross</span></span></strong></span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>unrealized loss</span></span></strong></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of </span></span>December&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">992</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20240730224938615_xbrl_20240730224858104">*</span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:58.5pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents an amount lower than $1.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651433100176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value measurements</a></td>
<td class="text">
          <div>
            <div>
              <div style="margin-left:63pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="margin-left:4.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value</span></span></div>
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hierarchy</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="3" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;text-indent:2pt">&#160;</div>
                      </td>
                      <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unaudited</span></p>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Short-term investments:</span></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. government bonds</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,688</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,742</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">
              <div>&#160;</div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651433986272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate intrinsic</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,373,745</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.65</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.61</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,912</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">40,500</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.08</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,744</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.84</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(282,455</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.55</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(140,000</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.08</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,990,046</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.58</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.19</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,205</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,245,345</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.68</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.99</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">124</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate fair value of options granted</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92.7%-95.9</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">75.9%-76.4</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.9%-4.5</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.3%-4.2</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.02</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.0-5.1</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>805</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,002</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">785</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">821</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,633</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,782</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428335136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
            <div>
              <div style="margin-left:90pt">
                <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                    <tr>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td rowspan="1" style="vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
                      </td>
                      <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,770</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,671</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">796</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(38</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,528</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,697</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651527959152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfRevenueTableTextBlock', window );">Schedule of revenue</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%">

              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Six months ended</span></span></span></div>
                  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June 30,</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2024</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unaudited</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Revenue from sales to customers:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>United States</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,261</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Europe</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,000</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Total revenues</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9,261</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of  revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651434025120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelatedPartyBalancesAndTransactionsAbstract', window );"><strong>Related Party Balances And Transactions Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade and other payables (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>22</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>

                      <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                            <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>
                          <tr>
                            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses (a)</span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>74</span></span></span></div>
                            </td>
                            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                            </td>
                            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          </tr>

                      </table>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelatedPartyBalancesAndTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelatedPartyBalancesAndTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651433070880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted losses per share</a></td>
<td class="text">
              <table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>9,390</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>18,615</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">89,518,778</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,903,741</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.10</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.21</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651429045856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
<th class="th"><div>Oct. 10, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,390<span></span>
</td>
<td class="nump">$ 18,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,703<span></span>
</td>
<td class="num">$ (18,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MilestonePaymentReceivable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram', window );">Potential milestone compensation company is now eligible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid', window );">Percentage of expected from upfront payment amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected from upfront payment amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone compensation company is now eligible for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480679/815-10-10-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480769/815-20-10-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651434161888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details) - Governmental bonds [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 32,711<span></span>
</td>
<td class="nump">$ 11,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 32,688<span></span>
</td>
<td class="nump">$ 11,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651424550704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Available-for-Sale Securities, fair value, less than 12 months</a></td>
<td class="nump">$ 32,688<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses', window );">Available-for-Sale Securities, gross unrealized losses, less than 12 months</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue', window );">Available-for-Sale Securities, fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses', window );">Available-for-Sale Securities, gross unrealized losses, less than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432306368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | U.S. government bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in marketable securities</a></td>
<td class="nump">$ 32,688<span></span>
</td>
<td class="nump">$ 11,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651537022432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember', window );">Commercial License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties paid to the IIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Royalty Contingent Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Start date of the agreement, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government And Other Grants [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651422361296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options granted, exercise price, minimum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options granted, exercise price, maximum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during period | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Share based compensation stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized estimated compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,002,799<span></span>
</td>
<td class="nump">7,460,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember', window );">Agreement [Member] | Registered direct offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,316,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember', window );">Sales Agreement With Leerink Partner LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,905,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum authorized proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelativeFairValueOfDeferredParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Relative fair value of deferred participation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelativeFairValueOfDeferredParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432833008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details) - Employees Directors And Non Employees [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">8,373,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited</a></td>
<td class="num">(282,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">7,990,046<span></span>
</td>
<td class="nump">8,373,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">5,245,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">4.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of year</a></td>
<td class="nump">4.58<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding</a></td>
<td class="text">6 years 2 months 8 days<span></span>
</td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable at end of year</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of year</a></td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of year</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651427644208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">4 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">92.70%<span></span>
</td>
<td class="nump">75.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk free interest rates range, minimum</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">95.90%<span></span>
</td>
<td class="nump">76.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk free interest rate range, maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428219376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details) - Employee Stock Purchase Plan [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 1,633<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing and business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">43<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651427305440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INCOME, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="nump">$ 1,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Amortization of discount on marketable securities, net</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Exchange rate differences and other</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 2,528<span></span>
</td>
<td class="nump">$ 1,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432340752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 4,261<span></span>
</td>
<td class="nump">$ 36,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 32,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligations percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651428210624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432223184">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_TradeAndOtherPayablesRelatedParties', window );">Trade and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related parties' expenses amounts charged to research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_TradeAndOtherPayablesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_TradeAndOtherPayablesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651424115440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for basic and diluted loss per share</a></td>
<td class="nump">$ 9,390<span></span>
</td>
<td class="nump">$ 18,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">89,518,778<span></span>
</td>
<td class="nump">86,903,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">89,518,778<span></span>
</td>
<td class="nump">86,903,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139651432805712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Gilead Sciences, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ClearanceTriggeredMilestonePayment', window );">Clearance triggered mlestone payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Plan 2010 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClearanceTriggeredMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of clearance triggered milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClearanceTriggeredMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cgen_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cgen_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_Plan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_Plan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !(X!ED'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  2. 999HC(5.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G>RV% G;7!1/"H(%Q5M(IFUPLPG)R&[?WFQLMX@^@,?,_/GF
M&YA.!Z%]Q.?H T:RF&XFUP])Z+!E1Z(@ )(^HE.ISHDA-_<^.D7Y&0\0E/Y0
M!X26\PTX)&44*9B!55B(3'9&"QU1D8]GO-$+/GS&OL",!NS1X4 )FKH!)N>)
MX33U'5P!,XPPNO1=0+,02_5/;.D .R>G9)?4.([UN"JYO$,#;T^/+V7=R@Z)
MU* Q_TI6T"G@EETFOZ[N[G</3+:\75?\MN*;7=,(SD6[?I]=?_A=A9TW=F__
ML?%%4';PZR[D%U!+ P04    "  2. 99F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M !(X!ED"_%[=6@,  *@+   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9;;<MHP$(9?1>/.]"K$!\XI, .D-&E.-(=VVDXOA+V )K;E2G((;]^5;0S)
M&$%O0)*UOS^MI-_;6W'Q+)< BKQ&82S[UE*IY,RVI;^$B,I3GD",3^9<1%1A
M5RQLF0B@0184A;;G."T[HBRV!KUL;"H&/9ZJD,4P%42F443%>@0A7_4MU]H,
MW+/%4ND!>]!+Z (>0#TE4X$]NU0)6 2Q9#PF N9]:^B>C=R6#LAF?&>PDCMM
MHI<RX_Q9=RZ#ON5H(@C!5UJ"XM\+C"$,M1)R_"U$K?*=.G"WO5&?9(O'Q<RH
MA#$/?[! +?M6QR(!S&D:JGN^NH!B04VMY_-09K]DE<^MURWBIU+QJ A&@HC%
M^3]]+1*Q$^!V]P1X18"7<><ORBC/J:*#GN K(O1L5-.-;*E9-,*Q6._*@Q+X
ME&&<&IQS/\4D*T+C@'R.%5-K<AGGNXU9Z]D*7Z*GVGXA.,H%O3V"+7+#8[64
M*!9 \#;>1KB2T-L0CCRCX-<T/B5UYX1XCM<PZ-7+%=<SO?H>O3%_ 4%^#V=2
M"3P3?ZJ6F"LTJA7T13F3"?6A;^%-D"!>P!I\_."VG$\&OD;)US"I#XI-N(<%
MTX2X-;<T@BI*L\[X[F;Z].7S+;E^/#\U<#5+KN8Q7&,\+(*&>$@">"57L*XB
M,RLYCN.Z;K?=-FUGJ\1JF9>9"J'/[X1)'[%^ A7ZZ!&\#95),ZO5:JY7J[L&
MKG;)U38JE1?K<9U4@IC#6[4K T2GA.@8589($&04DY NJBC,\7,:2C!P=$N.
M[G')F()@/#!ND%FI=(-#=N Z6P=TCH,KCE#!.,%A6>E_9KEOGHEJQY?=_Z+*
M#O9^)K/8H5QY6RKO&!.8L!#(;1K-0%32F$7P_M?J3M<Q)FIKYZ[1C3=(PR!
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M5)3,C3IB4BPFN#T6+%91',0= FO6$3?K6O7>?LQ6.3HY1;L%;WYDC P+*F$
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M!O#\D7/U>J,/" \'PL/_ 5!+ P04    "  2. 991TL7*ZP"  !/!P  &
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MVB6'C>3P79+5W2 DSM7BJDUW^%;=;8&MNNVM<J>OFFO,5R07B,)209U.3V6
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MK!%KV+1%*LB2OW3BW"JLPV@Z&1'I\'%8(^/0"_3Z5SKGQ:,@4%8$),AL)K0
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M4\&GO-\,>/_/N-9/]KV583O)WZ)X80C]E 'VV*RPPM;9*&5W>-M1#$730WY
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M -XO#+I=?" !Z1>\J_\ 4$L#!!0    ( !(X!EGOW 7^K@0  /T+   8
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M-WI^V0AB6EZC;R]J9>(46*%*:8F0-=%J<Y*\CYZ5L2I/8Y3M)],7:-$0:@C
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M-8[&(H^<?Z=<+FYOWGULA -5Z)V\S.N'/5XG"N6T3;U0'&<0O&H(GE5%I6V
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M I.T ._GUH;ZAA0T'^)/_P102P,$%     @ $C@&62R[WXLG#   -B$  !D
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M?QM0-@'?KZ4T^\ 6:/Y?HS]02P,$%     @ $C@&69#$2D'O @  ;08  !D
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M6%TC3K8/PS[0TDGB*I$J2<7QO^^1DA6[=;-U _9%)*6[YYY[%8<;J3[I#-'
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M'RHK0-\3*<WN8 VTM\CQ%U!+ P04    "  2. 996/^XM2$#  "A!P  &0
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M[E#43H'^SY2RFXUS4-_*O5]02P,$%     @ $C@&69C-IT2+ @  < 4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL?511;]HP$'[/K["R:=JDCH1
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M05F2]>)1W!LE*4G\84J&_G! !KWQ(.H@UHH)9$:2L)>&(8G\,.O.]E84Y'R
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MK ">KZ0T^X6]H/OHF?T#4$L#!!0    ( !(X!EEC>: NKP(  +\%   9
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M7_0Z+HAZ7-2&XFO;HDNN=,/;;:XG+ KCH.\SSM7>, &:F1W_ U!+ P04
M"  2. 99WNP_"EX"   L!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q]5-]OTS 0?L]?81F$0!I+FG9EE#;2.CH!TM"T;N,!\> FER::8P?[LH[_
MGK/S@R)U?;%]]MWG[SO?>;[3YM$6 ,B>*ZGL@A>(]2P,;5I )>RIKD'12:Y-
M)9!,LPUM;4!D/JB281Q%T[ 2I>+)W._=F&2N&Y2E@AO#;%-5POQ9@M2[!1_Q
M?N.VW!;H-L)D7HLMK 'OZQM#5CB@9&4%RI9:,0/Y@E^,9LN)\_<.#R7L[-Z:
M.24;K1^=\35;\,@1 @DI.@1!TQ-<@I0.B&C\[C#Y<*4+W%_WZ%=>.VG9" N7
M6OXH,RP6_)RS#'+12+S5NR_0Z3ES>*F6UH]LU_K&$6=I8U%773 QJ$K5SN*Y
MR\->P/E+ 7$7$'O>[46>Y6>!(ID;O6/&>1.:6WBI/IK(E<H]RAH-G984A\GM
MZF'U_7ZU9F_OQ$:"?3</D6#=89AV$,L6(GX!8LJNM<+"LI7*(/L_/B0Z Z>X
MY[2,CP)^:]0I&T<G+([BR1&\\:!Q[/'&+VF$)U -L)\7&XN&ZN#7(9$MQN0P
MANN-F:U%"@M.Q6_!/ %/WKP:3:-/1QA.!H:38^C)FGHM:R0PG5.E>[:'*!X%
M.4QQ73ZSJGT><,_#*+G@DANXY+IA'-PKT60E0A;TF<J-KI@55 \,=5>&8.R,
M7)T?6Z- L,'K8'(23T<TOP]6C:&?(C@[B:*(S#N-0O9:G.?'WI,=RE>X5\%T
MT];WJ66I;A2VQ3SL#E_!1=L!_]S;?^1:F&VI+).04VAT^N&,,]/V9FN@KGT_
M;#22++\LZ#L#XQSH/-<:>\-=,'R0R5]02P,$%     @ $C@&60J7&VBK @
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M5=]OFS 0_E=.K)I:J0T$Z ]E!"E-4RU3,U6AZ1ZF/3CD$JP:F]F&=-+^^-E
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MS4DUYGW.RC);;'Z\%\E,Y/43JG^_S;+RZ9>Z@X<L_[)YF5?_#U!+ P04
M"  2. 99_S,67,\$   *%P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6RUF&MSXC84AO^*QMUI-S.[V!+&0 K,D$ GVVDV:=ATI]/I!X$/H%G;HI*
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M4^R@A@T.PMX0BFE$</8.5]V)O54-=MZYU_&V27>-7/\RV&*UUSIB#GQF!H5
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M1GC(9=5W5!,M"OMT/PB-C8 =IMBJ@30&N+\60N\GY@--\Q?]!E!+ P04
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MU_'C.IJK*IK!"]%<P*T4)M6P$ DF;;U/9 W>X!'O:M!I&&%Q L/@'0R"P>A
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M--2*NMN46AA4=@*]7TMI'@=V@>;_C]F_4$L#!!0    ( !(X!EDL!IA+6 ,
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M$<P!>,"0,#3OP9WW4;!Y3P7U_SE'OP%02P,$%     @ $C@&69>*NQS
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M(BR)#<@) #GY/9 7+K2>HV")V8+$B!J0MP#D[14CV6ON.P#RSB[D@C 2X="
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M_=])=;Q=ZY^WOR\?F[V'<,?9P2^-U2]02P,$%     @ $C@&68B,J3>E 0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ $C@&66:(R%3N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M$C@&69E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  2. 99 OQ>W5H#  "H"P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M$C@&65FS[1H,!P  '!X  !@              ("!G0L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !(X!EE'2Q<KK (  $\'   8
M          " @=\2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  2. 99CUP/3X,%   &%0  &               @('!%0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ $C@&6<;]-S")!@  KR(
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M965T.2YX;6Q02P$"% ,4    "  2. 99HLE5_$8$  #Q"@  &0
M    @($2/@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M !(X!EFU->M=A (  'P%   9              " @8]"  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ $C@&6<_2D.;)"   E!<  !D
M             ("!2D4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  2. 99++O?BR<,   V(0  &0              @(%*3@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !(X!EDB@]XOIP(
M +\%   9              " @:A:  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ $C@&6>3?T&FB P  5 @  !D              ("!
MAET  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  2. 99
MT/F=V0<#  #+!@  &0              @(%?80  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( !(X!EF0Q$I![P(  &T&   9
M      " @9UD  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ $C@&67!66\!X P  4P<  !D              ("!PV<  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  2. 99MLKH3#,$  !1"@
M&0              @(%R:P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( !(X!EE8_[BU(0,  *$'   9              " @=QO  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ $C@&69C-IT2+
M @  < 4  !D              ("!-',  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  2. 99<@]%W T$    "0  &0
M@('V=0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !(X
M!EEC>: NKP(  +\%   9              " @3IZ  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ $C@&6=[L/PI> @  + 4  !D
M         ("!('T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  2. 99"I<;:*L"  "Y!0  &0              @(&U?P  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !(X!EG .;O,Q0(  /L%
M   9              " @9>"  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ $C@&6;1L2Z>M!0  -"T  !D              ("!DX4
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  2. 992-FY
M#B@#  "I"   &0              @(%WBP  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( !(X!EG=>B?S* ,  &()   9
M  " @=:.  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M$C@&6>3VZM1V @  +P8  !D              ("!-9(  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  2. 99&K3J]Y<%  #*'P  &0
M            @('BE   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( !(X!ED?8,!29@\  -#-   9              " @;":  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ $C@&6?\S%ES/!
M"A<  !D              ("!3:H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  2. 99:Q^](;D#  "S#P  &0              @(%3
MKP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !(X!EG=
MM97UH ,  .D.   9              " @4.S  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ $C@&62JDZ"GO @  Q0<  !D
M     ("!&K<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !(X!EEK.+B60 ,  (L,   9              "
M@2''  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ $C@&
M62P&F$M8 P  ]!0   T              ( !F,H  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  2. 99EXJ[',     3 @  "P              @ $;S@
M7W)E;',O+G)E;'-02P$"% ,4    "  2. 99T[H!J<T#  ";&P  #P
M        @ $$SP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $C@&62E=
MB*"3 0  XA@  !H              ( !_M(  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ $C@&68B,J3>E 0  +QD  !,
M     ( !R=0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #$ ,0!.#0
&G]8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>208</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbs</Role>
      <ShortName>INTERIM CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-socise1</Role>
      <ShortName>INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements</Role>
      <ShortName>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIES</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se1</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - FINANCIAL INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fin</Role>
      <ShortName>FINANCIAL INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Revenue</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - LOSSES PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lps</Role>
      <ShortName>LOSSES PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - FINANCIAL INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fint</Role>
      <ShortName>FINANCIAL INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fin</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RevenueTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/Revenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - LOSSES PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lpst</Role>
      <ShortName>LOSSES PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lps</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd1</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesosced</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - FINANCIAL INCOME, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-find</Role>
      <ShortName>FINANCIAL INCOME, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fint</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - REVENUES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RevenueNarrativeDetails</Role>
      <ShortName>REVENUES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RevenueTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RevenueDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RevenueTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbatd</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails</Role>
      <ShortName>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lpst</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2431742.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgen-20240630.xsd</File>
    <File>cgen-20240630_cal.xml</File>
    <File>cgen-20240630_def.xml</File>
    <File>cgen-20240630_lab.xml</File>
    <File>cgen-20240630_pre.xml</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="exhibit_99-2.htm">exhibit_99-2.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="zk2431742.htm">zk2431742.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="359">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exhibit_99-2.htm zk2431742.htm": {
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "cgen-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgen-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "exhibit_99-2.htm",
      "zk2431742.htm"
     ]
    }
   },
   "keyStandard": 166,
   "keyCustom": 42,
   "axisStandard": 14,
   "axisCustom": 1,
   "memberStandard": 16,
   "memberCustom": 15,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://cgen.com/20240630": 1
   },
   "contextCount": 92,
   "entityCount": 1,
   "segmentCount": 31,
   "elementCount": 359,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 359,
    "http://xbrl.sec.gov/dei/2024": 13
   },
   "report": {
    "R1": {
     "role": "http://cgen.com/role/cgen-daei1",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431742.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431742.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cgen.com/role/cgen-cbs",
     "longName": "0002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS",
     "shortName": "INTERIM CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cgen.com/role/cgen-cbsp",
     "longName": "0003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cgen.com/role/cgen-csocl",
     "longName": "0004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "shortName": "INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cgen.com/role/cgen-socise1",
     "longName": "0005 - Statement - INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cgen.com/role/cgen-g",
     "longName": "0007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cgen.com/role/cgen-sap1",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements",
     "longName": "0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "shortName": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cgen.com/role/MARKETABLESECURITIES",
     "longName": "0010 - Disclosure - MARKETABLE SECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0011 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cgen.com/role/cgen-cac",
     "longName": "0012 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cgen.com/role/cgen-se1",
     "longName": "0013 - Disclosure - SHAREHOLDERS' EQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cgen.com/role/cgen-fin",
     "longName": "0014 - Disclosure - FINANCIAL INCOME, NET",
     "shortName": "FINANCIAL INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cgen.com/role/Revenue",
     "longName": "0015 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cgen.com/role/cgen-rpbat",
     "longName": "0016 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cgen.com/role/cgen-lps",
     "longName": "0017 - Disclosure - LOSSES PER SHARE",
     "shortName": "LOSSES PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "longName": "0018 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "0019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESTables",
     "longName": "0020 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "0021 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cgen.com/role/cgen-set",
     "longName": "0022 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cgen.com/role/cgen-fint",
     "longName": "0023 - Disclosure - FINANCIAL INCOME, NET (Tables)",
     "shortName": "FINANCIAL INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cgen.com/role/RevenueTables",
     "longName": "0024 - Disclosure - REVENUES (Tables)",
     "shortName": "REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:ScheduleOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cgen:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "cgen:ScheduleOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "cgen:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "longName": "0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cgen.com/role/cgen-lpst",
     "longName": "0026 - Disclosure - LOSSES PER SHARE (Tables)",
     "shortName": "LOSSES PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cgen.com/role/cgen-gd1",
     "longName": "0027 - Disclosure - GENERAL (Details)",
     "shortName": "GENERAL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20130801to20130805",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESDetails",
     "longName": "0028 - Disclosure - MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of available-for-sale marketable securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails",
     "longName": "0029 - Disclosure - MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of gross unrealized losses and fair values on investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "0030 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "longName": "0031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
     "longName": "0032 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
     "longName": "0033 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
     "longName": "0034 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cgen.com/role/cgen-sesosced",
     "longName": "0035 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cgen.com/role/cgen-find",
     "longName": "0036 - Disclosure - FINANCIAL INCOME, NET (Details)",
     "shortName": "FINANCIAL INCOME, NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cgen.com/role/RevenueNarrativeDetails",
     "longName": "0037 - Disclosure - REVENUES (Narrative) (Details)",
     "shortName": "REVENUES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "cgen:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "cgen:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cgen.com/role/RevenueDetails",
     "longName": "0038 - Disclosure - REVENUES (Details)",
     "shortName": "REVENUES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630_srtStatementGeographicalAxis_countryUS",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfRevenueTableTextBlock",
       "div",
       "div",
       "cgen:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://cgen.com/role/cgen-rpbatd",
     "longName": "0039 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "cgen:TradeAndOtherPayablesRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "cgen:TradeAndOtherPayablesRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
     "longName": "0040 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "shortName": "LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "longName": "0041 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "cgen:ClearanceTriggeredMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "cgen:ClearanceTriggeredMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES [Abstract]",
        "verboseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r582"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "cgen_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued milestone payment.",
        "label": "Accrued Milestone Payment",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r48",
      "r95",
      "r433",
      "r454",
      "r455"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive income [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r15",
      "r301",
      "r304",
      "r346",
      "r450",
      "r451",
      "r620",
      "r621",
      "r622",
      "r626",
      "r627",
      "r628",
      "r629"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r626",
      "r627",
      "r628",
      "r629",
      "r694",
      "r747"
     ]
    },
    "cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AdjustmentForExchangeRateDifferencesLossGainOnCashBalances",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment For Exchange Rate Differences Loss Gain On Cash Balances",
        "negatedLabel": "Exchange rate differences loss (gain) on cash balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Member]",
        "label": "Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AgreementStartDate",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of the agreement, in CCYY-MM-DD format.",
        "label": "Agreement, start date"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination description.",
        "label": "Agreement termination description",
        "terseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r279"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "verboseLabel": "Increase in interest receivables and exchange differences on short-term bank deposits",
        "negatedLabel": "Increase in interest receivables and exchange differences on short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Discount And Accrued Interest On Marketable Securities",
        "documentation": "Represent the amount of Amortization of discount and accrued interest on marketable securities",
        "negatedLabel": "Amortization of discount and accrued interest on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfDiscountOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AmortizationOfDiscountOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of amortization of discount on marketable securities.",
        "negatedLabel": "Amortization of discount on marketable securities",
        "label": "Amortization Of Discount On Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmountIncurredMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AmountIncurredMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount incurred milestone payments.",
        "label": "Amount incurred milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r94",
      "r115",
      "r143",
      "r145",
      "r151",
      "r152",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r296",
      "r298",
      "r332",
      "r429",
      "r491",
      "r558",
      "r559",
      "r582",
      "r605",
      "r659",
      "r660",
      "r706"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r96",
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r296",
      "r298",
      "r332",
      "r582",
      "r659",
      "r660",
      "r706"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r296",
      "r298",
      "r332",
      "r659",
      "r660",
      "r706"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AtMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AtMarketOfferingProgramMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Program [Member]",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "At The Market Offering Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r200",
      "r428"
     ]
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Fair Value",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, fair value.",
        "terseLabel": "Available-for-Sale Securities, fair value, greater than 12 months"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Greater Than 12 Months Gross Unrealized Losses",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, greater than 12 Months, gross unrealized losses.",
        "terseLabel": "Available-for-Sale Securities, gross unrealized losses, less than 12 months"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, fair value.",
        "terseLabel": "Available-for-Sale Securities, fair value, less than 12 months"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESScheduleOfGrossUnrealizedLossesAndFairValuesOnInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Gross Unrealized Losses",
        "documentation": "Represents the amount of available for sale securities, continuous unrealized loss position, less than 12 Months, gross unrealized losses.",
        "terseLabel": "Available-for-Sale Securities, gross unrealized losses, less than 12 months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r200",
      "r311",
      "r420",
      "r572",
      "r575",
      "r637",
      "r698",
      "r699",
      "r700"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketing and business development expenses",
        "label": "Marketing and business development expenses",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r93",
      "r554"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r59",
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares remain outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClearanceTriggeredMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ClearanceTriggeredMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearance Triggered Milestone Payment",
        "documentation": "Represents the amount of clearance triggered milestone payment.",
        "verboseLabel": "Clearance triggered mlestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborationAgreementWithUSAntibodyCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "CollaborationAgreementWithUSAntibodyCompanyMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With U.S. Antibody Company [Member]",
        "label": "Collaboration Agreement With U.S. Antibody Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "CollaborativeArrangementsTwoMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two Member.",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CommercialLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "CommercialLicenseAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Agreement [Member]",
        "label": "Commercial License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)",
        "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r73",
      "r431",
      "r478"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-cac"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r208",
      "r209",
      "r538",
      "r655",
      "r657"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r626",
      "r627",
      "r629",
      "r694",
      "r746",
      "r747"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, par value per share",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r479"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r479",
      "r497",
      "r747",
      "r748"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2024, and December 31, 2023; 89,531,937 and 89,237,465 shares issued and outstanding on June 30, 2024, and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r432",
      "r582"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r103",
      "r108",
      "r421",
      "r442",
      "r443"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r85"
     ]
    },
    "cgen_ContingentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ContingentFees",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent fees",
        "terseLabel": "Contingent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Governmental bonds [Member]",
        "verboseLabel": "U.S. government bonds [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r568",
      "r572",
      "r583",
      "r594",
      "r743"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r332",
      "r558",
      "r659"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties' expenses amounts charged to research and development expenses",
        "terseLabel": "Research and development expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale marketable securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ]
    },
    "cgen_DeferredParticipationOfBmsInRdExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "DeferredParticipationOfBmsInRdExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R&amp;amp;D expenses.",
        "label": "Deferred Participation Of Bms In Rd Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per share",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r131",
      "r133",
      "r135",
      "r136",
      "r137",
      "r142",
      "r291",
      "r294",
      "r308",
      "r309",
      "r422",
      "r444",
      "r556"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r133",
      "r135",
      "r136",
      "r137",
      "r142",
      "r291",
      "r294",
      "r308",
      "r309",
      "r422",
      "r444",
      "r556"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r139"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lps"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSSES PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r138",
      "r140",
      "r141"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period over which compensation expense will be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized estimated compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "cgen_EmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "EmployeeSharePurchasePlanMember",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the Employee Share Purchase Plan member.",
        "label": "Employee Share Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-sesosced",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation ESPP",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "cgen_EmployeesDirectorsAndNonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "EmployeesDirectorsAndNonEmployeesMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Directors And Non Employees [Member]",
        "documentation": "Information about the employees, directors and non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r129",
      "r144",
      "r193",
      "r194",
      "r204",
      "r231",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r346",
      "r440",
      "r450",
      "r451",
      "r452",
      "r465",
      "r519"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity investment",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_EuropeanUnionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EuropeanUnionMember",
     "presentation": [
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "European Union [Member]",
        "verboseLabel": "Europe",
        "documentation": "Economic and political union of member states, located primarily in Europe."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r750",
      "r751",
      "r752"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r322",
      "r572"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r322",
      "r572"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r696",
      "r697",
      "r702"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r324",
      "r359",
      "r360",
      "r361",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r572",
      "r575"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r419",
      "r572",
      "r576"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r233",
      "r238",
      "r312",
      "r313",
      "r322",
      "r360",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r572"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r324",
      "r359",
      "r360",
      "r361",
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r572",
      "r575"
     ]
    },
    "cgen_FinancialIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "FinancialIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/cgen-find": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of financial and other income net of expense.",
        "negatedLabel": "Financial and other income, net",
        "label": "Financial Income Expense Net",
        "totalLabel": "Financial and other income, net",
        "verboseLabel": "Financial income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r228",
      "r229",
      "r306",
      "r329",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r441",
      "r561",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r650",
      "r651",
      "r652",
      "r653",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703"
     ]
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainContingenciesByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingencies, Nature [Axis]",
        "documentation": "Information by nature of gain contingency."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_GainContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainContingencyNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r501"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "cgen_GileadSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GileadSciencesIncMember",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilead Sciences, Inc [Member]",
        "documentation": "This member is stand for Gilead Sciences, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GovernmentAndOtherGrantsAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GovernmentAndOtherGrantsDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government And Other Grants [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GovernmentAndOtherGrantsLineItems",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Line Items]",
        "label": "Government and Other Grants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GovernmentAndOtherGrantsMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Member]",
        "label": "Government and Other Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "GovernmentAndOtherGrantsTable",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Table]",
        "label": "Government and Other Grants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r81",
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r332",
      "r557",
      "r558",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r659"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "terseLabel": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r76",
      "r81",
      "r423",
      "r438",
      "r557",
      "r558",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r316",
      "r318",
      "r323",
      "r447",
      "r449",
      "r504",
      "r550",
      "r574",
      "r717"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r316",
      "r318",
      "r323",
      "r447",
      "r449",
      "r504",
      "r550",
      "r574",
      "r717"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit (expense)",
        "negativeTerseLabel": "Tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Tax benefit (expense)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r128",
      "r129",
      "r143",
      "r149",
      "r152",
      "r283",
      "r284",
      "r287",
      "r445",
      "r571"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in trade receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in other accounts payable and accrued expenses",
        "verboseLabel": "Decrease in other accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 180.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in trade payables",
        "terseLabel": "Decrease in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in interest receivables from short-term bank deposits",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 140.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R&amp;amp;D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Decrease in deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "IncreaseDecreaseInDeferredRevenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 160.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Deferred Revenues",
        "documentation": "Represent the amount of deferred revenues",
        "negatedLabel": "Decrease in deferred revenues"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 170.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in operating lease right of use asset.",
        "negatedLabel": "Decrease in operating lease right of use asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 150.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in operating lease liability",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Amortization of Discount",
        "verboseLabel": "Amortization of discount on marketable securities, net",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "totalLabel": "Interest Income, Deposits with Financial Institutions, Total",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r148",
      "r152",
      "r558",
      "r623"
     ]
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of investment in Compugen",
        "documentation": "Nominal or face amount on the investment owned."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investment in marketable securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697",
      "r701"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r88",
      "r158",
      "r160",
      "r330",
      "r331",
      "r715"
     ]
    },
    "cgen_IssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "IssuanceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of Issuance expenses",
        "label": "Issuance Expenses",
        "verboseLabel": "Issuance expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r74",
      "r435",
      "r582",
      "r625",
      "r654",
      "r704"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r92",
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r297",
      "r298",
      "r299",
      "r332",
      "r582",
      "r659",
      "r706",
      "r707"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r39",
      "r40",
      "r115",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r297",
      "r298",
      "r299",
      "r332",
      "r659",
      "r706",
      "r707"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "LongTermDeferredParticipationinResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;D expenses.",
        "label": "Long Term Deferred Participationin Research And Development Expenses",
        "verboseLabel": "Long-term deferred revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investment in marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in marketable securities:",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized gain on sale of marketable securities, net",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "MasterClinicalAgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum authorized proceeds from issuance of common stock.",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r240",
      "r280",
      "r315",
      "r387",
      "r446",
      "r448",
      "r456",
      "r470",
      "r471",
      "r525",
      "r527",
      "r529",
      "r530",
      "r532",
      "r548",
      "r549",
      "r560",
      "r564",
      "r569",
      "r575",
      "r576",
      "r580",
      "r581",
      "r592",
      "r661",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum royalty repaid as percentage of grant received",
        "terseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_May2012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "May2012AgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the May 2012 Agreement.",
        "label": "May 2012 Agreement [Member]",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Receivable",
        "documentation": "Amount of milestone payment receivables.",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r240",
      "r280",
      "r315",
      "r387",
      "r446",
      "r448",
      "r456",
      "r470",
      "r471",
      "r525",
      "r527",
      "r529",
      "r530",
      "r532",
      "r548",
      "r549",
      "r560",
      "r564",
      "r569",
      "r575",
      "r576",
      "r580",
      "r592",
      "r661",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-gd1",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for basic and diluted loss per share",
        "negatedTerseLabel": "Net loss for basic and diluted loss per share",
        "zeroTerseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r61",
      "r77",
      "r90",
      "r100",
      "r102",
      "r106",
      "r115",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r134",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r291",
      "r294",
      "r309",
      "r332",
      "r439",
      "r499",
      "r517",
      "r518",
      "r603",
      "r659"
     ]
    },
    "cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NonRefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "NonRefundableUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Refundable Upfront Payment",
        "documentation": "Amount of non-refundable upfront payment.",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "verboseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r557",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturity of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right to use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL [Abstract]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r71",
      "r457",
      "r458"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) from marketable securities, net",
        "verboseLabel": "Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r48",
      "r99",
      "r191"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Other comprehensive income (loss) from marketable securities, net",
        "verboseLabel": "Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r191"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL AND OTHER INCOME, NET [Abstract]",
        "verboseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "FINANCIAL AND OTHER INCOME, NET",
        "verboseLabel": "FINANCIAL INCOME, NET",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r693"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Exchange rate differences and other",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r426",
      "r427",
      "r618"
     ]
    },
    "cgen_ParticipationRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ParticipationRights",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.",
        "label": "Participation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Royalties",
        "terseLabel": "Royalties paid to the IIA",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance expenses",
        "verboseLabel": "Issuance expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in short-term bank deposits",
        "label": "Payments to Acquire Short-term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "cgen_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "PercentageOfExpectedFromUpfrontPaymentAmountPaid",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Expected From Upfront Payment Amount Paid",
        "documentation": "Percentage of expected from upfront payment amount paid.",
        "terseLabel": "Percentage of expected from upfront payment amount paid"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties on net sales.",
        "label": "Percentage of royalties on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_Plan2010Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "Plan2010Member",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the plan 2010 member.",
        "label": "Plan 2010 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ]
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts receivable and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ordinary shares in offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturity of short-term bank deposits",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r638"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Equity Method Investments",
        "verboseLabel": "Proceeds from equity investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "totalLabel": "Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total",
        "verboseLabel": "Proceeds from maturity of marketable securities",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r159"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_PropertyLeaseGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyLeaseGuaranteeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office leases [Member]",
        "documentation": "A guarantee of performance by a third party lessee under terms of a lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r345",
      "r424",
      "r437",
      "r582"
     ]
    },
    "cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "PurchaseOfPropertyAndEquipmentAsNonCashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchase property and equipment as non cash transaction.",
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase Of Property And Equipment As Non Cash Transaction",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r232",
      "r240",
      "r269",
      "r270",
      "r271",
      "r280",
      "r315",
      "r362",
      "r371",
      "r387",
      "r446",
      "r448",
      "r456",
      "r470",
      "r471",
      "r525",
      "r527",
      "r529",
      "r530",
      "r532",
      "r548",
      "r549",
      "r560",
      "r564",
      "r569",
      "r575",
      "r576",
      "r580",
      "r581",
      "r592",
      "r597",
      "r656",
      "r661",
      "r699",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r232",
      "r240",
      "r269",
      "r270",
      "r271",
      "r280",
      "r315",
      "r362",
      "r371",
      "r387",
      "r446",
      "r448",
      "r456",
      "r470",
      "r471",
      "r525",
      "r527",
      "r529",
      "r530",
      "r532",
      "r548",
      "r549",
      "r560",
      "r564",
      "r569",
      "r575",
      "r576",
      "r580",
      "r581",
      "r592",
      "r597",
      "r656",
      "r661",
      "r699",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "cgen_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RelatedPartyBalancesAndTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RelatedPartyBalancesAndTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances And Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r239",
      "r350",
      "r351",
      "r430",
      "r436",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r498",
      "r524"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r705"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]",
        "verboseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r239",
      "r350",
      "r351",
      "r430",
      "r436",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r498",
      "r524",
      "r705"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r504",
      "r522",
      "r523"
     ]
    },
    "cgen_RelativeFairValueOfDeferredParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RelativeFairValueOfDeferredParticipation",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative fair value of deferred participation.",
        "label": "Relative Fair Value Of Deferred Participation",
        "verboseLabel": "Relative fair value of deferred participation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "verboseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses, net",
        "label": "Research and development expenses, net",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r550",
      "r558",
      "r714"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r93",
      "r113"
     ]
    },
    "us-gaap_RestrictedInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Investments, Current",
        "verboseLabel": "Restricted short-term bank deposit",
        "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r536",
      "r537"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of workforce reduction from restructuring activities",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs",
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r66",
      "r434",
      "r453",
      "r455",
      "r461",
      "r480",
      "r582"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r129",
      "r193",
      "r194",
      "r204",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r300",
      "r302",
      "r303",
      "r305",
      "r307",
      "r341",
      "r342",
      "r450",
      "r452",
      "r465",
      "r747"
     ]
    },
    "cgen_RetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retainer fee per month.",
        "label": "Retainer Fee",
        "terseLabel": "Retainer fee"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RevenueDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Disclosure [Text Block]",
        "documentation": "The entire disclosure for revenue.",
        "terseLabel": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RevenueLineItems",
     "presentation": [
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r552",
      "r555"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "verboseLabel": "Remaining performance obligations",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://cgen.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "verboseLabel": "Remaining performance obligations percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "cgen_RevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RevenueTable",
     "presentation": [
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/RevenueDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Revenue from sales to customers",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r107",
      "r115",
      "r143",
      "r146",
      "r147",
      "r150",
      "r152",
      "r153",
      "r154",
      "r156",
      "r192",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r332",
      "r423",
      "r558",
      "r659"
     ]
    },
    "cgen_RoyaltyContingentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RoyaltyContingentObligations",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "terseLabel": "Contingent royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty percentage based on future revenues",
        "terseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-sesosced",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SalesAgreementWithLeerinkPartnerLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "SalesAgreementWithLeerinkPartnerLlcMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the Sales Agreement with Leerink Partner LLC member.",
        "label": "Sales Agreement With Leerink Partner Llc [Member]",
        "terseLabel": "Sales Agreement With Leerink Partner LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expenses",
        "terseLabel": "Schedule of stock-based compensation expenses",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lpst"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of basic and diluted losses per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fint"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of financial and other income, net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party balances and transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ScheduleOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ScheduleOfRevenueTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of  revenue.",
        "terseLabel": "Schedule of revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Option Activity",
        "terseLabel": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r68"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted",
        "terseLabel": "Schedule of weighted-average assumptions used to estimate fair value of options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of gross unrealized losses and fair values on investments",
        "verboseLabel": "Schedule of unrealized loss on investments",
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value)."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r467",
      "r468",
      "r469",
      "r526",
      "r528",
      "r531",
      "r533",
      "r535",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r553",
      "r565",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r597",
      "r662",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r745"
     ]
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and business development expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "cgen_SeverancePayFundNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "SeverancePayFundNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Non Current",
        "terseLabel": "Severance pay fund"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "SeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Increase in severance pay, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Expected risk free interest rates range",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rate range, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rates range, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares available for issuance | shares",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding at end of year",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding at beginning of year",
        "periodEndLabel": "Options outstanding at end of year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding at beginning of year",
        "periodEndLabel": "Options outstanding at end of year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual life",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and expected to vest at end of year",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "verboseLabel": "Number of shares purchased for ESPP",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r247",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, minimum",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, maximum",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "terseLabel": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-se1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;D expenses.",
        "label": "Short Term Deferred Participation In Research And Development Expenses",
        "verboseLabel": "Short-term deferred revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sap1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r114"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r45",
      "r46",
      "r89",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r129",
      "r144",
      "r193",
      "r194",
      "r204",
      "r231",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r346",
      "r440",
      "r450",
      "r451",
      "r452",
      "r465",
      "r519"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r467",
      "r468",
      "r469",
      "r526",
      "r528",
      "r531",
      "r533",
      "r535",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r553",
      "r565",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r597",
      "r662",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r745"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r144",
      "r342",
      "r388",
      "r459",
      "r466",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r501",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r598"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r144",
      "r157",
      "r342",
      "r388",
      "r459",
      "r466",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r501",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r598"
     ]
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees And Directors Value",
        "terseLabel": "Stock-based compensation issued to employees, directors and non-employees",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP, shares",
        "terseLabel": "Issuance of ESPP shares, (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r66"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares, net, (in shares)",
        "verboseLabel": "Ordinary shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r66",
      "r460",
      "r519",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Options exercised",
        "negatedLabel": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r66",
      "r253"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP",
        "terseLabel": "Issuance of ESPP shares",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r66"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares, net",
        "verboseLabel": "Value of shares issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r66",
      "r465",
      "r519",
      "r534",
      "r604"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r45",
      "r46",
      "r66"
     ]
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation stock options",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r63",
      "r481",
      "r497",
      "r520",
      "r521",
      "r582",
      "r605",
      "r625",
      "r654",
      "r704",
      "r747"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r355"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-sesosced",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "SupplementalRightOfUseAssetAndOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the Right-of-use asset obtained in exchange for operating lease liability",
        "label": "Supplemental Right Of Use Asset And Operating Lease Liability",
        "verboseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r73"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r73"
     ]
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company [Member]",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_TradeAndOtherPayablesRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "TradeAndOtherPayablesRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payables related parties.",
        "label": "Trade And Other Payables Related Parties",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://cgen.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r228",
      "r229",
      "r306",
      "r329",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r441",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r650",
      "r651",
      "r652",
      "r653",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://cgen.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Consolidated Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsTextBlock",
     "presentation": [
      "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of unaudited interim consolidated financial statements.",
        "label": "Unaudited Interim Consolidated Financial Statements [Text Block]",
        "verboseLabel": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20240630",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r137"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "10",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480679/815-10-10-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "20",
   "Section": "10",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480769/815-20-10-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001178913-24-002418-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-24-002418-xbrl.zip
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MZ)?3=&RK^>/KW8,W1".W@0F/7.(MH 2:(KC6V=E9,WD+0SG^Q!/X.^JY4<)
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M-&LB5;5#WKMNBUVI/AYT:+@N]Z7:JQ_K%;B.\Z:8] F\X>?_ U!+ P04
M"  2. 99N0!F]0T;  !4O $ %0   &-G96XM,C R-# V,S!?9&5F+GAM;.T]
MV7;;.++O\Q6^GF?'D>QT)SE)SY$=V5=G;,LCV>F^3SPT"<F<4*2&BV/-UU^
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MM\Q=.XT)G0VW^.PGO>"D;D--'V*<+!3#YX4]F;Z<HB%1'/4?_P]02P,$%
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M]QZ)7-B+J/#:; M\'F([*C[S]-W2==<-7HO?U/P6OY@WT@-C]M^ R(Z;NXD
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M+G7P;-JVUL\T,$"\O,7;=%\SR0D!B6GK*V!(Z?:UDQ;PF+;2VSS=!<OG;+:
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M-32XQHM2FM^+\35;3%[<($3GM+A%[2V''CT"=N.>Q8BP&_<^1H3=N$\CX_3
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MQM(&%/F K.(D"_Y@#_]H6.]Y'*6!3Y+B5W?@9[F)]SR)_ OR0L)X3>U*SO8
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MXAS-T;0ND4A3,Y2=XWFUX$ ;3[)%N2SLGF_KDA#_ +S.R-"E*<.>@N^I)'<
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M-M22M" ^:G4[COB89;:87;E@H8ZOEL=AEQPWXK'_/G#LKN*D$L+@YX%D$=[
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M.(&+ ,M+1OX=J 47=]G0\8N6SB8@H3T!/'4+X*F/ #!)#G_$*^1AL+#W.']
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M@U5UI9$-,?ZJ<1S7>RW3J9B,O:J ++VBRF+ZZYW38@M::V@#=^ 0O?T39H&
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MS'V.*TLC$T/'<W=,EHX4VRDW!GW2KO@.3P*%'W!:Y7UOI([XBY5A")81S4$
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M_Y%Z=:+X,]]'T-6]K9'6)AZ^^Z&K^Z/7'KY3HZM[6[LR,?]WP&6$.>]_YOM
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MWU/[2< _\B -,G)/DI? (^QZ!2Q\O(QH+\5+B7:23&/?'HM<D;'("ZC74R_
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MO:,/.!HR1*/D.'A,@Q5MV7"J;$<-DOU<8>08C(L&D7YL)AQ"R!&;;GF1/CS
MQU&>;GEI_M/S1+6U/"AW3D@Y6M1'DS2?<I@Y$M5'DR@_WZJUTFG/Z_O9.*MV
MM[ H;YX@P]FQNX5%^<PPN;K:[0$YP/FN^Z@1Y<?[5#T'X:KR2+E1J0AM69OS
M#<Y2/5#C'/N@!TMRTB@JZDN+ZX^2.+MSIZQ$WS:X>K"D(UFO_BJ6NBJ"JA<+
MAR?T<.)E)WFO?BOL*^RZ5<])%N;9YS#?'!R\"/-=>0L#)UONJ\HKZNHP?6%L
M6=>KO(FG7ZB:NMIO<!IF1PUSP,@0(R<-7D?GH87U%Z,+G)(9R@CRE86#(3Y
M1J8_&!X#9+R^<:YLTC>,5I_BE4HC75OH7;#4PX#"_CK_$*1_J[S(<WB!TR/W
MUB4B#DU9/)TCR5Q!LO+/5%_,+G#:Y!Y:9&!M.;E+^!B^PDI*QL3P%%92Q)R2
MZ?VKB:=BN&@2=1)9\>JM2O,@C/7+0WWEP5#^MF^D%SCQ\F1MRHB-L?O1@26-
MW*;'>+1>*)#!YAKJ)HEH4L\*/-0?D%%URGJ,CVY<.(=TIZQ@?S4K&LXI[:Q#
MAO_>ZHJ/L48$65?+T])LAXRJY6D9\55:8T44Y$B,E P_Z*-XM2L@%6H7$(@
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MO.A"$R_-R#']<5DD$"M>'1Y7#KG 27Y[Z_(Z1_;&S:SA/75YG&GK1;8J&4?
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M)VZI9%(XDAL!L?7,V[:=^#SPH\!SU^C40-X9@QWPXVBY.;>CITLO^,%=:OX
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M0GNH,0["(ZLZPVO1,[Q6R-W%)LV:MEZ^A[/[V?\\S!:KV>_P?_?<13ELKQJ
MA1V&<"V?@>@NX?5O"^#-].Z?L]7T['IV/SN'<*S@[<0#BMBG"T#$V#JC9Q=
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M9VW'E0Y";2_3867Q#8 L8EVFI)UNX9,=Y9-'G(\EX_%[JXIPK9I1SKT@PBI
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M?-"LXIX%0II$KN5WT/LNG'\-TT$W&USJ@@]SCQOY)%QN8 #PV?=!IZ.*QD6
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MTF@WXQ@6GX=@:\"3\P,)O-)C@3@TI3XS"$.1 P<ASKF71+P\X9X#^$ L0<
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MUZUJLOA0YFU_@W-#/'^SCHO[FGC>TW2\+]MV(&I$]BQE?4O+!LZZR#-^#2:
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M0MQSYO!4LX@J,Y%=K#HKZU%A8%/CF!LP\$,(1C!W0$A*5D%X %%:,GJ&Y]Z
M4YS>B0X9]1IDF(L)X[ AK$CT]AO5<WFB7!H?[#RMX'-]>VH<C6)^#59[TE+H
M4#E<8W]")NT9NA&Q?[!NO/4M8]6-,_.S0AA7%!U6]'.5#MU]H]Y:);(5#_(*
M C:G/60;Q-K;\X;L:2;2OW=NJURZQ0BX*3OFBZ4O,6-%7[9H!'ZZ/NS5A?3U
M*Y&*3Q!YH4/USN;ELL->N/#;[6;=O(U5ZH1U:Q0EF7LZ7+F0+,G%K;N6,"K#
MF>7&GE0@J-QBL"0WBWWZ*4^:H+N,*.;EKSLT3Q!=QW O\B6*;R)^21Z)S]A
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M[!M5;&@(8^0<D\*VWZZP9182] J</'<$"BMB6N\O&)TCDH%I/P,+00\!JH'
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MLA"FIH\(S8KD+7#\)&/YA&16MV/$AJ?V'BJ4+<[UNWFQP3W)0L-AL/$?@8V
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M65:TU=-<\DVWA0J-B 9=I!5H0/7G!FO/$/FCR3U\J=*. Q[F-+X->\DJ#PM
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M[L59S8:W@0D$AA,\68@+2_VO[$QY45>(,PYOVIK(' V %?%PA?6]AMKC\42
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MGZ"'B!S,YLCV8*A25-B![P TFUO.*R)[G(;I(MUW7 ] VP!8_)K)AXS*'RM
MS!Q!.V=#'![UFSS)&&.6%BMBQQQ!'.I!H=JEEB;)77G5@=,DK=M2DHUW_1G9
MH6WSA:P %ZD%X Y9^%_[^=X9S<GO7FC]W#M7,>+W;>,R7@^H(<3>YA67SIV
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MOD6B/9KT?T#3(@TMKAV7?#A&.OED?_LEBM:0^.MUSXOYPI*N,4G4$0) NSH
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MB0& ?^G;QJV+/!*O);^.)M>Q13!.#(++I(SP'D_K%\O1OQ=QPA&V@^=$%MP
M[8ZIZ\1F%82HK0AT9%F1Q?K;"7XW^9V8I/'OA9*M0<A_$$8JE^4OO:JEJ"3J
MM:RC&6_H#4'6\%U:^[2#7[QB=>/%8X=PZ][ $\AGS56%6>^.+(V38E'.*'.$
MX2UK^-*[4[*V%]9DO[7T1KQ.7]WU;SX_N1\3?:\F/VB;A_5>-*^=6KX!R0OJ
M@](Y[6CO5/Q*A!EF/$,V-;P2LQJ[VL$SLL&-;YR"#\2A_J^_=!5%^G01.N'T
M-_G3K\#$;CC0L7[0P6*W^AD1_]O%:V& &4"+\AW,C+#:PT _D.70;$\0N?,
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M;6/!Z GKY89]C\Z4N4PKJ^17'5\H;^!\&U+K\+'D\# 3>P\)2^J[7;A?$XG
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M\N&NU5#R%716>'FPK-<KYA0(8Z'ZQL*$=V.A@&<.VQ\/8\>$V@>Y2[&KD6J
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M)*>F0FXDG<+OOGC&^( \"G'#'JG&\\J/RR3I 8=6S9K4W+/BNQGU]79S7BI
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M7SI3TR++U9X-0EC?Z,#'F;H9,D51^ FPWH?8+K1GS&.1^<UC:=9[(H]%0+2
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M!V8:76<K^'#GXO)G&&<@/\BO=) @D]EK8A)32[(7,VJ>%@HU^M*DD](M_:2
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MK]E4O063/IWNF[>=[$/RRM;_ 5!+ P04    "  2. 994U?50H@,  "C3@
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MV#U#@^')L#LXJJE[:Q\Q#ZN@Y%4GIR$9R-:7:BN(6[7U,"-$'1!37V\C2J/
M<S:)_'> JB^!&G1/K_N]8:\[0"<79ZC[Z?3=R<7;+H*X^K$W&/0N+PK0^UO0
M/)Q 7T%I33'^P-R%O9X(0(_/JJ=5R!,:]=:*<"-6Z_SZPFCJAP\J];=7B'/8
M@J"5^*2"BTSA/B\#B0E[+\MJ5#8$KTR&MBUF=9K:^_78\W44US4E68@'@/Z.
MRG(_]>STNU>7_2&Z/$?GE_UN[^T%NNKW_@V."(%!77?[Z.JZ/[@^N1BBX27J
M7W_H(L/"L!=$EWUD-!RXVH7)/28"UQ=G(.;P71=EW$OJ6DY.%3A&RZK?7= =
MZ<<.P0";0\(E: K#7!2,T4DX";DH8X8-TVR9D'07)K@RE2^;WG:B'5&!2>[8
MN3\0EJ?!=$JYK-VA<^H1!&*,""OET9IFO=G,01GMQR2=B$P9#&'O!4EU2U]/
M^I^*)M\OR#0?(>MH+J-PJ06#W8RU8<'Z9$*Y+*B)"V@ILVC9&D'UF5O JZ$L
M)7JJIB*="4O1^/7% 43M0ZX 0]07 >KZ$X]R]_434\['"4)E=&P?-*796->Q
M$\=AA//XXP-(893RL$WT#K/@RY1.T4 P0L1C:-N3 ]5L6:UB4$_A\I(-@UN_
M#*3O8'_LKZ(8ZV(97NI6:]\LY.4JX )[_Z6ST\ IY4H:!P>- [E?R#.T5RH$
M[3?V]8-F,3!1F;],02AZE'!<B9]A)(\/)&'B5SH]SC#QGKNGBV&17NZ*4=^F
M,^RA[IS8H: W!%V.Q]0F_+&<VR-*WO,=:F-!Y*-'VR7V%S3%[ NZ=0GDD5$R
MN73[: P)#(#$T"WU//4-8=\/ 2M&9@$3'(6^ \/LX ;^ YAJ$VCJVKD<I+[4
MX4O[R02)W>;BL>B_OFCMUYN'$#2-5B/Y2,&(FNMKV_\=86)[D,>#ZQ9NKIRF
MKY73(@0R5/)T9GA"M!$C^(N&QP!M&WNW>,%71FRH=&JWU!%N6U4J5WE1=4W9
M$O4Q=/V?26G37%8V=?6WH;(9-61+DHJ#-3B>3PR$3<@LG! ??1!.]9MYGT(E
M6(,F@][_8.-)QXL=@G/I)_O;YIYZ!K>'<GBA5])]R5S5!)&WE_/D0.PO8E#5
M&./P-8(-8$@<A-%,A0=&0&,YB;T=]2?*0<9CTZ18LH(@5 :^@_X,,0,E@A$\
M], _WH&E*S5E/YIRA;$]8,D.9@OI8V]=:KO *1J'S(<47/++(7BY=$0%:K6J
M!H+\7+A4$I-\([FEE>ZGJ;VOHC^H<)489&Z369+KRQOF$0]G"7_@T 5$"B]>
M7;70X#GRUI'9YO$I]CQ9?_<=X#V<0=YB/0@]%M.#R..@^H.0%&Y,<H89GC \
M<WF"06X1]M0MZJ>G*U3ZA(&\ W?7^\M%@2A*(+9"3A$P !]"K2-C;?J02G6@
M?DGCOJ=YEWD"HQK;%')4:C^FBQM$AO)[;"C*>,ZICR$)@[RB']G-3M%Y*&^X
M[OP>,]\8@O:%/@X=*I0Z IBP-01LU7-"I7?C%%;8B@@B:WNIHL=.3%D5A=L\
M'''J4,P6TIM IW^%/D&6'GE:U>V,V$35Q"Q#W;74W7%<@^1T'M4A.2*0%#H;
M"$1C&"GT7.86SQ5Q^C6S0A^Q#YF*%#7USV>4VV%4V9,T3GSL+3A50L;J)B\O
M9\EQ$M5KJ9*GH*XTZR=3Z-2XNV"P173K;XM>,EW842KP UC;ED"P>=G*A -5
M3-N4522U2#7=(+'?E/ZY9NW%A>J@BBS+TLQ]O770>)9J\+22\-@J2P:AKT?:
M1^6Z)-,"CT!U;.)Y,^RH$\H5O:*^PP [^5[J:$S^S$9>I.S&+K/(\LA)?G>W
MHF*KFTK!5O>9\J:3,!C-LF_"A*M)83!;VZ)^78=W5^/<M@6($'(@/XJLOJV*
M*Y*[2B=ZC%1TVJ0@.XKL3C@EL%.G?39A]_2@."/<9C3=N6S7^_AC'0.XQPIU
M#AJE??RX%K.[5<<H.M='HF7[W&II1M45TTI'[ER/:KC\$MY%C0M<P#<1-+]G
MC%+U?&&CN@6'TE;^4\.?C(:;J8:;W[>&QX)>WV-?NM-=YT^#^KX,RDH-ROJ^
M#2H6] E7-7Z:UO,U+4,WO@_3D>69<>!YP:U\2+.,+]F2S9@%T_P#HTRM9;5V
MLQ>?@XAB&.JI'S0B^8M&](J23\G/T-";D$,#3TC(V3]@?Q*"M;YN0]?7FR/@
M"'OR1ZN(NX3<)?8= LDBFOD:KPV",N)*/F\(\@)@\8XQ4\U5<C(79(8U J2X
MBV%:V,(1QF-\D?PAGEC<9_Z;<M-C[J(Q+/X]9)17KV :/Q @@ C*9RRE'^$\
MF-/[>1;@1SH+,  ^L AAL_C]'4.Z"AD/Y0FCN/C-I(M@^2=4 V*'#%(4(I^3
M1!X&G=A"-LOS_7NKAY5<\*).Z"W '80<;%95Y:,G]W*:D70*$UFQ!S<OGWB-
MB(N]L:S&"_4H37JLJ(,\"D5"69A7]"#,N0$#P7=[)"-*:2)#2;.9[R>[:< D
M*[E"Y&WN49\M?.P=F7A1\@(RR04[KE@I> _#T:,>$<J?.'_H$+1E.5/XZD7P
M3:GC>.0Q%O1.C.],#W>VR/*WU^V5HN .JO[6,X#BS:*-=B%ZHT#VE1]EF_E?
M7C\E9&J\AKH0^M ;V,^<0>*[ Y@,\[XJ4N8P[C,U^WN&GUV9WH.P4V0.3TGA
ML\I^%UW_9@R_)3YAJM@6^ES^:N+'L\\'W](6O74BO5Q>+-O*O'YC]1T;F==O
MK+Z9X[%>OU&PT2YZ+4<L>?SFD_A_]&(B]::CSO\!4$L! A0#%     @ $C@&
M6<-2"9*D$   3J,  !$              ( !     &-G96XM,C R-# V,S N
M>'-D4$L! A0#%     @ $C@&62%GO:_E"@  .Y(  !4              ( !
MTQ   &-G96XM,C R-# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( !(X!EFY &;U
M#1L  %2\ 0 5              "  >L;  !C9V5N+3(P,C0P-C,P7V1E9BYX
M;6Q02P$"% ,4    "  2. 992_U"S7^'  !%]P8 %0              @ $K
M-P  8V=E;BTR,#(T,#8S,%]L86(N>&UL4$L! A0#%     @ $C@&6;.P\,@3
M-   65X# !4              ( !W;X  &-G96XM,C R-# V,S!?<')E+GAM
M;%!+ 0(4 Q0    ( !(X!EG4(?H\E2,  ,D[ @ 0              "  2/S
M  !E>&AI8FET7SDY+3$N:'1M4$L! A0#%     @ $C@&63?J7\0)NP  ]ZP-
M !               ( !YA8! &5X:&EB:71?.3DM,BYH=&U02P$"% ,4
M"  2. 99'_YIPY$(  "[)0  $               @ $=T@$ 97AH:6)I=%\Y
M.2TS+FAT;5!+ 0(4 Q0    ( !(X!EE35]5"B P  *-.   -
K  "  =S: 0!Z:S(T,S$W-#(N:'1M4$L%!@     )  D 0 (  (_G 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>zk2431742_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20240630"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20240630.xsd" xlink:type="simple"/>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20181010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20211110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-10</instant>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20180301to20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-30</endDate>
        </period>
    </context>
    <context id="C_20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="C_20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20240731_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:Plan2010Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_20240731_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cgen:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-14</endDate>
        </period>
    </context>
    <context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-05</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="NIS_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20240630" id="FFact_306">0001119774</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_20240101to20240630" id="FFact_307">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_20240101to20240630" id="FFact_309">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20240101to20240630"
      id="Fdei_DocumentFiscalPeriodFocus20220803133013452">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodEndDate
      contextRef="C_20240101to20240630"
      id="Fdei_DocumentPeriodEndDate20220803135349061">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132217335">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803135229207">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132624667">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132653437">COMPUGEN LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132710165">26 Harokmim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132729395">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132743972">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220803132757086">IL</dei:EntityAddressCountry>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      id="Fxbrl_20240730203500532"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      id="Fxbrl_20240730211801692_xbrl_20230728101905592"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses
      contextRef="C_20231231"
      id="Fxbrl_20240730224938615_xbrl_20240730224858104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_1"
      unitRef="usd">11877000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_2"
      unitRef="usd">13890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_3"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_4"
      unitRef="usd">365000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_5"
      unitRef="usd">47439000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_6"
      unitRef="usd">25053000</us-gaap:OtherShortTermInvestments>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730191448508_Fact_5"
      unitRef="usd">333000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730191448508_Fact_6"
      unitRef="usd">0</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_5"
      unitRef="usd">32688000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_6"
      unitRef="usd">11742000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730181947327_xbrl_20230728025352671_Fact_5"
      unitRef="usd">5000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730181947327_xbrl_20230728025352671_Fact_6"
      unitRef="usd">61000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_9"
      unitRef="usd">4796000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_10"
      unitRef="usd">2529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_11"
      unitRef="usd">102133000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_12"
      unitRef="usd">114579000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_13"
      unitRef="usd">922000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_14"
      unitRef="usd">1233000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_15"
      unitRef="usd">3023000</cgen:SeverancePayFundNonCurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_16"
      unitRef="usd">2977000</cgen:SeverancePayFundNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_17"
      unitRef="usd">3061000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_18"
      unitRef="usd">1329000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_19"
      unitRef="usd">1028000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_20"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_21"
      unitRef="usd">8034000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_22"
      unitRef="usd">6755000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_23"
      unitRef="usd">110167000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_24"
      unitRef="usd">121334000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713620_0"
      unitRef="usd">2378000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713621_1"
      unitRef="usd">3502000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713621_2"
      unitRef="usd">11252000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713622_3"
      unitRef="usd">11149000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713622_4"
      unitRef="usd">449000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713622_5"
      unitRef="usd">632000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730191521156_20220719213713622_4"
      unitRef="usd">8218000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730191521156_20220719213713622_5"
      unitRef="usd">7858000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713623_6"
      unitRef="usd">2472000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713623_7"
      unitRef="usd">3125000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713623_8"
      unitRef="usd">24769000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713623_9"
      unitRef="usd">26266000</us-gaap:LiabilitiesCurrent>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730191548740_20220719213713624_12"
      unitRef="usd">21028000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730191548740_20220719213713625_13"
      unitRef="usd">25392000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713624_12"
      unitRef="usd">2580000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713625_13"
      unitRef="usd">719000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713625_14"
      unitRef="usd">3450000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713625_15"
      unitRef="usd">3398000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713627_16"
      unitRef="usd">27058000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713627_17"
      unitRef="usd">29509000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20240630"
      id="Fxbrl_20240731133215233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      id="Fxbrl_20240731133231257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220719214834949"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20240630"
      decimals="INF"
      id="F20220719213713628_18"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220719214917721"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20240630"
      decimals="INF"
      id="F20220719213713628_20"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240630"
      decimals="INF"
      id="Fxbrl_20220719215055193"
      unitRef="Shares">89531937</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20240630"
      decimals="INF"
      id="F20220719213713629_22"
      unitRef="Shares">89531937</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220719215111705"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="F20220719213713629_24"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713630_26"
      unitRef="usd">248000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713630_27"
      unitRef="usd">247000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713630_28"
      unitRef="usd">542032000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713631_29"
      unitRef="usd">539837000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730190751125_20220719213713630_28"
      unitRef="usd">-23000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730190751125_20220719213713631_29"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713631_30"
      unitRef="usd">-483917000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713632_31"
      unitRef="usd">-474527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713632_32"
      unitRef="usd">58340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713632_33"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="F20220719213713633_34"
      unitRef="usd">110167000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="F20220719213713633_35"
      unitRef="usd">121334000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730192631151_Fact_61"
      unitRef="usd">9261000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730192631151_Fact_62"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730192632885_Fact_61"
      unitRef="usd">3654000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730192632885_Fact_62"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730192634852_Fact_61"
      unitRef="usd">5607000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730192634852_Fact_62"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_61"
      unitRef="usd">12593000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_62"
      unitRef="usd">15206000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_63"
      unitRef="usd">248000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_64"
      unitRef="usd">165000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_65"
      unitRef="usd">4670000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_66"
      unitRef="usd">4977000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_67"
      unitRef="usd">17511000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_68"
      unitRef="usd">20348000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730192637254_Fact_61"
      unitRef="usd">-11904000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730192637254_Fact_62"
      unitRef="usd">-20348000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_69"
      unitRef="usd">2528000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_70"
      unitRef="usd">1697000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730192002297"
      unitRef="usd">-9376000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_72"
      unitRef="usd">-18651000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_71"
      unitRef="usd">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_72"
      unitRef="usd">-36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_75"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_76"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728034213148"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_75"
      unitRef="usd">-9415000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_76"
      unitRef="usd">-18615000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220719220126329"
      unitRef="USD_per_share">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_77"
      unitRef="USD_per_share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220719220147427"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_78"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220720012025614"
      unitRef="Shares">89518778</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_81"
      unitRef="Shares">89518778</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220720012118943"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_82"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223132738_Fact_109"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_110"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_111"
      unitRef="usd">533213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203355538"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_112"
      unitRef="usd">-455773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_113"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_96"
      unitRef="Shares">1609123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223710614"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_98"
      unitRef="usd">1150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730204103741_xbrl_20230728041429297_xbrl_20220727223504334_Fact_99"
      unitRef="usd">1154000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_126"
      unitRef="usd">1782000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_127"
      unitRef="usd">1782000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730203933885_xbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730204146662"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_128"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_129"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823781_Fact_130"
      unitRef="Shares">88233766</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_131"
      unitRef="usd">244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_132"
      unitRef="usd">536145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_133"
      unitRef="usd">-474388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_134"
      unitRef="usd">62001000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_109"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_110"
      unitRef="usd">247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_111"
      unitRef="usd">539837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203526337"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_112"
      unitRef="usd">-474527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_113"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823749_Fact_114"
      unitRef="Shares">1744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_116"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203617529"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_117"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_96"
      unitRef="Shares">292728</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223710614"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_98"
      unitRef="usd">561000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203638338"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_99"
      unitRef="usd">562000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">1633000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203654521"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">1633000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20240730203654521"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730203841073_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730203708038"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_128"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_129"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_130"
      unitRef="Shares">89531937</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_131"
      unitRef="usd">248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_132"
      unitRef="usd">542032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240730204035595"
      unitRef="usd">-23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_133"
      unitRef="usd">-483917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_134"
      unitRef="usd">58340000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728044607285"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728044615653"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_137"
      unitRef="usd">1633000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_138"
      unitRef="usd">1782000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_139"
      unitRef="usd">238000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_140"
      unitRef="usd">237000</us-gaap:Depreciation>
    <cgen:AmortizationOfDiscountOnMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_139"
      unitRef="usd">796000</cgen:AmortizationOfDiscountOnMarketableSecurities>
    <cgen:AmortizationOfDiscountOnMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_140"
      unitRef="usd">13000</cgen:AmortizationOfDiscountOnMarketableSecurities>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052418474_Fact_139"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052418474_Fact_140"
      unitRef="usd">2000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <cgen:SeverancePayNet
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111210380"
      unitRef="usd">6000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010915535_xbrl_20240731010405127_xbrl_20240301111218731"
      unitRef="usd">3000</cgen:SeverancePayNet>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010405127_xbrl_20240301111210380"
      unitRef="usd">-12000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010405127_xbrl_20240301111218731"
      unitRef="usd">-44000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_145"
      unitRef="usd">-332000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_146"
      unitRef="usd">-290000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010448920_xbrl_20230214015508662"
      unitRef="usd">299000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010448920_Fact_0000000000236"
      unitRef="usd">140000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010456201_Fact_0000000000238"
      unitRef="usd">-56000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010456201_Fact_0000000000239"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010511242_Fact_0000000000241"
      unitRef="usd">2267000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010511242_Fact_0000000000242"
      unitRef="usd">448000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728053037345"
      unitRef="usd">-311000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_154"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220719232044563"
      unitRef="usd">-1137000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728053025234"
      unitRef="usd">-85000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010554260_xbrl_20230214015610319"
      unitRef="usd">-293000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010554260_Fact_0000000000251"
      unitRef="usd">-894000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_159"
      unitRef="usd">-386000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_160"
      unitRef="usd">-394000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010540990_xbrl_20240228013913681_xbrl_20230214015610319"
      unitRef="usd">4261000</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010540990_xbrl_20240228013913681_Fact_0000000000251"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_161"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_162"
      unitRef="usd">-325000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_163"
      unitRef="usd">39703000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_164"
      unitRef="usd">-18573000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_165"
      unitRef="usd">25011000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_166"
      unitRef="usd">51350000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_167"
      unitRef="usd">47086000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_168"
      unitRef="usd">23220000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_139"
      unitRef="usd">15825000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_140"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_139"
      unitRef="usd">36000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_140"
      unitRef="usd">5536000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_169"
      unitRef="usd">37000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_170"
      unitRef="usd">63000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_173"
      unitRef="usd">-42287000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_174"
      unitRef="usd">23531000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_175"
      unitRef="usd">562000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_176"
      unitRef="usd">1351000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_179"
      unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_180"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_181"
      unitRef="usd">563000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_182"
      unitRef="usd">1351000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731010623321_xbrl_20240301111408147"
      unitRef="usd">-12000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731010623321_xbrl_20240301111411299"
      unitRef="usd">-44000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220719232250681"
      unitRef="usd">-2033000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728053102843"
      unitRef="usd">6265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_185"
      unitRef="usd">13910000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_186"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_187"
      unitRef="usd">11877000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_188"
      unitRef="usd">17686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728044639062"
      unitRef="usd">-13000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728044646863"
      unitRef="usd">8000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_139"
      unitRef="usd">2064000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_140"
      unitRef="usd">70000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:IssuanceExpenses
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230728052434971_Fact_139"
      unitRef="usd">0</cgen:IssuanceExpenses>
    <cgen:IssuanceExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052434971_Fact_140"
      unitRef="usd">197000</cgen:IssuanceExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730183507230">
        &lt;div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 1:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;GENERAL&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. &lt;span style="color:rgb(0, 0, 0)"&gt;The Company&lt;/span&gt;&#x2019;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from the Company&#x2019;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trials. The Company&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#x2019;s most advanced &lt;span style="color:rgb(0, 0, 0)"&gt;early-stage &lt;/span&gt;program, COM503, was licensed to Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) in December 2023, see also Note 12. COM503 is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#x2019;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $9,390 during the six months ended June 30, 2024, has an accumulated deficit of $483,917 as of June 30, 2024, and has an accumulated negative cash flow from operating activities in the amount of $39,703 for the six months ended June 30, 2024. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25"&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and additional aggregate milestone payments of approximately $23,000. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902. Rilvegostomig entered the clinic in September 2021, initiated a Phase 3 with first patient dosing in the first indication Phase 3 study in December 2023, and first patient dosing in the second indication Phase 3 study in May 2024. Compugen received a $10,000 upfront payment and received or accrued $30,500 milestone payments out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol Myers Squibb Company (&#x201c;Bristol Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#xae; &#xb1; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.&lt;br/&gt;&#160;&lt;br/&gt;In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 investment in Compugen, see Note 7a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 7a.&lt;br/&gt;&#160;&lt;br/&gt;On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On December 18, 2023, the Company entered into an exclusive license agreement (the &#x201c;License Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;), pursuant to which the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#x2019;s COM503 product candidate (&#x201c;COM503 License&#x201d;), and additional products that may be so developed by Gilead (together with COM503, the &#x201c;Licensed Products&#x201d;).&lt;br/&gt;&#160;&lt;br/&gt;Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60 million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#x201c;IND&#x201d;). The Company is eligible to receive from Gilead $30 million in the form of a milestone payment upon clearance of the IND for COM503, see also Note 12. The Company is also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti- PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.&lt;br/&gt;&#160;&lt;br/&gt;During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.&lt;br/&gt;&#160;&lt;br/&gt;Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gilead withheld at source 15% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
        &lt;/div&gt;
      </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230802202124242"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230802202128417"
      unitRef="usd">-483917000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230802202134755"
      unitRef="usd">39703000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_193"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="Fxbrl_20230728104443796"
      unitRef="usd">23000000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201751108"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201758034"
      unitRef="usd">30500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20180330"
      decimals="-3"
      id="Fxbrl_20230802201804474"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20181010"
      decimals="-3"
      id="FFact_199"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211110"
      decimals="-3"
      id="Fxbrl_20220728112859416"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <cgen:NonRefundableUpfrontPayment
      contextRef="C_20240101to20240131"
      decimals="-6"
      id="Fxbrl_20240730185336641"
      unitRef="usd">60000000</cgen:NonRefundableUpfrontPayment>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20240101to20240131"
      decimals="-6"
      id="Fxbrl_20240730185916012"
      unitRef="usd">30000000</cgen:MilestonePaymentReceivable>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram
      contextRef="C_20231218"
      decimals="-6"
      id="Fxbrl_20240730190011813"
      unitRef="usd">758000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram>
    <cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid
      contextRef="C_20240101to20240131"
      decimals="2"
      id="Fxbrl_20240730190156394"
      unitRef="Pure">0.15</cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730190419712">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 2:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;
            &lt;div style="line-height:1.25"&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="font-family:Times New Roman, Times, serif;width:16pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:40pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto"&gt;
                    &lt;div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, are applied consistently in these interim consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

                        &lt;div&gt;
                          &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"&gt;&#160;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;

                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730190507632">
                        &lt;div&gt;
                          &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"&gt;&#160;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730190633689">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating results for the six-month period ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ended December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      </cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730225731047">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 4:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;MARKETABLE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following is a summary of available-for-sale marketable securities as of June 30, 2024 and December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of &lt;/span&gt;&lt;/span&gt;December&#160;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730211801692_xbrl_20230728101905592"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:58.5pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="text-align:justify;margin-left:58.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2024 and &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;December 31, &lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023, and the length of time that those investments have been in a continuous loss position:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less than 12 months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;12 months or greater&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Gross&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of &lt;/span&gt;&lt;/span&gt;December&#160;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730224938615_xbrl_20240730224858104"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:58.5pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024, the Company had no significant unrealized losses related to marketable securities (which were accumulated in a period of less than 12 months) and determined the unrealized losses are not due to credit related losses, therefore, the Company did not record an allowance for credit losses for its available-for-sale marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024, all of the Company&#x2019;s available-for-sale marketable securities were due within one year.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company had no sales of marketable securities during the six-month periods ended June 30, 2024 and 2023, and accordingly no realized gains or losses were recorded.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730225623383">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized gains&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of &lt;/span&gt;&lt;/span&gt;December&#160;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730211801692_xbrl_20230728101905592"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:58.5pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101843888"
      unitRef="usd">32711000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101901825"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101905592"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20240630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101909777"
      unitRef="usd">32688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101843888"
      unitRef="usd">11740000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101901825"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240730211801692_xbrl_20230728101909777"
      unitRef="usd">11742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730225639031">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less than 12 months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;12 months or greater&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Gross&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;unrealized loss&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of &lt;/span&gt;&lt;/span&gt;December&#160;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20240730224938615_xbrl_20240730224858104"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:58.5pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Represents an amount lower than $1.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730224851563"
      unitRef="usd">32688000</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730224858104"
      unitRef="usd">23000</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsGrossUnrealizedLosses>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730224900895"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240730224903439"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_xbrl_20240730224851563"
      unitRef="usd">992000</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_xbrl_20240730224900895"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsFairValue>
    <cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240730224938615_xbrl_20240730224903439"
      unitRef="usd">0</cgen:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionGreaterThan12MonthsGrossUnrealizedLosses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240731003515663">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 5:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="margin-left:63pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value measurements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;as of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="3" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&#160;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unaudited&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unaudited&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Short-term investments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. government bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;
              &lt;div&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240731003432350">
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="margin-left:63pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:89%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value measurements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;as of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="margin-left:4.5pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="3" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&#160;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unaudited&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unaudited&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Short-term investments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S. government bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;
              &lt;div&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240731003317319"
      unitRef="usd">32688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20230630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20240731003321695"
      unitRef="usd">11742000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240731004811654">
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 6:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $286 in favor of its offices and car leases in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the six-month periods ended June 30, 2024 and 2023, the Company recorded royalties to the IIA as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ 278 and $ 0, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $8,870.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#x201c;Contingent Fees&#x201d;). For the six-month periods ended June 30, 2024 and 2023, the Company did not incur Contingent Fees.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to 4% of the cash considerations that may be received under such transactions.In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the six months ended June 30, 2024 and 2023, the Company has not paid nor accrued any expenses related to the May 2012 Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#x201c;CLA&#x201d;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2024 and 2023, the Company did not incur milestone payments. We also entered into a CLA in February 2024 with the European cell line development company for COM503. Under the agreement the Company is required to pay an annual maintenance fee and certain amounts upon the occurrence of specified milestones events.&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2024 and 2023 the Company did not incur milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230802221055283"
      unitRef="usd">286000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062450451"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062556413"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062648820"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_20240101to20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20240731004745902"
      unitRef="usd">278000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20240731004750701"
      unitRef="usd">0</us-gaap:PaymentsForRoyalties>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20240630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20220720062746091"
      unitRef="usd">8870000</cgen:RoyaltyContingentObligations>
    <cgen:AgreementStartDate
      contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20230802220955963">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      decimals="2"
      id="Fxbrl_20240731004146118"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20240101to20240630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20240731004001019">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:PercentageOfRoyaltiesOnNetSales
      contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"
      decimals="2"
      id="Fxbrl_20240805154741994"
      unitRef="Pure">0.01</cgen:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20240101to20240630" id="FFact_289">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;NOTE 7:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Issuance of Shares:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 Ordinary Shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#x201c;Warrants&#x201d;). The Warrants were exercisable at a price of $4.74 per Ordinary Share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of 3,955,696 Ordinary Shares were exercised with proceeds of approximately $18,750, and the remaining warrants to purchase up to 297,469 Ordinary Shares expired in June 2023.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 equity investment in the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of the Company&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d; and $7,788 (net of $91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;) and $14,958 (net of $42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#x2019;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#x201c;at the market offering&#x201d; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#x2019;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of June 30, 2024, 2,905,550 shares were issued and sold through the ATM, with proceeds of approximately $3,643 (net of $530 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share option plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions related to the grant of options to employees, directors and non-employees under the Company&#x2019;s 2010 Share Option Plan, as amended, during the six-month period ended June 30, 2024, were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;40,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(282,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(140,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,990,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,245,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month period ended June 30, 2024, the Company&#x2019;s Board of Directors granted 40,500 options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $1.80 to $2.09 per share, with vesting to occur in up to four years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92.7%-95.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;75.9%-76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.9%-4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.3%-4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.0-5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;Weighted average fair value of options granted during the six-month periods ended June 30, 2024 and 2023 were $&lt;/span&gt;&lt;span&gt;1.41&lt;span style="color:rgb(0, 0, 0)"&gt; and $0.53, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;During the six-month periods ended June 30, 2024 and 2023, the Company recorded share based compensation related to stock options in a total amount of $&lt;/span&gt;&lt;span&gt;1,633&lt;span style="color:rgb(0, 0, 0)"&gt; and $1,782, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;As of June 30, 2024, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $&lt;/span&gt;&lt;span&gt;3,405&lt;span style="color:rgb(0, 0, 0)"&gt; which is expected to be recognized over a weighted average period of approximately&lt;/span&gt;&lt;span style="font-weight:bold;color:rgb(0, 0, 0)"&gt;&#160;&lt;/span&gt;1.85&lt;span style="color:rgb(0, 0, 0)"&gt; years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months ended June 30, 2024 and 2023, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,002,799&lt;span style="color:rgb(0, 0, 0)"&gt;&#160;&lt;/span&gt;and 7,460,568, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,002&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,782&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_223"
      unitRef="Shares">5316457</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_224"
      unitRef="USD_per_share">3.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_225"
      unitRef="Shares">4253165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_226"
      unitRef="USD_per_share">4.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      id="FFact_227">P5Y</cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_228"
      unitRef="usd">19767000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_229"
      unitRef="usd">1233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230728024501070"
      unitRef="Shares">3955696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230728024514846"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230728024526061"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_235"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_236"
      unitRef="Shares">2424243</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_237"
      unitRef="USD_per_share">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_238"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_239"
      unitRef="usd">4121000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_240"
      unitRef="usd">7788000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_241"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="Fxbrl_20220720034631668"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="Fxbrl_20220720034743180"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="5"
      id="Fxbrl_20220720034904580"
      unitRef="USD_per_share">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="Fxbrl_20220720034949299"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035100582"
      unitRef="usd">5000000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035407188"
      unitRef="usd">14958000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035509163"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_242"
      unitRef="Shares">8333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_243"
      unitRef="USD_per_share">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_244"
      unitRef="USD_per_share">8.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_245"
      unitRef="Shares">483005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_246"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_247"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_248"
      unitRef="usd">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031246595"
      unitRef="usd">50000000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="INF"
      id="Fxbrl_20230728031257218"
      unitRef="Shares">2905550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031311578"
      unitRef="usd">3643000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20240630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031320267"
      unitRef="usd">530000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730214959874">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;40,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(282,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(140,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,990,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,245,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214617051"
      unitRef="Shares">8373745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="2"
      id="Fxbrl_20240730214440322_Fact_0000000000541"
      unitRef="USD_per_share">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240731023155518">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240731020116330"
      unitRef="usd">1912000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440323_Fact_0000000000545"
      unitRef="Shares">40500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440323_Fact_0000000000546"
      unitRef="USD_per_share">2.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000549"
      unitRef="Shares">1744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214715608_xbrl_20240730214440324_Fact_0000000000550"
      unitRef="USD_per_share">0.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000549"
      unitRef="Shares">282455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000550"
      unitRef="USD_per_share">4.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000551"
      unitRef="Shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000552"
      unitRef="USD_per_share">8.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000553"
      unitRef="Shares">7990046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440324_Fact_0000000000554"
      unitRef="USD_per_share">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240730214440324_Fact_0000000000555">P6Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240730214440324_Fact_0000000000556"
      unitRef="usd">1205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440325_Fact_0000000000557"
      unitRef="Shares">5245345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="Fxbrl_20240730214440325_Fact_0000000000558"
      unitRef="USD_per_share">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="Fxbrl_20240730214440325_Fact_0000000000559">P4Y11M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="Fxbrl_20240730214440325_Fact_0000000000560"
      unitRef="usd">124000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220720040533152"
      unitRef="Shares">40500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220720040558485"
      unitRef="USD_per_share">1.8</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_251"
      unitRef="USD_per_share">2.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_20240101to20240630" id="FFact_252">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730213706599">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92.7%-95.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;75.9%-76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.9%-4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.3%-4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.0-5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20220727222002683"
      unitRef="Pure">0.927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20220727222015231"
      unitRef="Pure">0.959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20220727222026940"
      unitRef="Pure">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20220727222103489"
      unitRef="Pure">0.764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20240101to20240630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20220727222244528"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20240101to20240630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20220727233307366"
      unitRef="Pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      decimals="3"
      id="Fxbrl_20220727233317706"
      unitRef="Pure">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="Fxbrl_20220727235651276"
      unitRef="Pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20240101to20240630"
      decimals="2"
      id="Fxbrl_20220727235701651"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20230630"
      decimals="2"
      id="Fxbrl_20220727235716123"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220727235725275">P4Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20230728030223347">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20230728030231097">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_267"
      unitRef="USD_per_share">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_268"
      unitRef="USD_per_share">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_269"
      unitRef="usd">1633000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_270"
      unitRef="usd">1782000</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_271"
      unitRef="usd">3405000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20240101to20240630" id="FFact_272">P1Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220720041818515"
      unitRef="Shares">8002799</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_274"
      unitRef="Shares">7460568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730215035617">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,002&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,782&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455558_Fact_0000000000578"
      unitRef="usd">805000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455558_Fact_0000000000579"
      unitRef="usd">1002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455562_Fact_0000000000581"
      unitRef="usd">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455562_Fact_0000000000582"
      unitRef="usd">-41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455565_Fact_0000000000584"
      unitRef="usd">785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214455565_Fact_0000000000585"
      unitRef="usd">821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20240630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214502424_Fact_0000000000587"
      unitRef="usd">1633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20240730214502424_Fact_0000000000588"
      unitRef="usd">1782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730195846781">
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 8:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;FINANCIAL INCOME, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;

            &lt;div&gt;
              &lt;div style="margin-left:90pt"&gt;
                &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                    &lt;tr&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td rowspan="1" style="vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&#160;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,770&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,528&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,697&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220727231515518">
            &lt;div&gt;
              &lt;div style="margin-left:90pt"&gt;
                &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                    &lt;tr&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td rowspan="1" style="vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&#160;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,770&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,528&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,697&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_290"
      unitRef="usd">1770000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_291"
      unitRef="usd">1671000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240730200046696_Fact_290"
      unitRef="usd">796000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240730200046696_Fact_291"
      unitRef="usd">15000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220720002002984"
      unitRef="usd">-38000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_293"
      unitRef="usd">11000</us-gaap:OtherNonoperatingIncomeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_294"
      unitRef="usd">2528000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_295"
      unitRef="usd">1697000</cgen:FinancialIncomeExpenseNet>
    <cgen:RevenueDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240731004145161">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;NOTE 9:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;REVENUES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The following represents the total revenue for the six-month periods ended June 30, 2024 and 2023 by region based on the invoicing address of customers&lt;span style="font-weight:bold"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&#160;&lt;div style="margin-left:63pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Total revenues&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Contract Balances&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-indent:28.1pt;margin-left:28.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Of the $ 36,541 of deferred revenue recorded as of December 31, 2023, the Company recognized $ 4,261 as revenue during the six months ended June 30, 2024. The Company had no deferred revenues as of December 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Remaining Performance Obligation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:56.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company&#x2019;s remaining performance obligations are comprised of revenue not yet delivered. As of June 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $32,280, that the Company expects to recognize as revenue. As of June 30, 2024, the Company expects to recognize 35% of its remaining performance obligations as revenue over the next 12 months.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </cgen:RevenueDisclosureTextBlock>
    <cgen:ScheduleOfRevenueTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240731004159739">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Total revenues&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </cgen:ScheduleOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240731004232764"
      unitRef="usd">4261000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240731004238489"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember"
      decimals="-3"
      id="Fxbrl_20240731004255449_xbrl_20240731004232764"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630_srtStatementGeographicalAxis_usgaapEuropeanUnionMember"
      decimals="-3"
      id="Fxbrl_20240731004255449_xbrl_20240731004238489"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731004257177_xbrl_20240731004232764"
      unitRef="usd">9261000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240731004257177_xbrl_20240731004238489"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240731005201296"
      unitRef="usd">36541000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240731005208072"
      unitRef="usd">4261000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240731005233655"
      unitRef="usd">32280000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="C_20240630"
      decimals="2"
      id="Fxbrl_20240731005354782"
      unitRef="Pure">0.35</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220727224715083">
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                            &lt;tr&gt;
                              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 10:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                            &lt;/tr&gt;

                        &lt;/table&gt;
                        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div style="margin-left:63pt"&gt;

                      &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;

                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;div&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                  &lt;div style="margin-left:63pt"&gt;

                      &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;

                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:56.75pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:28.3pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730193838627">
                      &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;

                      &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr&gt;
                            &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                              &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                    </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_298"
      unitRef="usd">22000</cgen:TradeAndOtherPayablesRelatedParties>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_299"
      unitRef="usd">53000</cgen:TradeAndOtherPayablesRelatedParties>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_300"
      unitRef="usd">74000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_301"
      unitRef="usd">70000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730195318260">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
            &lt;div style="line-height:1.25"&gt;
              &lt;div style="line-height:1.25"&gt;
                &lt;div style="line-height:1.25"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 11:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                          &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                            &lt;div style="font-weight:bold"&gt;
                              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;LOSSES PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:0pt;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted losses per share for the six-month periods ended June 30, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:63pt"&gt;

              &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;9,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;18,615&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;89,518,778&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,903,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240730195348408">
              &lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:89%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;9,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;18,615&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;89,518,778&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,903,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="F20240730141359513_1"
      unitRef="usd">-9390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="F20240730141359513_2"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20240730195604484"
      unitRef="Shares">89518778</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="F20240730141359513_3"
      unitRef="Shares">89518778</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20240730195622412"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="F20240730141359513_4"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="F20240730141359514_12"
      unitRef="USD_per_share">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="F20240730141359514_7"
      unitRef="USD_per_share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="F20240730141359514_13"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="F20240730141359514_8"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20220728193545297">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                                &lt;tr&gt;
                                  &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;NOTE 12:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                  &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                                    &lt;div style="font-weight:bold"&gt;
                                      &lt;div style="font-weight:bold"&gt;
                                        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                      &lt;/div&gt;
                                    &lt;/div&gt;
                                  &lt;/td&gt;
                                &lt;/tr&gt;

                            &lt;/table&gt;
                            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On July 29, 2024, the Company announced that the U.S. Food and Drug Administration has cleared the IND application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead. The IND clearance triggered a $30,000 milestone payment from Gilead which is expected in the third quarter of 2024.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On July 31, 2024, following recommendation of the compensation committee, the Company&#x2019;s board of directors increased the total number of shares reserved for issuance under the Company&#x2019;s 2010 Plan by 300,000 and reduced the total number of shares reserved for issuance under the ESPP by 114,146 to zero.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:SubsequentEventsTextBlock>
    <cgen:ClearanceTriggeredMilestonePayment
      contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_cgenGileadSciencesIncMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-3"
      id="Fxbrl_20240731022746637"
      unitRef="usd">30000000</cgen:ClearanceTriggeredMilestonePayment>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20240731_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230728015337735"
      unitRef="Shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20240731_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230728015343566"
      unitRef="Shares">114146</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
